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Introduction
In 2007 in the Netherlands there were about 238.000 people with osteoarthritis of the hip, 
two-thirds of this population is female and over 65 years of age, with 27.000 new cases regis-
tered each year.1 Osteoarthritis of the hip can significantly influence daily functioning, and the 
osteoarthritis patient may become dependent on their environment and health care facilities. 
The recommended first choice of treatment for this condition is a combination of acetamino­
phen (if necessary combined with non­steroidal anti­inflammatory drugs (NSAID)) and physi­
cal therapy to reduce pain and improve physical function.2,3 If this initial treatment does not 
improve symptoms, total hip arthroplasty (THA) may be indicated for the elderly patient with 
 advanced osteoarthritis. Almost 21.000 hip arthroplasties are implanted each year in the 
Netherlands, and based on a expected 53% increase of incidence of osteo arthritis of the hip, 
in 2030 the number of THA is expected to be 32.000. The trend projection suggests even a 
149% increase to 51.680 THA’s.4 In the treatment of secondary osteoarthritis in young pa-
tients, joint preserving surgery (like femoral and acetabular osteotomies) can be conside-
red.2,3 However, due to the great success of the THA, with promising results, a good quality 
of life and little to no loosening of the prosthesis, the age limits for hip replacement have been 
lowered. Unfortunately, the long-term outcome is worse for young patients than for the older 
age groups. Ten year survival ranges from 72%-86% in patients less than sixty years of age, 
versus 90-96% in older patients.5 Since the young, active and high-demand patient is recog-
nized to have relatively disappointing results after a conventional THA, there is still ongoing 
research for better solutions for this troublesome patient category. Innovations in hip arthr o-
plasty focus on potential improvement in implant survival rates, which is expected to come 
from alternative bearing materials. 
Figure 1 Resurfacing hip arthroplasty (RHA) (Conserve® Plus; Wright Medical Technology, Arlington, TN).
This thesis is about the results of resurfacing hip arthroplasty (RHA) (Figure 1), which unlike 
conventional hip replacement does not replace the femoral head. The osteoarthritic femoral 
head is reshaped and covered with a rounded metal cap. The socket is pressfitted with a 
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metal cup, which is similar to a conventional acetabular cup, although for the latter generally 
a polyethylene liner is used. The different design of an RHA results in a bigger hip-ball, no 
invasion of a stem in the femoral canal and a metal-on-metal (MoM) bearing instead of, for 
example, metal-on- polyethelene (MoP). 
History
Due to its clinical success total hip arthroplasty (THA) has already been called ‘the operation 
of the century’.6 In the 1960s, total hip replacement completely changed the quality of life 
of patients with disabling osteoarthritis. A disease that had left millions of people ‘crippled’ 
suddenly had a cure. Since the beginning of the 20th century ways were explored to treat 
patients with osteoarthritis of the hip surgically by less invalidating methods than performing 
a girdlestone or hip arthrodesis. In 1923 Smith-Peterson introduced a mould interposition 
arthroplasty of glass, pyrex and bakalite. However, none of these implants could withstand 
the forces applied during motion and failed relatively soon during use. In 1938 subsequently 
he developed a vitalium cup covering the femoral head, also with poor results. At the same 
time Wiles implanted the first uncemented total hip arthroplasty with matched acetabular and 
femoral components of stainless steel, which can be considered the first MoM hip implant.7 
McKee and Watson­Farrar developed a cobalt­chromium­molyb denum (Co­Cr­Mo) MoM hip 
arthroplasty of the ball-and-socket type in 1956 (Figure 2A).8,9 The first hip arthroplasties 
implanted already consisted of a metal-on-metal bearing and the concept itself is not new.
Figure 2 A McKee­Farrar metal­on­metal total hip arthroplasty.8 B Charnley low-friction arthroplasty.10 
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In 1962 Charnley revolutionized the total hip arthroplasty design with the idea of a low friction 
arthroplasty, the use of acrylic cement to fix the components to living bone and the introduc-
tion of high-density polyethylene (UHMPWE) as a bearing material (Figure 2B).10 Until the 
1970s K.M. Sivash, P. Ring, J. Scales, M. Postel, M. Muller and A. Huggler experimented with 
the MoM design.9 Analysis of this first generation of MoM THA (from 1960s and 1970s) with 
a chrome­cobalt­molyb denum alloy and a press­fit acetabular fixation, suggested that the 
failures were not due to the MoM bearing surface. Low in vivo wear rates were measured in 
both the  McKee­Farrar and Metasul retrievals and the bearing surface showed to be durable 
as established by the retrieval study of implants more than 20 years after the index opera-
tion.11 The rate of component loosening of the MoM total hip replacements and the supe-
rior clinical results of Charnley’s prosthesis with a  metal-on-polyethylene bearing during the 
1970s discouraged the use of the MoM bearing. There are reports of comparable loosening 
rates for Charnley’s low friction and  McKee­Farrar’s arthroplasty after 20 years,13 but others 
found significant  differences to the detriment of McKee­Farrar 14 years after implantation.14 
Although in general the cemented total hip arthroplasty of Charnley proved to be a supe-
rior design in its time, an increasing number of aseptical loosening was found, especially in 
younger patients.15,16 Initially, this premature loosening and osteo lysis was addressed as 
 cement disease17 and therefore cementless press­fit designs were developed. Regardless of 
these new fixation techniques  peripros thetic osteolysis continued to exist and it was found to 
originate from the use of poly ethelene. Implants wear at the point where the head moves 
(under load) in the socket. As a result, the cyclic loading of a MoP THA leads to polyethylene 
wear particles, which in their turn result in a foreign body reaction with osteolysis. Osteo lysis 
is regarded the main long-term problem in THA which, in time, will lead to aseptic loosening 
of the components. This phenomenon is particularly problematic in younger, more active 
patients who will put more load on their implant and will  likely outlive their hip prosthesis. 
Hence, especially for this group of younger patients, an ongoing search for improvements, 
related to the wear properties of polyethelene, alternative bearing materials and enhanced 
fixation techniques took place. This led to the introduction of highly cross­linked polyethyle-
ne, the addition of vitamine E, improvements in cementing techniques and uncemented de-
signs. Alternative bearing materials that were considered are ceramic-on-ceramic, ceramic- 
on-polyethelene, ceramicized metal-on-polyethelene and the concept of metal-on-metal was 
re-introduced.
Metal-on-metal hip resurfacing
The search for an other than metal-on-polyethylene bearing facilitated the initiation of a 
 second and third generation of MoM RHA’s in the 1980s and 1990s. This resulted in the 
 development of a low wear, high-carbon chrome-cobalt-molybdenum  alloy18 with a combined 
annual linear wear rate of 1 to 6 microns according to  implant retrieval studies.19-21 In the third 
generation the alloy evolved into hard high-carbon cobalt-chromium, and this allowed a thin-
ner acetabular component design, which accommodates corresponding larger femoral 
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heads.9 Manufacturers used modern manufacturing techniques which resulted in very 
smooth surfaces, and therefore very little wear particle release. The design features, like 
roundness and radial clearance (the distance between the articulating surfaces) of RHA 
were further optimized.22 The combination of a large femoral head and low radial clearance 
would promote fluid film lubrication between femoral head and cup and diminish wear. The 
femoral component of RHA has a large contact area and will have more sliding distance and 
greater speed than a component with a small radius. In MoP articu lations increasing head 
size leads to increased wear. However, in MoM arti cu lations the bigger femoral head and 
thus the bigger sliding distance, theoretically, helps to promote fluid film formation which 
keeps the irregularities of the articulating surfaces apart.23 
In hip simulator studies, it was found that MoM hip bearings generate 100-fold less wear 
debris than MoP.24 In addition to the attractive wear characteristics of MoM implants, the 
design of hip resurfacing was also appealing as no more bone than necessary has to be 
removed. In case of a femoral revision from RHA to THA, the normal surgical procedure of a 
THA can be followed and the concept of resurfacing thus introduced an extra revision option. 
After placement of a rigid intrame dullar THA stem the loading forces will be transferred 
through the prosthesis instead of through the medial femoral cortex (calcar). In the long-term, 
this stress-shielding effect results in a decrease of proximal femoral bone stock.25,26 RHA 
enables a more natural loading of the femur with reduced stress-shielding, which will preser-
ve the patient’s femoral bone stock.27 In this young patient population, the preservation of 
bone is very important, in view of inevitable future revisions. Another theoretical advantage of 
RHA is the jump distance, the maximum distance between femoral head and acetabulum 
before the joint dislocates. In a THA, the head and socket are small, resulting in a small jump 
distance. Resurfacing has a larger jump distance, because of the more anatomically sized 
femoral head, which results in a signifi cantly lower dislocation rate.28-30 Because of the larger 
femoral head, improved joint mechanics with a greater range of motion, faster speed and gait 
were claimed.29,31 It is, however, debatable whether the improved range of motion does not 
only apply to the combination of a large head and a slim neck,32 while the small head-neck 
ratio of the RHA might even cause impingement.33 The claimed advantages of RHA, low vo-
lumetric wear, preservation of femoral bone stock with easy revisions, better functional out-
comes and a better stability26,34-37 are only clinically beneficial if the survivorship is equal or 
better than the gold standard. The early clinical results of RHA showed to be favorable, with 
survivorship of 94% to 99% survivorship after two to five year follow­up in young patients.38-41
Current concept
The RHA was marketed as the latest advancement in hip replacement and was targeted 
at young active patients who needed a hip that would last a lifetime. The disadvantages, 
however, like the more technical demanding procedure, with a potential risk of femoral neck 
fractures, the occurrence of excessive metal ion release and the adverse reactions to metal 
debris (ARMD),35,42-45 were less widely specified and in hind view maybe underestimated. 
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Based on all mentioned (theoretical) advantages RHA and MoM were appealing concepts to 
both surgeon and patient. Despite the absence of long-term results, there was a rapid global 
increase in the use of large diameter MoM hip implants. In 2007 the worldwide use of large 
dia meter MoM implants peaked, and in the UK MoM hip prosthesis accounted for 20% of the 
market.46 In this rapidly emerging market of RHA, we felt that there was a lack of literature 
where this new concept was balanced against the ‘gold standard’ of conventional THA. In a 
period with considerable promotion for the use of MoM implants we designed a randomized 
clinical trial between RHA and an established THA (with a small-diameter MoM bearing) to 
determine whether some of the pro posed benefits of RHA could be clinically confirmed. 
Aims of the thesis
With the rapidly increasing global use of and patient demand for RHA — despite only short-
term results — we felt the need to introduce this implant in a controlled setting and perform 
an objective comparison with the gold standard, a conventional THA. The overall aim of this 
thesis is to evaluate the clinical outcome, metal ion blood levels and bone mineral density 
evolution after RHA and compare these results with THA. Therefore, this thesis seeks to an-
swer a number of research questions that can be divided into the following seven objectives: 
• To determine the single surgeon learning curve of RHA
• To compare RHA and 28-mm MoM THA with regard to short-term metal ion evolution, 
functional results and complications
• To assess whether a profound patient preference for RHA did influence clinical outcome 
and patient satisfaction 
• To determine the interchangeability and provide a conversion formula between serum 
and whole blood metal ion measurements
• To assess the difference in trend evolution of metal ions after well and sub-optimal 
functioning RHA
• To determine the rate of silent pseudotumors in a cohort of hip resurfacing patients 
• To compare bone mineral density evolution after RHA and a 28-mm MoM THA
Outline of the thesis
The surgical technique of RHA is technically demanding and optimal implant positioning is 
crucial for a good clinical outcome. In Chapter 2 the learning curve of a single surgeon judg-
ed by radiographic analysis of implant position is evaluated.
The expectations of patients and orthopaedic surgeons about the RHA were high. In Chap-
ter 3 the two-year results of a prospective randomized clinical trial are described. This was 
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designed to investigate whether RHA gives better functional results, more stability and fewer 
complications than a small-diameter MoM THA. Furthermore, a detailed analysis of the evo-
lution of the ion levels in both patient groups was performed.
Some patients have an extremely high preference for RHA. This impeded rando mization for 
our randomized clinical trial, since a group of patients refused participation and demanded 
an RHA. This gave the opportunity to evaluate the effect of preference on the postoperative 
satisfaction and functional results between two groups of RHA patients, one from the rando-
mization RHA arm in the RCT and the other not willing to be randomized in the RCT, followed 
in the RHA cohort. The influence of preference bias after RHA is presented in Chapter 4. 
The MoM bearing of the RHA generates cobalt and chromium ions. There is no consensus 
whether whole blood or serum should be used as surrogate measure of metal ion expo sure. 
In Chapter 5 we explain whether whole blood and serum measurements could be used 
 interchangeably, provide a conversion formula be tween serum and whole blood and present 
guidelines for interpretation of metal ion analysis in clinical practice. 
In national screening protocols for potential dysfunctioning implants a single metal ion 
measurement is recommended, however consensus about cut off values is not available. We 
hypothesize that the trend in metal ion levels in time is more informative for implant function 
than single measurements. In Chapter 6 we analyzed whether short-term trend differences of 
metal ion levels can differentiate between a well or a sub-optimal functioning implant.
Wear of MoM implants can lead to ARMD, which includes pseudotumors. Patients with pseu-
do tumor formation can present themselves with complaints and high systemic metal ion le-
vels. However, suspicion arises that silent pseudotumors occur as well. Silent pseudotumors 
are considered an ARMD, visible on ultrasound or MRI, in completely asymptomatic patients. 
In Chapter 7 the incidence of silent pseudotumors in a cohort of RHA patients is presented.
RHA claims to be bone preserving by preserving the femoral head and collum. However, 
periprosthetic stress shielding could lead to loss of bone stock on both the femoral and 
acetabular side. It might play a role in the evolution of neck narrowing and neck fractures. 
One of the proposed benefits of hip resurfacing is the ease of revision (and conversion to a 
THA). How is the evolution of bone mineral density in femoral and acetabular after RHA in 
comparison to an established THA? Is there bone preservation which provides future revision 
with good bone stock? The differences in bone mineral density after RHA and a 28-mm MoM 
THA are presented in Chapter 8 and Chapter 9.
A summary of the preceding chapters and general discussion is presented in Chapter 10 
and Chapter 11 (Dutch). 
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Chapter 2
Abstract
Background Operation of hip resurfacing prosthesis is a technically demanding procedure 
accompanied by a learning curve. To our knowledge no objective data on this learning curve 
are available in the literature.
Methods For the first forty resurfacing hip prostheses implanted by a single­ surgeon radio-
graphic ‘learning curve’ analysis was performed. Optimal implant positioning on pre-opera-
tive digital templating was compared with the eventual implant position postoperatively, 
measured by six establishes radiographic parameters and compared for four chronological 
cohorts of patients. 
Results A learning curve was clearly present and an optimal result was established in the last 
cohort. Pitfalls were a relatively steep cup position initially and a stem position in the posterior 
one-third of the collum. Besides marginal medialization a fully anatomic reconstruction of the 
center of rotation was achieved.
Conclusion In total hip resurfacing one should recognize the presence of a learning curve. 
This learning curve appears to be acceptable and a reproducible optimal implant positioning 
can be achieved quickly.
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Introduction
The results of total hip arthroplasty (THA) as treatment for osteoarthritis are excellent in the 
older age group, but long term survival of the implant remains a matter of concern in young 
patients.1-3 Since young and active patients can also suffer from debilitating osteoarthritis, 
the concept of total hip resurfacing has been introduced and is rapidly increasing in popu-
larity.1,4-6
Several advantages of total hip resurfacing have been described, which make the implant 
suitable for especially the younger age group. A greater inherent stability can be achieved 
with a resurfacing implant as compared to a regular THA.4 More importantly, the femoral head 
is retained and thus the proximal femoral bone mass is preserved, which facilitates potential 
revision surgery at a later stage. In addition, revision of a modern generation metal-on-metal 
resurfacing arthroplasty to a regular THA is expected to be relatively straightforward and 
easier to perform for both the surgeon and the patient.7,8 For example, Beaulé and associates 
reported a survivorship of 94% at ten years in a group of ninty converted resurfacings where 
the primary socket was retained.9 This theoretical advantage of an easy revision surgery was 
also supported by a recent study on the early results of conver sions to a regular THA.10 They 
reported on a match-paired analysis of 21 failed hip resurfacings where the socket was re-
tained and 58 primary cementless total hip replacements, done during the same period. At a 
mean follow-up of 46 months, functional outcome hip scores were comparable and no diffe-
rences were found between the two groups in the perioperative and postoperative course. In 
terms of surgical effort, safety and early clinical outcomes, the revision procedure appeared 
to be comparable with a primary total hip arthroplasty operation.7,10
Besides these advantages, also the possible disadvantages of hip resurfacing have al-
ready been described in the literature. There appears to be a risk of femoral neck fracture, 
early implant loosening has been described and there are anatomic limitations to the indi-
cation for hip resurfacing.11,12 Moreover, the operation is a technically demanding procedure 
accompanied with a substantial learning curve for surgeons.11 Beaulé once claimed that 
surface arthroplasty should not be considered a standard arthroplasty and should not be 
done than only by surgeons with considerable experience in hip reconstruction.1 Since sur-
gical technique, optimal implant positioning and cementing technique are crucial for a good 
clinical outcome of the procedure,12 we believe that further insight in the potential learning 
curve of total hip resurfacing should be established. 
The aim of our study was to evaluate the learning curve on optimal implant positioning 
of a single surgeon series of total hip resurfacing. Since the number of surgeons performing 
hip resurfacing is rapidly increasing, lessons can be learned from such a learning curve and 
pitfalls may be avoided in future learning curves. 
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Materials and methods
From July 2005 total hip resurfacing is performed in Rijnstate Hospital Arnhem. The first 40 
implants were considered to represent the learning curve of a single sur geon, experienced 
in hip surgery. All operations were performed by the same surgeon (JvS) without the use of 
computer navigation. A modern third-generation hip resurfacing implant was used (Conser-
ve® Plus, Wright Medical Technology, Arlington, TN, USA) with both components made of a 
cast, heat-treated solution-annealed Co-Cr alloy. This metal on metal resurfacing arthroplasty 
has been introduced in the United States in 1996 and has a press fit cementless fixation of 
the acetabular component, whereas for the femoral component cement fixation is used.2 In 
all cases a posterolateral approach was used. 
Pre- and postoperative radiographic measurements were carried out on all implants. On 
the calibrated pre-operative AP pelvic X-rays anatomical radiographic parameters, such as 
the femoral offset, body moment arm (BMA) and abductor moment arm (AMA), as well as the 
neck shaft angle (NSA), were measured as previously described (Figure 1A).13 Subsequently, 
the surgeon (JvS) performed pre-operative planning of the ideal implant positioning using 
the available digital templating software (Philips, Easyvision). Ideally the stem of the femoral 
component should be placed in the centre of the proximal femoral neck, maybe with a slight 
valgus positioning on anteroposterior radiographs as described by Beaulé et al.13 On these 
pre-operatively planned ideal implant positioning, the cup abduction angle (CA), stem shaft 
angle (SSA) and equator angle between cup and femoral component (called cup head an-
gle, CHA) were determined by an independent observer (SW) (Figure 1B).
After surgery, the postoperative calibrated follow-up radiographs were used for repeated 
measurements. Both the anatomical radiographic parameters (femoral offset, BMA and 
AMA) and the final implant positioning (CA, SSA and CHA) were blindly determined on 
antero posterior pelvic radiographs (Figure 2A).
In addition, stem positioning of the femoral component was determined on the AP and 
lateral view (Figure 2B). To establish stem positioning the femoral neck was divided in three 
equal thirds on both views. Only with the entire length of the femoral stem situated in the mid-
dle third of the femoral neck, the stem position could be classified as in the optimal central 
region. Valgus positioning of the implant could then result in a stem positioning in the inferior 
region, whereas varus positioning ended in the superior region (Figure 2B).
For all radiographic parameters pre-operative values on the digital templating radio-
graph with optimal implant positioning were compared to the same parameters from the 
post operative radiograph by an independent observer (SW). In order to establish a possible 
learning curve effect the entire study population was divided in four chronological cohorts of 
each ten patients. Radiographic parameters for each subgroup of patients were clustered 
and compared. Statistical analysis of the data was performed with One-Way ANOVA models 
in SPSS analysis software. 
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Figure 1 Radiographic measurements on pre-operative X-ray. A Anatomic references for femoral offset, 
body moment arm (BMA), abductor moment arm (AMA) and neck shaft angle (NSA). B Digital templa-
ting for cup angle (CA), stem shaft angle (SSA) and cup head angle (CHA).
 
Figure 2 Example of radiographic measurements on the postoperative X­ray from the first cohort. A 
Anteroposterior radiograph with the CA, SSA, CHA and stem position in the frontal plane. B Lateral radio-
graph showing stem position in the middle-third of the collum.
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Results
Forty implants were placed in 38 patients (21 males and 17 females). The mean age at sur-
gery was 53 years (23-65). Left- and right-sided implants were equally divided with twenty on 
either side. The pre-operative diagnosis of the vast majority of patients (97,5%) was primary 
arthritis and one patient (2,5%) had a secondary osteoarthritis following an acetabular frac-
ture. The average blood loss was 391 cc (250­800), with no statistically significant difference 
between the four separate cohorts. In contrast, the time of surgery did show a significant 
learning curve effect. The mean operation time in the first cohort of ten patients was 89 minu-
tes, with a significant decrease (p=0.013) to 79 minutes in the last cohort (Figure 3). 
Figure 3 Learning curve for operation time. The mean operation time in the first cohort of ten patients 
was 89 min, with a significant decrease to 79 min in the last cohort.
The average cup abduction angle (CA) on postoperative radiographs for the first cohort of 
ten patients was relatively high (mean 52°, ranging from 41° to 76°) as compared to the situ-
a tion on templated pre-operative radiographs (mean 44°, ranging from 46° to 54°), which 
indicates a rather steep cup placement initially. This was corrected in the second cohort of 
patients, where the average final CA (mean 49°, ranging from 40° to 59°) approached the 
pre-operative planning, although ranges remained substantially (50°, ranging from 45° to 
52°). Subsequently, in cohort three and four, a trend to overcorrection towards a lesser steep 
cup placement can be observed (Figure 4A). No statistically significant differences between 
the four cohorts could be detected. The mean SSA for the entire group of forty patients was 
134° (SD 7.4°) both for the final implant positioning and for the pre­operative planning. Apart 
from a slight tendency to a more valgus positioning of the stem in the last cohort, overall no 
significant differences between the actual implant positioning and the pre­operative planning 
could be detected (Figure 4B).
A trend towards more valgus positioning of the stem in relation to the anatomy of the 
proximal femoral neck also appeared from the calculated SSA versus the NSA (Figure 4C).
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Figure 4 Learning curve trends of prosthesis implantation. Differences between pre-operative planning 
and ultimate implant position measures for A Cup-abduction-angle, B Stem-shaft-angle, C Neck-shaft-
angle versus stem-shaft-angle, D Cup-head-angle. Positive values indicate a relatively high value on 
final implant position as compared to the pre­operative planning. 
The average NSA for the entire group of patients was 132° (SD 6.3°), whereas the postope-
rative SSA increased in later cohorts. The CHA is defined as the angle be tween cup (i.e. 
cup-angle) and the femoral component. This angle is also important from a biomechanical 
point of view, since values close to zero degrees indicate optimal coverage of the femoral 
component by the cup, thus preventing peak stresses.12 For the entire group a CHA of 7.6° 
(SD 4.3°) on average was calculated on final implant positioning and no significant diffe-
rences could be detected with values from pre-operative planning. For each subsequent 
cohort, however, a dramatic decrease in standard deviation was visible indicating improved 
accuracy in implant positioning (Figure 4D). This trend with a decreased standard deviation 
was statistically significant on heterogeneous variance analysis (p=0.006). 
26
Chapter 2
Like described by Beaulé, ideally the stem of the femoral component should be placed in the 
centre of the proximal femoral neck, maybe with a slight valgus positioning on antero pos-
terior radiographs.13 We defined optimal stem positioning with the entire length of the stem in 
the middle third of the femoral neck on both antero posterior and lateral radiographs. In the 
frontal plane the stem was placed in the inferior third of femoral neck in 26% and in the cen-
tral region in 74% of the entire group. On the lateral view especially in the first cohorts there 
was a tendency of posterior placement of the stem (Figure 5). Over time, a clear trend to-
wards optimal stem positioning in the central third of the femoral neck in both radiographic 
planes could be detected throughout the four cohorts. Due to a relatively small number of 
patients no significant difference could be calculated for this trend (p=0.163).
Figure 5 Percentage of stem position in central 1/3 posi-
tion on AP and/or lateral X-rays for each of the four chrono-
logical cohorts of ten patients; AP+ Lat+ stands for stem 
position in the central third of collum in both AP and lateral 
radiographs.
Anatomic joint reconstruction was established comparing the pre- and post operative body -
moment-arm (BMA), abductor-moment-arm (AMA) and femoral off-set (Figure 1A). In spite of 
a rather large standard deviation overall for these three parameters the pre-operative values 
on templated radiographs were actually  matched on postoperative radiographs with final 
implant positioning (Figure 6). Only on average a slightly negative value was encountered for 
the planned versus the established BMA, which was obligatorily compensated by a compa-
rable posi tive value for the AMA. These two minor changes indicate some medialization of 
the centre of rotation (COR). No cranial or caudal migration of the COR was observed. The 
femoral offset on postoperative radiographs on average equalized the offset pre- operatively 
templated (Figure 6).
Figure 6 Globally reached anatomic joint reconstruction, with 
slight trend of medialization as can be concluded from a slight 
decrease in BMA after surgery and a slight increase in AMA.
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Discussion
Hip resurfacing is an alternative to total hip replacement, but it is clearly a more demanding 
procedure. The skin incision is generally larger and both the operation time and the learning 
curve seem to be longer for hip resurfacing than for THA.5 In this study we tried to elucidate 
aspects of the recognized learning curve and attempted to further define pitfalls in this lear­
ning curve. 
Our data clearly indicate the presence of a learning curve in total hip resurfacing. Due 
to the relatively small number of patients in each subsequent cohort and the relatively large 
standard deviations, only for some radiographic parameters significant differences could 
be detected between cohorts initially. On the other hand, some clear trends were obser-
ved. First, the overall standard deviation in differences in radiographic parameters between 
pre­operatively templated and postoperative eventual implant positioning significantly de-
creased in time, thus indicating improved reproducibility in outcome. 
We saw that SSA increased in later cohorts, so that the stem was placed in a progres-
sively valgus position, what is in accordance with current recommendations from the literatu-
re.12,13 Thus a slight valgus positioning of the stem in the femoral neck, like we attained in the 
later cohorts, seems favorable. Secondly, the 7° CHA appeared to reach highly reproducible 
values with very small standard deviations for the fourth cohort of ten patients. Furthermore, 
in the beginning there appeared to be tendency towards relatively steep cup placement, 
varus positioning of the stem on frontal radiographs and posterior placement on the lateral 
radiographs. These all were typical learning curve pitfalls, which appeared to be controlled 
in the fourth cohort of patients. 
Obviously, this learning curve revealed no dramatically significant differences in time and 
thus the learning curve appears to be relatively mild and with a total number of approximately 
forty patients of an acceptable length. However, optimal implant positioning remains a rather 
subjective criterion. Until now the literature only provides us with a hypothetically optimal 
implant positioning and there is no clinical data to support this. For example, it is commonly 
recog nized that a slight valgus position of the femoral implant should be established, since 
this may lead to stress reduction in the collum and decreased risk of femoral neck fractu-
res.12-14 This way it is also recommended to aim for a CHA close to zero, with the cup in a 
parallel position with the head. In our series, however, an average CHA of 7.2° was calcula-
ted on templated pre-operative radiographs. We recognize that from a biomechanical point 
of view the CHA should be as close to zero as possible, however, clearly this is not always 
feasible due to the limitations from the pre-existing pelvic cup anatomy and valgus orienta-
tion of the femoral neck. 
Besides comparing the templated optimal versus the postoperative actually  established 
implant positioning, we also wanted to evaluate whether anatomic joint reconstruction was 
realised. Girard et al. already evaluated the biomechanical and anatomical joint reconstruc-
tion following conventional THA versus surface replacement arthroplasty in a randomized 
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study with 120 patients.15 They found that the radiological parameters of acetabular recon-
struction were similar in both groups and that restoration of the normal proximal femoral 
anatomy was more precise with resurfacing. In our study population an anatomic joint recon-
struction was also achieved, with only a slight medialization of the COR. This phenomenon 
has been recognized before, where medialization of the COR of approximately 6 mm has 
been described in both resurfacing hip and conventional THA.16 
Weaknesses of our study are the limited number of patients and the fact that our data are des-
cribing the results of only one surgeon. It has been described in the literature that poor implant 
positioning after hip resurfacing can lead to early failures,12 although there is still a lack of evi-
dence based information on long term clinical outcome measures. Nevertheless, orthopaedic 
surgeons starting with hip resurfacing can expect a moderate learning curve, so in spite of 
these limitations we still believe important lessons can be learnt from these learning curve data. 
One should beware of a rather steep cup positioning initially. As for the femoral component, at-
tention should be paid to avoid a varus and posterior positioning in relation to the femoral neck. 
Overall we are of the opinion that the learning curve of the first forty RHA appears acceptable. 
In general, one thinks that computer-assisted orthopaedic surgery technology may improve 
task performance by providing continuous feedback, which may be advantageous to lear-
ning.17 The role of computer navigation has also been advocated in total hip resurfacing to 
support optimal implant positioning,5,18 but in literature there is still no consensus on the truly 
effects. Since we were able to encounter an acceptable learning curve and reproducible op-
timal implant positioning without using any form of navigation, we wonder whether could be 
the benefit of computer navigation in hip resurfacing. So we are looking forward to the results 
of further research and learning curves of computer navigation supported implantations of 
resurfacing hip prostheses. 
The aim of our study was to evaluate the learning curve on optimal implant positioning 
of a single surgeon series of total hip resurfacing. Since the number of surgeons performing 
hip resurfacing is rapidly increasing, lessons can be learned from such a learning curve and 
pitfalls may be avoided in future learning curves. 
29
Learning from the learning curve in total hip resurfacing
2
References
1. Beaulé PE, Dorey FJ, Le Duff MJ, Gruen T, Amstutz HC. Risk factors affecting outcome of metal -on-
metal surface arthroplasty of the hip. Clin Orthop Relat Res. 2004;418:87-93.
2. Grigoris P, Roberts P, Panousis K, Bosch H. The evolution of hip resurfacing arthroplasty. Orthop 
Clin North Am. 2005;36(2):125-134, vii.
3. Kim WC, Grogan T, Amstutz HC, Dorey F. Survivorship comparison of THARIES and conventional 
hip arthroplasty in patients younger than 40 years old. Clin Orthop Relat Res. 1987(214):269-277.
4. Amstutz HC, Ball ST, Le Duff MJ, Dorey FJ. Resurfacing THA for patients younger than 50 years: 
Results of 2- to 9-year followup. Clin Orthop Relat Res. 2007;460:159-164.
5. Barrett AR, Davies BL, Gomes MP, Harris SJ, Henckel J, Jakopec M, et al. Preoperative planning 
and intraoperative guidance for accurate computer-assisted minimally invasive hip resurfacing sur-
gery. Proc Inst Mech Eng H. 2006;220(7):759-773.
6. Vail TP, Mina CA, Yergler JD, Pietrobon RMD. Metal-on-metal hip resurfacing compares favorably 
with THA at 2 years followup. Clin Orthop Relat Res. 2006;453:123-131.
7. Amstutz HC, Beaule PE, Dorey FJ, Le Duff MJ, Campbell PA, Gruen TA. Metal-on-metal hybrid sur-
face arthroplasty. Surgical technique. J Bone Joint Surg Am. 2006;88(1_suppl_2):234-249.
8. Schmalzried TP. The optimal metal-metal arthroplasty is still a total hip arthroplasty: In opposition. 
J Arthroplasty. 2006;21(4, Supplement 1):77-79.
9. Beaule PE, Le Duff MJ, Dorey FJ, Amstutz HC. Fate of cementless acetabular components retained 
during revision total hip arthroplasty. J Bone Joint Surg Am. 2003;85-A(12):2288-2293.
10. Ball ST, Le Duff MJ, Amstutz HC. Early results of conversion of a failed femoral component in hip 
resurfacing arthroplasty. J Bone Joint Surg Am. 2007;89(4):735-741.
11. Cuckler JM. The optimal metal­metal arthroplasty is still a total hip arthroplasty: In the affirmative. 
J Arthroplasty. 2006;21(4 suppl 1):74-76.
12. Long JP, Bartel DL. Surgical variables affect the mechanics of a hip resurfacing system. Clin Orthop 
Relat Res. 2006;453:115-122.
13. Beaule PE, Lee JL, Le Duff MJ, Amstutz HC, Ebramzadeh E. Orientation of the femoral component 
in surface arthroplasty of the hip. A biomechanical and clinical analysis. J Bone Joint Surg Am. 
2004;86-A(9):2015-2021.
14. Anglin C, Masri BA, Tonetti J, Hodgson AJ, Greidanus NV. Hip resurfacing femoral neck fracture 
influenced by valgus placement. Clin Orthop Relat Res. 2007;465:71-79.
15. Girard J, Lavigne M, Vendittoli PA, Roy AG. Biomechanical reconstruction of the hip: a rando-
mised study comparing total hip resurfacing and total hip arthroplasty. J Bone Joint Surg Br. 
2006;88(6):721-726.
16. Silva M, Lee KH, Heisel C, Dela Rosa MA, Schmalzried TP. The biomechanical results of total hip 
resurfacing arthroplasty. J Bone Joint Surg Am. 2004;86-A(1):40-46.
17. Gofton W, Dubrowski A, Tabloie F, Backstein D. The effect of computer navigation on trainee lear-
ning of surgical skills. J Bone Joint Surg Am. 2007;89(12):2819-2827.
18. Cobb JP, Kannan V, Brust K, Thevendran G. Navigation reduces the learning curve in resurfacing 
total hip arthroplasty. Clin Orthop Relat Res. 2007;463:90-97.

3Metal ion levels and functional results after 
either resurfacing hip arthroplasty or 
conventional metal-on-metal hip arthroplasty. 
Short-term outcome of a randomized 
controlled trial
José M.H. Smolders
Annemiek Hol
Willard J. Rijnberg
Job L.C. van Susante
Acta Orthopaedica 2011;82(5):559–566 
32
Chapter 3
Abstract
Background Modern metal-on-metal hip resurfacing was introduced as a bone- preserving 
method of joint reconstruction for young and active patients; however, the large diameter of 
the bearing surfaces is of concern for potentially increased metal ion release. 
Patients and methods 71 patients (< 65 yrs) were randomly assigned to receive  either a 
resurfacing (RHA) (n=38) or a conventional metal­on­metal (THA) (n=33) hip arthroplasty. 
Functional outcomes were assessed pre-operatively, and at 6, 12 and 24 months. Cobalt and 
chromium blood levels were analyzed pre-operatively, and at 3, 6, 12 and 24 months. 
Results All functional outcome scores improved for both groups. At 12 and 24  months the 
median UCLA Activity score was 8 in the RHA patients and 7 in THA patients (p<0.05). At 24 
months OHS was median 16 in THA patients and 13 in RHA patients (p<0.05). However, in 
spite of randomization UCLA scores also appeared to be higher in RHA patients at baseline. 
Satisfaction was similar in both groups at 24 months. Cobalt concentrations were statistically 
significantly higher for RHA only at three and six months. Chromium levels remained signifi-
cantly higher for RHA until 24 months. No pseudotumors were encountered in either group 
so far. One RHA was revised for early aseptic loosening and in two THA’s a cup insert was 
exchanged for recurrent dislocation. 
Conclusion RHA patients scored higher on UCLA, OHS and satisfaction at some intervals, 
however, as for the UCLA pre-operative levels were already in favor of RHA. The differences, 
although statistically significant were of minor clinical importance. Chromium blood levels 
were statistically significantly higher for RHA at all follow­up measurements, whereas for 
cobalt this was only observed up to six months. The true value of RHA against THA will be 
determined by longer follow-up and a possible shift of balance between their respective (dis)
advantages.
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Introduction
Hip resurfacing arthroplasty has been proposed as the best treatment option for advanced 
osteoarthritis of the hip in young and active patients, with a component survivorship of 94% 
to 99.8% at three to eight years follow-up.1,2 In comparison to a conventional total hip arthro-
plasty, resurfacing claims several advantages including femoral bone stock preservation, 
better functional outcomes, and lower rates of dislocation.2-4 There is, however, very limited 
evidence available to support these claims. 
Only a limited number of studies have been published in which the clinical results of 
resurfacing and a conventional hip arthroplasty were compared. Most of these studies were 
matched cohort series, since true randomized controlled trials (RCT) are difficult to perform. 
There has been only one RCT where the clinical results of a resurfacing arthroplasty were 
compared with the clinical results a of a 28-mm metal-on-metal hip arthroplasty.5 Both in that 
RCT and in some of the  matched cohort series, a statistically significantly better functional 
score was found in selected outcome parameters for resurfacing at short-term follow-up; 
however, the clinical relevance is argued by the authors.2,6-8 In addition, the higher level of 
activity encountered for resurfacing hip prostheses in some series applies to both pre- and 
postoperative values.6-8 Another confounding factor, especially in the matched cohort series, 
may also have been the profound implant preference in the resurfacing group — which may 
have biased the eventual functional outcome relative to that of a conventional hip arthro-
plasty group.7,9
In contrast to the potential advantage of a resurfacing, there is increasing concern about 
the possible toxic effects of focal and systemic metal ion exposure from these implants. It is 
well recognized that hip arthroplasties with a metal-on-metal bearing lead to an increase in 
blood levels of metal ions, especially cobalt (Co) and chromium (Cr).10-13 High wear from me-
tal bearings may cause severe complica tions such as pseudotumor formation and soft tissue 
necrosis.14-16 In general, one would expect higher release of Co and Cr from resurfacing, with 
a relatively large articulating metal-on-metal bearing, as compared to a regular metal-on- 
metal hip arthroplasty, but there have been no conclusions in the literature about this issue.17 
In the only RCT that has been published (from Canada) clinical results of resur facing 
were compared to those from a conventional 28-mm metal-on-metal hip arthroplasty.5,18 Sin-
ce the amount of metal ion release may play an important role in the eventual outcome and 
revision rate of an implant, we decided to perform a similar trial comparing resurfacing with 
a conventional 28-mm metal-on-metal hip arthroplasty. 
In contrast to the earlier trial,18 besides functional outcome we also assessed the blood 
levels of Co and Cr for both implants with time. In this RCT, we questioned whether the func-
tional results of resurfacing would indeed be superior to a conventional metal-bearing hip 
arthroplasty and whether a large-diameter resurfacing bearing would induce more release of 
metal ions than a similar but relatively small 28-mm bearing. As there is currently a lot of de-
bate in the literature about the potential (dis)advantages of resurfacing, we felt that it would 
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be appropriate to present the data of our exploratory RCT after short-term follow-up.
Patients and methods
Study design and randomization procedure
The present RCT was an exploratory study designed to compare the functional results and 
metal ion blood levels of patients who received a resurfacing total hip arthroplasty (RHA) 
against those from a conventional uncemented metal-on-metal total hip arthroplasty (THA) in 
the short term, medium term, and long term.
From June 2007 through January 2010, 82 patients were randomly assigned to receive 
one of the two hip implants (RHA or THA). A computer-generated variable block schedule 
was used for randomization. The randomization list was generated by an independent sta-
tistician and the resulting treatment allocations were stored in sealed opaque envelopes. 
Randomization occurred at the outpatient consultation by the orthopedic surgeon at the time 
of planning the hip arthroplasty. The patient and surgeon could not be blinded regarding the 
eventual type of implant; neither of them could, however, affect the outcome of randomiza-
tion. 
The criteria for inclusion were patients under 65 years who needed a primary hip replace-
ment for arthritis. Patients were excluded if they had had (previous) infec tion of the hip or at 
other sites, hip fracture, avascular necrosis with collapse, osteo porotic bone mineral density, 
neoplasm, or renal failure. Inclusion and subsequent follow-up of patients is summarized in 
Figure 1. A per-protocol analysis was used in this study, because revised patients cannot 
be followed for metal ions. Five patients (three in the RHA group and two in the THA group) 
were lost to follow­up: directly after operation (n=1), after 12 months (n=3), or after 24  months 
(n=1). Four patients did not participate in all follow­ups because of revision at 12 months 
(n=1) or 24 months (n=2), and one patient did not attend the 24­month follow­up (Figure 1). 
Of the randomized patients, seventy had a minimal follow-up of 12 months: 38 patients in the 
RHA group, and 32 patients in the THA group. We obtained approval from the regional ethics 
committee of Radboud University Nijmegen Medical Center (LTC 419-071206). All patients 
agreed to sign an informed consent statement. The study was performed in compliance with 
the Helsinki declaration and has been registered in EudraCT (2006-005610-12).
Surgical technique
All operations were performed by one of three experienced hip surgeons using a postero-
lateral approach. In the RHA group, a resurfacing prosthesis was implanted with both com-
ponents made of a cast, heat-treated solution-annealed Co-Cr alloy (Conserve® Plus; Wright 
Medical Technology, Arlington, TN). Mean resurfacing femoral head size was 48.7 mm (SD 
3.5). The femoral component was cemented with low-viscosity cement after preparation of 
the femoral head with multiple subchon dral anchor holes, and the HA coated cup was press- 
fitted into the acetabulum. The surgical technique has been described previously.19 In the 
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THA group, an uncemented tapered stem and a threaded titanium cup with a polyethylene 
insert with a metal liner was placed (Zweymüller® Classic; Zimmer Orthopaedics, Warsaw, 
IN) together with a metal 28-mm head (Metasul®; Zimmer Orthopaedics). Both groups re-
ceived identical antibiotic prophylaxis with Cephalosporine pre-operatively and 24 hours 
postoperatively, periarticular ossification prophylaxis using Diclofenac for three days, and 
thrombosis prophylaxis with fraxiparine during hospital admission and until six weeks later. 
Patients were rehabilitated with immediate unrestricted weight bearing according to what 
they could tolerate.20
Figure 1 Consort statement – flow chart of participants throughout the study.
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Clinical evaluation
Questionnaires that included the SF-12, Oxford hip score (OHS), and VAS implant satisfac-
tion were filled in pre­operatively and at 6, 12, and 24 months. The Harris hip score (HHS) 
and the University of California at Los Angeles (UCLA) activity score were assessed by an 
independent member of the research staff (AH). 
Blood levels of cobalt and chromium 
Whole blood samples were collected pre-operatively and at 3, 6, 12, and 24 months postope-
ratively, and assessed for Co and Cr concentrations. Blood was collected in metal-free Va-
cutainers and the first 5 mL was discarded to eliminate metal contamination from the needle. 
Tubes were stored at 2–8°C and sent to the toxicology laboratory of Ghent University Hos-
pital, Belgium for analysis. The metal ion levels in serum and whole blood were determined 
using an inductively-coupled plasma mass spectrometer (ICP-MS).
Since nine patients (five in the RHA group and four in the THA group) with a bilateral 
implant (Figure 3) had double exposure to wear and thus tended to have higher blood levels 
of metal ions, these data are presented separately from those of unilateral implants. Extrac-
ted data from the unilateral group were considered to represent the metal ion concentration 
curves in the RHA and THA groups most reliably. Following the recommendations of Daniel 
et al.,21 we only report on metal ion levels in whole blood.
Statistics
Metal ion data distributions were asymmetric and are expressed as a group median and 
range. Friedman’s ANOVA was used for analysis. To determine the be tween-time differen-
ces with in the groups, we used the non-parametric Wilcoxon signed-ranks test. To protect 
against type-1 error, a Bonferroni correction was applied. To determine differences between 
the two groups and between functional results, we used the Mann-Whitney U test. Symmetri-
cal data are represented by mean and standard deviation (SD). 
In box plots, the outliers are represented by a dot (º) and extreme outliers (more than 
three times deviation of the interquartile range from the upper quartile) are characterized 
by an asterisk (*). Differences were considered statistically significant at p­values of <0.05. 
Lack of information about metal ion levels and functional results because of patients not 
participating in all follow-ups, the small number of patients, and multiple endpoints made 
this an exploratory trial. The results should therefore be read as provisional. Because of the 
exploratory nature of the study, formal adjustment for multiplicity between endpoints was not 
made. All the statistical analyses were performed using SPSS software version 17.0.
Results
The patient characteristics, without statistical significant differences between the two groups, 
are given in Table 1. Mean follow-up for both groups was twenty  months. Of the seventy-one 
patients, we present a follow-up of seventy at one year, and of forty at two years. Mean ope-
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rating time was longer for the RHA group, 77 min as opposed to 57 min (p<0.001). Median 
blood loss was the same for the two groups.
Table 1 Patients characteristics
RHA
(n=38)
THA
(n=33)
Median age in years (range) 58 (24–65) 59 (37–65) 
Mean body mass index (SD) 26 (3.1) 28 (5.1) 
Sex ratio (men:women) 21:17 21:12
Uni- or bilateral MoM prosthesis 33:5 29:4 
Diagnosis (OA/AVN/CHD) a 35/1/2 31/0/2
Charnley category (A/B) 24/14 23/10 
a OA = osteoarthritis; AVN = avascular necrosis; CHD = congenital hip dysplasia. 
Table 2 Clinical scores and satisfaction (VAS), values are median (range) 
Pre-operative 12 months 24 months
RHA
(n=38)
THA
(n=33)
RHA
(n=38)
THA
(n=32)
RHA
(n=19)
THA
(n=21)
Harris hip score 57
(28-77)
53
(25-82)
98
(60-100)
96
(49-100)
96
(63-100)
95
(47-100)
UCLA activity 5 b
(2-10)
4 b
(2-8)
8 b
(4-10)
7 b
(2-9)
8 b
(5-10)
7 b
(2-10)
SF-12 88 b
(59-112)
79 b
(55-113)
107
(71-116)
107
(51-117)
110
(69-117)
110
(51-133)
Oxford hip score 34
(20-46)
37
(21-44)
13
(12-31)
15
(12-40)
13 b
(12-34)
16 b
(12-37)
VAS satisfaction 89 a
(49-100)
82 a
(10-100)
92 b
(52-100)
85 b
(12-100)
92
(37-100)
89
(15-100)
a VAS satisfaction: 6-month value. b Significant difference between resurfacing (RHA) and conventional 
(THA) hip arthroplasty (p≤0.05).
Clinical evaluation
The clinical scores are summarized in Table 2 and Figure 2. In spite of the fact that we 
performed a randomized trial, the pre-operative values of UCLA activity score and SF-12 
were lower in the THA group. The HHS, OHS, UCLA activity score, and SF-12 all improved 
after surgery in both groups (p<0.001). This improvement in clinical scores remained stable 
throughout the 24-month follow-up. At 6 and 24 months, we found a better OHS in the RHA 
group than in the THA group (p=0.04, r=–0.33). The median UCLA activity score was better 
38
Chapter 3
for the RHA group at all three time points with medium effect size (6 months: p=0.01, r=–0.30; 
at 12 months: p=0.002, r=–0.38; and at 24 months: p=0.04, r=–0.32). At 24 months, there 
was one negative outlier in the THA group with a UCLA activity score of 2. This patient has a 
contralateral hip arthritis, which may explain his low activity score since his satisfaction score 
for the operated side was 98/100. RHA patients were more satisfied after 12 months than 
THA patients (p=0.01, r=–0.30); this difference remained but was not statistically significant 
at 24 months.
Figure 2 A Boxplot of Harris hip score. B Boxplot of UCLA activity score. a Significant differences bet-
ween the RHA and THA groups. C Boxplot of SF-12. D Boxplot of Oxford hip score. a Significant differen-
ces between the RHA and THA groups. 
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Since we encountered statistically significantly better functional scores for RHA patients at 
some time points, including the pre-operative one, we also compared the actual improve-
ment in score between groups. In this analysis, statistically significant differences in actual 
improvement in the various clinical scores could no longer be detected. 
Blood levels of cobalt and chromium 
The concentrations of Co and Cr in whole blood of patients in the RHA and THA groups for 
each time point are summarized in Table 3 and Figure 3. As expected, baseline pre-operative 
Co and Cr concentrations were below the reference level of 0.1 μg/L for patients with a uni-
lateral implant (both groups).22 Blood Co and Cr levels increased (p<0.001) in both groups 
after surgery until six months postoperatively, with stable concentrations thereafter. Co con-
centrations were higher for RHA patients than for THA patients only at 3 months (p<0.001, 
r=–0.50) and 6 months (p=0.006, r=–0.35). Co levels stabilized after 6 months in the RHA 
group, and the initially statistically significant difference between groups could no longer be 
detected at 12 months (p=0.1) and 24 months (p=0.1). Cr concentrations were also higher 
in the RHA group, but this time at all time points until 24 months and with a large effect size 
(p<0.001, r=–0.50). We could not establish any correlation between metal ion concentration 
and gender, femoral component diameter, or age.
Four patients (three in the RHA group and one in the THA group) had extremely high levels of 
metal ions at 12 and 24 months (Figure 3). At these time points they had good clinical scores 
with HHS of 98 (95–100), OHS of 13 (12–16), and a median UCLA activity score of 6.5 (6–8). 
These patients will be monitored closely.
Table 3 Whole-blood cobalt and chromium concentrations, values (μg/L) are median (range) 
Pre-operative 6 months 12 months 24 months
RHA THA RHA THA RHA THA RHA THA
Unilateral implants
(n=33) (n=29) (n=33) (n=29) (n=33) (n=28) (n=16) (n=17)
Co 0.1
(0.1-0.8)
0.1
(0.1-0.6)
1.3 a
(0.1-23) 
0.85 a
(0.1-4.0) 
1.25
(0.6-8.3)
1.0
(0.1-4.2)
1.2
(0.5-22)
0.9
(0.1-2.7)
Cr 0.1
(0.1-1.4)
0.1
(0.1-0.1)
1.1 a
(0.1-15) 
0.1 a
(0.1-2.9) 
1.0 a
(0.1-6.1) 
0.5 a
(0.1-2.0) 
1.2 a
(0.1-10) 
0.5 a
(0.1-2.1) 
Bilateral implants
(n=5) (n=4) (n=5) (n=4) (n=5) (n=4) (n=3) (n=4)
Co 0.3
(0.1-1.1)
0.1
(0.1-1.8)
1.7
(1-7.9)
0.85
(0.5-2.2)
1.9
(0.9-11)
1.15
(0.8-1.3)
2.0
(0.7-6.0)
1.4
(0.7-1.8)
Cr 0.1
(0.1-0.9)
0.1
(0.1-0.8)
1.7
(0.1-3.8)
0.25
(0.1-1.5)
2.2
(0.1-4.9)
0.5
(0.1-0.8)
1.5
(0.1-2.3)
0.75
(0.6-0.8)
a Significant difference between resurfacing (RHA) and conventional (THA) hip arthroplasty (p ≤ 0.05). 
40
Chapter 3
Figure 3 A Boxplot Co concentrations of unilateral prosthesis in blood in μg/L. Two extreme outliers are not 
represented for clarity purposes, this concerns two RHA patients at 6 and 24 months with Co concentration 
of respectively 22.80 and 22.00 μg/L. B Boxplot Cr concentrations of unilateral prosthesis in blood in μg/L. 
One extreme outlier was not represented for clarity purposes, this concerns an RHA patient at 6 months with 
a Cr concentration of 14.90 μg/L. a Significant differences between the RHA and THA groups. 
The subgroup of bilateral metal­on­metal implants did not have statistically significantly 
higher metal ion concentrations than the unilateral group, but it should be noted that the 
bilateral subgroup was small (Table 3). One extreme outlier of Co with a concentration of 
10.6 μg/L at 12 months was encountered in a male patient (RHA) with a bilateral implant. This 
patient had a high UCLA activity score of 9, HHS of 98, and an excellent satisfaction score 
of 95/100. There were no statistically significant differences between unilateral and bilateral 
prostheses regarding Co levels (p=0.2) and Cr levels (p=0.8) at 12 months.
Complications
There were three THA patients with recurrent dislocation, for which two patients had an early 
re-intervention with cup insert and head exchange, and there were no dislocations after-
wards. In addition, two early deep infections were encountered in the THA group without 
recurrence of infection after lavage. In the RHA group, one early revision was encountered; 
an early aseptic loosening from avascular necrosis of the femoral head dictated conversion 
to an intramedullary stem with a large femoral head. The metal acetabular cup was kept sin-
ce the patient had been pain­free for two years and the whole­blood Co level was 2.3 μg/L 
prior to revision. 
Discussion
The most important findings of this exploratory study were that after one and two years, 
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Cr concentrations were higher in patients with resurfacing hip arthroplasty, and Co concen-
trations were comparable with those in patients with a conventional arthroplasty. The func-
tional results improved substantially in both groups without any major differences between 
groups. 
The functional results — tested by validated functional scales — showed a  highly signifi-
cant postoperative improvement in both groups, which is in line with other studies.2,3,6-8,12,18,23 A 
limitation of some of these studies was that the pre-operative values of the resurfacing group 
were different from those in the control group.2,6,7 In our RCT, this confounding factor was 
not apparent, as the pre-operative HHS and OHS values were similar. In spite of the rando-
mized nature of the present study, the pre-operative UCLA activity score and SF-12 score 
were higher in the RHA patients. The pre-operative values of the SF-12 in the THA group 
were lower, and the mental part of the SF-12 accounted for this difference. The difference in 
pre­operative SF­12 is difficult to explain; perhaps the THA patients were less satisfied with 
the implant allocated to them. Obtaining the SF-12 result before informing the patient about 
the implant allocated to him or her could perhaps have prevented this confounding variable. 
This idea is also supported by our experience that inclusion for randomization proved to be 
extremely difficult. Generally speaking, patients tended to prefer a resurfacing arthroplasty. 
It was only after considerable explanation that we managed to include 82 patients. The diffi-
culty we encountered in performing a well-designed RCT was also illustrated by the relatively 
high number of exclusions after randomization in the THA group; four patients still decided 
to have further treat ment at another hospital and withdrew from the study after having been 
allocated to total hip arthroplasty.
Some functional outcome scores showed a statistically significant difference in favor of 
the RHA group at certain time points. For example, satisfaction by VAS at 12 months favored 
the RHA group; however, this difference was inapparent at the 24-month follow-up. The OHS 
was also significantly better in the RHA group at 6 and 24 months, with a medium effect size, 
whereas there was no significant difference in the pre­operative baseline levels. The UCLA 
activity score was significantly higher for the RHA group at each time point until 24 months, 
however, it has been noted that this difference also already applies for the pre-operative 
scores, despite the randomization procedure. These findings correspond to those in earlier 
studies. From their large, retrospective comparative study Stulberg et al.23 reported an initial 
advantage in HHS from resurfacing at 6 and 12 months, but the results were comparable 
after 24 months. Higher UCLA activity scores after five to seven years were also described 
for resurfacing in another matched cohort study with THA patients.8 There has only been one 
other RCT comparing resurfacing with conventional metal -on-metal hip arthroplasty.5 The 
authors also reported initial UCLA activity scores in favor of the RHA group. However, in a 
recent three to six year follow­up report of the same study, the statistical significance of this 
difference was no longer apparent.18 In their matched control study, Mont et al. also found a 
significantly better activity level after three years, and no significant differences in HHS and 
satisfaction. They claimed that the activity scores were influenced by higher baseline levels 
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and selection bias from targeted choice of implant.7 Selection bias was excluded in our study 
by randomization; however, patient outcome can still be influenced by patients having recei-
ved their ‘preferred’ implant.
With three patients having a re-intervention, the percentage of early revision in this study 
was 4%. Of these three patients, two in the THA group underwent a relatively simple insert 
exchange for recurrent dislocation and one RHA patient had a femoral component revision 
because of early aseptic loosening from avascular necrosis. Three patients in the THA group 
of 33 patients suffered a dislocation, which is an unusually high percentage. We do not have 
a clear explanation for this phenomenon, and do not recognize this high number from our 
own practice/experience. In two patients, a stabilizing insert exchange was performed after 
CT scanning had revealed proper implant positioning; no dislocations occurred after this 
exchange of insert.
Besides functional results as a measurement of postoperative outcome, determination of 
metal ion levels is becoming increasingly common after metal-on- metal arthroplasties and 
serves as an indicator of bearing performance and device safety.11 High metal ion concen-
trations may lead to adverse biological reactions including local soft tissue toxicity; hyper-
sensitivity reactions; impaired renal, endocrine, and immune function; bone loss; and risk of 
carcinogenesis.14,16 In the present study, initially, resurfacing gave a larger increase in Co and 
Cr concentrations than a 28-mm metal bearing hip arthroplasty. After their respective run-in 
phases, Co blood levels were similar between the two groups at 12 months. Only Cr blood 
levels remained statistically significantly higher in the RHA group at all time points. Since Co 
is known to be relatively toxic compared to Cr, it is important to have esta blished that blood 
Co levels (specifically) stabilize after a run­in phase of six  months, and that the difference in 
blood levels with the THA group in this study could only be established during the first six 
months of follow-up. As compared to most of the published case-controlled or retrospective 
reports on the performance of several types of resurfacing implants,10,11,24 the metal ion le-
vels after unilateral resurfacing in our study appeared to be rather low — with median blood 
levels of Co of 1.3 μg/L and of Cr of 1.2 μg/L. This observation may be an implant­related 
phenomenon. 
The relationship between relatively high metal ions and the need for revision surgery after 
resurfacing has already been explored.25 In spite of this recognized association between 
elevated Co and Cr levels in blood and malfunctioning implants, there is limited information 
about the range of acceptable metal ion concentrations and where toxicity is introduced. 
The best­defined reference values are the exposure equivalent of carcinogenic substances 
(EKA values)26 for industrial workers and those in the Mayo Medical Laboratories interpretive 
handbook.22 The EKA upper limits for Co have been defined to be 5 μg/L in whole blood 
and those for Cr to be 17 μg/L in erythrocytes (as no whole blood upper limits have been 
reported). From their own clinical series with malfunctioning resurfacing implants, De Smet 
et al. proposed an upper acceptable limit of 4.4 μg/L for Co and 5.1 μg/L for Cr in serum.27 
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The median ion levels in the present study were well below this limit, although a few outliers 
were encountered. Since a strong correlation between high metal ion concentrations and 
component wear has been established, forthcoming early revisions can still be expected in 
our group of patients with longer follow-up.25
On theoretical grounds,17 the wear of small- and large-diameter bearings — and therefore 
the metal ion concentrations — should be equal. In the present study, this applied to Co, 
but not to Cr. This is partially consistent with results from the literature.10,13 The medium-term 
follow­up of Moroni et al. showed that after five years there were no differences in metal 
ion concentrations between large-diameter resurfacing hip arthroplasty and small-diameter 
metal -on-metal hip arthroplasty.13 Differences found at 3 and 6 months between RHA patients 
and THA patients (28-mm) for Co — and at all time intervals for Cr — may be attributed to a 
run-in phase. Interestingly, the run-in phase of the small-diameter head in hip arthroplasty ap-
peared to be longer, with a peak at 12 months, while the large-diameter head concentrations 
peaked at 6 months and stabilized thereafter.
In conclusion, we believe that the results of our study are supported by the only other publis-
hed RCT comparing resurfacing with a 28-mm conventional hip arthro plasty.18 The strength 
of our study compared to that study is that we combined clinical follow-up with prospective 
evaluation of metal ion levels. In addition, two independent RCT’s with comparable outcome 
lead to an increase in the level of evidence of the findings. On the other hand, there are also 
clear limitations to our study. Inclusion of patients proved to be extremely difficult, and the 
number of patients available was therefore limited. Due to the limited number of patients, we 
can only present our data as an exploratory trial, mainly because it had insufficient power 
to allow us to draw firm conclusions, but also because the report deals with a short­term 
follow-up. Especially in the light of reports in the literature on a peak in revi sions after resur-
facing at three years of follow-up,25 we can expect that more revi sions in the RHA group will 
appear. Also, from the fact that at 24 months after surgery we encountered some clinically 
well-functioning resurfacings with relatively high levels of metal ions, these patients may still 
become symptomatic in the near future and the revision rate may increase. We will continue 
to monitor these patients with repeated metal ion measurements and functional assessment. 
Longer follow-up of these two groups of patients may help us to understand the potential 
advantages and disadvantages of resurfacing compared to conventional arthroplasty.
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Abstract
Background and purpose Hip resurfacing arthroplasty (RHA) is done in patients who often 
have a high preference for the method. This preference can influence the clinical outcome 
and satisfaction. We evaluated the potential influence of this preference bias. 
Patients and methods From an ongoing randomized trial comparing RHA with total hip arthro-
plasty, 28 consecutive patients (28 hips) who had been allocated to an RHA were charac-
terized as the ‘randomized’ group. Twenty-two other patients (24 hips) who had refused 
participation and had especially requested an RHA were characterized as the ‘preference’ 
group. Harris hip score (HHS), Oxford hip score (OHS), University of California at Los Ange-
les activity scale (UCLA), Short Form 12 (SF-12), and visual analog scale satisfaction score 
(VAS) were assessed in both groups. 
Results Both groups had a high implant satisfaction score (97/100 for the ‘preference’ group 
and 93/100 for the ‘randomized’ group) at 12 months. The HHS, OHS, and UCLA were similar 
at baseline and also revealed a similar improvement up to 12 months (p<0.001). Regar-
ding the SF-12, the ‘preference’ group scored lower on the mental subscale pre-operatively 
(p=0.03), and there was a greater increase after 12 months (p=0.03). 
Interpretation We could not show that there was any influence of preference on satisfaction 
with the implant and early clinical outcome in patients who underwent RHA. The difference 
in mental subscale scores between groups may still indicate a difference in psychological 
profile. 
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Introduction
The outcome of any surgical treatment is influenced by several factors. Apart from the surgi-
cal intervention itself, co-morbidities and postoperative rehabilita tion — and also factors such 
as patients’ perception, confidence, and expectations — contri bute to the final result and 
patient satisfaction. Nowadays, most patients have access to the internet and other sources 
of information, and are well-informed. Their conceptions will lead beliefs and expectations, 
which will in turn lead to preferences. Preference for a specific treatment can influence the 
outcome,1-6 and can introduce bias into assessments of satisfaction and acceptability. This 
might be a confounding factor in a trial, and may affect the validity of the results. To obtain 
hard evidence of any possible preference effects is problematic, as it is difficult to reliably 
distinguish between simple therapeutic effects and preference effects mediated through psy-
chological pathways in experiments.7 
The dilemma of a possible influence of preference is frequently encountered in studies in 
orthopedic surgery. For example, the interest in resurfacing hip arthro plasty (RHA) has grown 
in the past 15 years8-10 and has received much international attention. The results reported 
regarding the short-term and long-term follow-up of RHA appear to correspond with the re-
sults of conventional total hip arthroplasty (THA)11-16 and the satisfaction rates reported have 
been 90–100%.14,15,17 Hip re surfacing surgeons generally deal with patients with a profound 
preference for this particular implant. We have not found any studies that have incorporated 
the possible influence of preference of the patient for an RHA into their results, and it can be 
speculated whether these results are influenced by this preference and perception on the 
part of the patients. 
In an ongoing randomized trial comparing RHA with conventional THA, we encountered 
— as expected — some difficulty in recruiting patients for inclusion,  since several patients 
had a specific demand for RHA. In this way, RHA’s were performed in two groups of pa-
tients: (1) an unbiased ‘randomized’ group without any preferences, willing to participate in 
the ongoing trial, and simply allocated to RHA; and (2) a ‘preference’ group of potentially 
biased patients with a specific demand for RHA and who declined participation in the trial. 
We could therefore evaluate the potential role of preference bias on implant satisfaction and 
early clinical outcome. We hypothesized that patients in the ‘preference’ group would be 
more satisfied than the patients in the ‘randomized’ group. On the other hand, patients with 
a high degree of preference could have such high expectations of the treatment that they 
might be difficult to fulfill, which would lead to lower satisfaction compared to patients without 
any preference. 
Patients and methods
From April 2007 through March 2010, patients under 65 years with primary osteo arthritis of 
the hip were evaluated for eligibility to enter the randomized controlled trial (RCT) comparing 
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RHA with THA. After having given informed consent, patients with a strong preference for 
RHA (and who were therefore unwilling to be randomized) entered the prospective cohort 
study — the ‘preference’ group. Patients with no preference were enrolled in the RCT to recei-
ve either an RHA or a THA. The current study included all patients in the ‘preference’ group 
and all patients in the RCT who were allocated to RHA, with a minimum follow-up of 6 months. 
The criteria for inclusion in both the RCT and the cohort were identical: patients between 
35 and 65 years old, eligible for primary hip replacement because of osteo arthritis, conge-
nital hip dysplasia, or posttraumatic arthritis. Patients were excluded in case of (previous) 
infection of the hip, hip fracture, avascular necrosis with collapse, osteoporotic bone mineral 
density index levels of the involved hip (t-score <2.5), renal failure, or hip revision of the pri-
mary index procedure. 
All patients received a Conserve® Plus RHA (Wright Medical Technology, Arlington, TN). 
The operations were performed through a standard posterolateral approach by a senior hip 
surgeon with considerable experience in RHA implants.18 Both groups received identical 
antibiotic prophylaxis, periarticular ossification prophylaxis, and thrombosis prophylaxis du-
ring hospital admission, and six weeks afterwards. The patients had identical rehabilitation 
protocols with unrestricted weight bearing according to individual tolerance, starting on the 
first postoperative day. 
Table 1 Demographics of patients
‘Preference’ group 
(n=24)
‘Randomized’ group
(n=28)
p-value
Age, median (IQR) 52 (48-56) 58 (52-62) 0.01
Sex ratio (men:women) 15:9 13:15 0.2
Diagnosis (OA/AVN/CHD) a 24/0/0 26/1/1 0.5
a OA = osteoarthritis; AVN = avascular necrosis; CHD = congenital hip dysplasia.
Figure 1 Recruitment of patients to the study.
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Fifty patients were included in the study, with 28 implants (28 patients) in the ‘randomized’ 
group and 24 implants (22 patients) in the ‘preference’ group (Table 1 and Figure 1). All pa-
tients in the ‘preference’ group and 22 of the 28 patients in the ‘randomized’ group completed 
the follow-up term of 12 months. The remaining six patients had a follow-up of 6 months. 
All patients completed a questionnaire that included the Short Form 12 (SF-12) and Oxford 
hip score (OHS) pre-operatively, at 6 months, and at 12 months. The Harris hip score (HHS) 
and the University of California at Los Angeles activity scale (UCLA) were assessed by an 
independent member of the research staff (AH) who collected and registered all the forms. 
Satisfaction with the implant was measured on a numeric scale (visual analog scale satisfac-
tion score (VAS)) of 0–100 mm, where 100 mm corresponded to being completely satisfied. 
Approval for the randomized clinical trial and the cohort follow-up was obtained from the 
regional ethics committee of the Radboud University Nijmegen Medical Centre, with issue 
number LTC 419-071206 and date of approval 01/02/2007. All patients agreed to sign an 
informed consent document. The EudraCT number assigned to the randomized controlled 
trial was 2006-005610-12. 
Statistics 
Variables were checked for normal distribution with the Shapiro-Wilk test. A value of <0.05 
was defined as the absence of a normal distribution. The mean and standard deviation (SD) 
were used for normally distributed variables and the median and interquartile range (IQR) 
for variables without normal distribution. Differences be tween the groups were determined 
by the Student’s t-test for variables with normal distribution, the Mann-Whitney test for va-
riables without normal distribution, and the Pearson Chi-square test for categorical varia-
bles (sex and diagnosis). Variables that were not normally distributed were: age, blood loss, 
the pre-operative OHS and UCLA scores, the VAS satisfaction score at 12 months, and the 
change in satisfaction score between 6 and 12 months. These p-values are marked with the 
super script ß. Significance was defined as p­values of <0.05. SPSS software version 15.0 
was used for statistical analysis. 
Results
The characteristics of the patients are given in Table 1. Both groups were similar regar-
ding sex and diagnosis, but the patients in the ‘preference’ group were younger than in the 
‘randomized’ group. Mean operation time (‘preference’ group: 81 min (SD 15); ‘randomized’ 
group: 76 min (SD 11); p=0.2) and median blood loss (‘preference’ group: 300 mL (288–313); 
‘randomized’ group: 300 mL (200–300); p=0.4β) were similar in both groups. Similar implants 
sizes were used in both groups (p=0.70).
The pre-operative HHS, OHS, and UCLA scores were similar in both groups (Figure 2). 
The SF-12 score, however, was higher (88 (SD 14)), in the ‘randomized’ group than in the 
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‘preference’ group (80 (SD 12)) (p=0.03). This difference mainly originated from intergroup 
differences in the mental subscale. A mean score of 47 (SD 13) on the mental subscale was 
found in the ‘preference’ group, as opposed to 53 (SD 10) in the ‘randomized’ group (p=0.05).
Figure 2 Clinical scores (HHS, Oxford, SF­12 and UCLA) with 95%­confidence interval pre­operatively, 
at 6 and 12 months. * In the horizontal axis of the SF­12 score represents a significant difference at base­
line pre-operative scores (p<0.05). 
The HHS, OHS, and UCLA scores all showed a postoperative improvement at 12 months 
compared to the pre-operative baseline scores for both groups (p<0.001) (Figure 2). These 
improvements were similar between the groups (p=0.8, p=0.7, and p=0.4, respectively). For 
the SF-12, however, at 12 months a better recovery was achieved from pre-operative levels 
in the ‘preference’ group than in the ‘randomized’ group (p=0.03). Patient satisfaction (VAS) 
was assessed at 6 and 12 months for both groups. Both groups had a high satisfaction 
 score, with a median of 97 for the ‘preference’ group and 93 for the ‘randomized’ group at the 
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12­month follow­up (p=0.7β). Similar scores were obtained at the 6-month follow-up. 
Two complications occurred in the ‘preference’ group. One patient had a perioperative collum 
fissure with a delayed, but uneventful, recovery — and with clinical and satisfaction scores 
that matched within the interquartile range. Another patient had complaints of possible ante-
rior impingement of the RHA. This patient had clinical and satisfaction scores that dropped 
below the interquartile range. With exclusion of both patients, the median satisfaction score 
remained at 97 for the ‘preference’ group and 93 for the ‘randomized’ group (p=0.6β). With 
this exclusion, there were minimal changes in clinical scores, but with no consequences for 
the differences between the ‘preference’ group and the ‘randomized’ group (p=1.0, p=0.9, 
p=0.3, and p=0.01 for HHS, OHS, UCLA, and SF­12, respectively). The other 50 RHA’s all 
had an uneventful clinical course. 
Discussion
In this prospective comparative study, patient satisfaction and early clinical outcome in 
 ‘biased’ patients with a high preference for resurfacing hip arthroplasty (the ‘preference’ 
group) did not differ statistically significantly from the results in un biased patients who were 
simply allocated to an RHA after randomization in a separate randomized controlled trial (the 
‘randomized’ group). There was, however, a trend toward better satisfaction in the ‘preferen-
ce’ group. Only for the pre-operative SF-12 values, and for the mental subscale in particu-
lar, was any statistically significant difference between groups encountered, in favor of the 
‘randomized’ group. 
In spite of the fact that the potential bias from treatment preferences is a well- recognized 
phenomenon in orthopedic practice, there have only been a few studies dealing with this 
clinical dilemma. Van der Windt et al.,3 for example, demonstrated a success rate of 85% in 
patients with shoulder pain who received their preferred therapy compared to a 64% success 
for those who underwent the same treatment against their preference. In another study,5 any 
direct influence of preference for a certain therapy on shoulder pain could not be confirmed; 
however, the authors revealed that in general patients with a preference before randomi-
zation tended to have a better overall outcome than those with no preference. 
Randomized controlled trials are usually regarded as the gold standard in comparing two 
therapeutic treatments, as they diminish possible confounding factors. To study the poten-
tial influence of preference bias on the outcome of one and the same surgical procedure, 
randomization is, however, not a feasible tool for obvious reasons. Our randomized controlled 
trial on THA and RHA confirmed for us the existence of patient preference for RHA; it was 
difficult to recruit patients for the trial. Many patients had a preference for RHA even after 
being informed about the absence of any evidence in the literature of a benefit of RHA over 
a conventional THA.15,16 The presence of a cohort of patients with a clear preference for RHA 
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and a group of patients allocated to RHA after randomization enabled us to gain some insight 
into the possible role of preference bias. 
Our study had some limitations, however. The number of patients in both groups was 
small, eventually resulting in a power of 59% to detect a clinical significant difference of 10 
on the VAS for patient satisfaction in a post hoc power analysis. A power of 80% was calcu-
lated to detect a difference of 13 on the VAS for patient satisfaction. Clearly, there was a small 
difference in outcome between the groups and a larger number of patients may eventually 
have revealed a statistically significant difference in patient satisfaction between the groups. 
On the other hand, the power in our study was substantial enough for us to question whether 
such a difference would have been of clinical importance. 
Another limitation of our study may have been the short follow­up. However, Khan et al. 
evaluated the Birmingham hip arthroplasty in a five to eight year follow­up study and de-
monstrated that the satisfaction rate did not change substantially after the first postoperative 
year.14 Lingard et al. also showed a ceiling effect after one year.17 In addition, it is debatable 
whether a potential difference in satisfaction after one year would be influenced by prefe-
rence, because expectations would be most manifest in the short period after the operation. 
Two patients with a bilateral prosthesis were included. One must assume that the outco-
me of two prostheses in the one patient cannot be interpreted independently. The result of 
the first prosthesis can either positively or negatively influence the outcome of the second, 
and vice versa.19 Study outcome in general may be biased by this phenomenon; however, 
the number of bilateral prostheses in our study was low and exclusion of the two patients 
with bilateral prostheses did not have any consequences for our findings (data not shown). 
Apart from the presence or absence of a profound preference for an RHA, both groups 
matched regarding most demographic features and pre-operative functional scores. The 
size of the femoral component of the implant was similar in both groups. This is important, as 
component size is known to influence the outcome of RHA.20,21 
The only differences between the groups were age and pre-operative SF-12 score. The 
difference in age between the groups suggests that younger patients are less willing to parti-
cipate in a randomized clinical trial. As for the SF-12, and for the mental subscale in particu-
lar, patients in the ‘preference’ group had a lower pre-operative score. There were no outliers 
that could explain this difference between the groups. One could argue whether there is 
reason to believe that patients with a high preference for a certain treatment generally have 
a different psychological profile than patients who are willing to participate in a randomized 
trial. This finding has been recognized before.2
In conclusion, we could not demonstrate any influence of preference on implant satisfaction 
and early clinical outcome in patients with an RHA. A trend towards a relatively higher degree 
of satisfaction was nevertheless established for patients with a specific request for RHA. The 
significant difference in mental subscale scores encountered between groups may indicate 
a difference in psychological profile. 
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Abstract
Metal ions generated from joint replacements are a cause for concern. There is no con-
sensus on the best surrogate measure of metal ion exposure, both serum and whole blood 
measurements are used in clinical practice. This study provides a guideline for interpretation 
of metal ion analysis in clinical practice. In a prospective  trial comparing hip resurfacing 
(RHA) with a conventional metal-on-metal (MoM) total hip arthroplasty (THA) cobalt and chro-
mium levels were determined for whole blood and serum in 343 paired samples at regular 
intervals up to 24 months postoperatively. Cobalt whole blood and serum levels increased 
significantly after either implant. Cobalt concentrations were significantly higher for the RHA 
group, as compared to the THA group, at 3, 6 and 12 months for whole blood and serum. At 
24 months cobalt levels decreased and differences between RHA and THA were no longer 
significant. In contrast, chromium whole blood levels remained significantly higher for RHA 
until 24 months. Whole blood and serum levels could not be used interchangeably. The mean 
difference for cobalt and chromium between blood and serum values were +0.13 µg/L and 
-0.91 µg/L respectively. Regression analysis provided a formula for conversion from serum 
to blood of 0.34 + [0.88 * Co serum] for cobalt and 0.14 + [0.58 * Cr serum] for chromium, 
with an acceptable prediction error below ±1.0 µg/L. Cobalt and chromium levels were sig-
nificantly higher for RHA versus THA, especially during the run­in phase of one year. Overall, 
the metal ion levels were well below 5 µg/L. We cannot recommend the use of whole blood 
over serum measurements or vice versa. The provided conversion formula between whole 
blood and serum in combination with the presented practical guidelines may be useful for 
clinical practice. 
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Introduction
Hip resurfacing (RHA) has been re-introduced as an attractive bone preserving  treatment 
option for young patients with osteoarthritis. In addition, ‘in vitro’ studies on the metal-on- 
metal (MoM) articulation revealed a twenty-fold reduction of volumetric wear in comparison 
with metal-on-polyethylene.1,2 The relatively small size of these metal particles (6-834nm)3 
accounts for this decrease in volumetric wear, since the total number of particles is higher. 
Liberated metal ions may bind to proteins and cells1,4 and can be transported elsewhere, 
resulting in elevated levels in blood, serum and urine.2,5-7 These elevated systemic metal ion 
levels are a cause for concern. Reports of hypersensitivity reactions,8,9 osteolysis9,10 and the 
growth of liquid or solid soft tissue reactions11,12 are available. There is increasing evidence 
that elevated levels of metal ions (especially cobalt) may have adverse long term systemic 
effects including polyneuropathy, cardiomyopathy and hypothyroidism.13,14 The uncertainty 
about the consequences of these elevated metal ion levels has raised concerns and dimin-
ished the use and acceptance of MoM bearings. 
In the United Kingdom, the Medicines and Healthcare Products Regulatory Agency 
(MHRA) has produced guidelines regarding the monitoring of systemic ion levels, and assay 
is recommended in cases with pain, adverse radiological abnormalities and small compo-
nent head size. Metal ion measurements and a knowledge of their interpretation have thus 
become important. 
Various matrices, such as whole blood (WB), serum (SE) and urine can be used. Analy-
ses in whole blood or serum is preferable, since urine requires a 24-hour collection and the 
levels seem to be more variable due to variation in hydration of the patient.15 Metal ion levels 
after different MoM hip implants have been reported.16-19 However, most studies report on ei-
ther metal ion concentrations in whole blood or serum, and data on repeated measurements 
over time are scarce, resulting in a lack of knowledge of how levels evolve over time. There 
may be superiority of serum over whole blood measurements, but whether these two levels 
can be correlated is not fully understood. 
The aim of our study was to present prospective follow-up of cobalt (Co) and chromium 
(Cr) levels in both whole blood and serum in a group of patients with an RHA versus a con-
ventional MoM total hip arthroplasty (THA). In addition, a conversion formula was generated 
to calculate serum from whole blood metal ion levels and practical guidelines were develo-
ped for clinical use in the interpretation of metal ion levels.
Patients and methods
Between May 2007 and April 2010 97 patients were prospectively followed in  ei ther a randomi-
zed controlled trial (RCT) comparing an RHA to a conventional MoM THA, or they participated 
in the cohort of RHA patients. Approval for both RCT and cohort was obtained from the regio-
nal ethics committee of the Radboud University Nijmegen Medical Centre (LTC 419-071206). 
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All patients agreed to sign an informed consent. 
Table 1 Demographic data of the study population 
RHA
(n=60)
THA
(n=32)
p-value
Gender (men:women) 36:24 20:12 1.000 b
Median age in years (range) 55.3 (25-65) 59.1 (36-65) 0.106 c
Mean body mass index in Kg/m2 (SD) 26.6 (4.8) 27.9 (5.2) 0.243 d
Pre-operative diagnosis (OA/AVN/CHD) a 57/1/2 30/0/2 0.786 e
Charnley category (A/B1/B2) 36/14/10 23/5/4 0.285 e
Mean operating time in minutes (SD) 78.1 (12.9) 55.5 (12.0) <0.001 d
Median blood loss in mL (range) 300 (100-600) 275 (100-900) 0.653 c
a OA = osteoarthritis; AVN = avascular necrosis; CHD = congenital hip dysplasia. b Fisher’s exact proba-
bility test, c Mann-Whitney U test, d Student’s t-test. e Kruskall­Wallis test.
Table 2 Demographic data of specimens
Cobalt
(n=79)
Chromium
(n=72)
Gender (men:women) (p-value) 48:31 (0.056) 39:33 (0.480)
Median femoral component size of RHA (range) 48 (42-54) 48 (42-54)
Total number of specimen 343 343
Number of specimen included 213 191
Below detection limit 130 152
Conserve/Metasul/Bilateral/No prosthesis 149/58/53/6 147/40/45/4
All patients under the age of 65 were asked to participate in the ongoing RCT. Patients who 
preferred not to participate but who requested RHA were followed in a separate cohort. Co 
and Cr levels were prospectively analysed in both whole blood and serum at consecutive 
time intervals. In the RHA group a resurfacing prosthesis was implanted with both compo-
nents made of a cast, heat-treated solution-annealed Co-Cr alloy (Conserve® Plus; Wright 
Medical Technology, Arlington, Tennessee, USA). Mean resurfacing femoral head size was 
48 mm (range 42-54). In the THA group, an uncemented tapered stem and a threaded ti-
tanium cup with a polyethylene insert with a metal liner was inserted (Zweymüller® Classic; 
Zimmer Orthopaedics, Warsaw, Indiana, USA) together with a metal 28 mm head (Metasul®; 
Zimmer Orthopaedics, Warsaw, Indiana, USA). A total of 343 paired whole blood and serum 
specimen were collected pre-operatively and at 3, 6, 12 and 24 months in 97 patients. 92 
patients had a follow-up of more than 3 months. Metal ion levels below the detection limit of 
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0.5 μg/L were excluded in the statistical evaluation of the correlation between whole blood 
and serum levels and in generating a conversion formula. After exclusion of these baseline 
levels below the detection limit 213 Co specimens and 191 Cr specimens remained in 79 
and 72 patients respectively. Demographic data of the study population and specimens are 
given in Table 1 and 2.
Cobalt and chromium blood levels
Blood samples were collected in metal­free vacutainers, the first 5 mL blood being discarded 
to eliminate metal contamination from the needle. A 6 ml BD ‘EDTA’ and a 5 ml ‘SST II Advan-
ce’ vacutainer system (Franklin Lakes, New Jersey, USA) was used for blood collection. After 
blood collection the tube with clot activator was set at rest for a minimum of 30 minutes and 
was then centrifuged at 3600 rpm for ten minutes. Both tubes were stored at a maximum of 
4°C and sent within 7 days to the laboratory of Toxicology of the University Hospital Ghent 
(Belgium) for analysis. The metal ion levels in serum and whole blood were determined using 
an induc tively-coupled plasma mass spectrometer (ICP-MS) on a Perkin Elmer Elan DRC-e, 
equipped with a standard cross­flow nebuliser and a Dynamic Reaction Cell (Perkin Elmer 
SCIEX, Canada).
Statistical analysis
Since metal ion data are not normally distributed they are represented by the median, and 
a non-parametric test (Mann-Whitney U) was used for analysis. The agreement between 
whole blood and serum levels was assessed with mean difference, regression analysis and 
the Bland-and-Altman limits-of-agreement between methods of measurement with multiple 
observations per individual, as is proposed by Bland-and-Altman.20 In this study several 
measurements in the same patients were used. Therefore we used the modification from 
Bland-Altman with adjustment for the repeated measurements.21 
The multiple observations per individual can have influence on the re gres sion analysis. 
Therefore prior to this analysis a mixed model analysis was used to analyse the influence of 
the repeated measurements on the linear regression. The Null Model Likelihood Ratio Test 
showed a p­value of >0.05 for all tests, indicating that there is no significant difference be-
tween a regression with ignorance of the re peated measurements and the regression with 
adjustment for the repeated measure ments. As a result the simple linear regression with the 
equation ‘whole blood level = α+β*serum level’ was used for all analyses in this study. To vali-
date our regression equation we randomly split the database into two. The patients in the first 
section were used to calculate a regression equation which could be tested on the second 
section. The data was processed in SPSS (Version 15.0 SPSS Inc. Chicago, IL) and analysed 
for statistical differences. Statistical significance was set at p≤0.05.
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Results
RHA versus THA metal ion levels
Patient characteristics are described in Table 1. The mean operating time was  longer for RHA 
(p<0.001), but median blood loss was equal between the two groups.
The concentrations of Co and Cr in whole blood and serum for RHA versus THA for each 
time interval are summarised in Table 3 and Figures 1A and 1B. Baseline pre-operative Co 
and Cr concentrations were, as expected, below the detection level of 0.5 μg/L for both 
groups. 
Table 3 Cobalt and chromium concentrations
Pre-operative 6 months 12 months 24 months
RHA THA RHA THA RHA THA RHA THA
Cobalt
(n=60) (n=32) (n=51) (n=30) (n=42) (n=23) (n=21) (n=8)
WB 0.10
(0.1-2.7)
0.10
(0.1-1.8)
1.30 a
(0.1-10.6)
0.90 a
(0.1-4.0)
1.40 a
(0.6-11.5)
1.10 a
(0.1-2.2)
1.20
(0.7-16.3)
1.00
(0.1-1.6)
SE 0.10
(0.1-2.6)
0.10
(0.1-1.3)
1.20 a
(0.1-11.4)
0.65 a
(0.1-4.1)
1.30 a
(0.1-11.4)
0.80 a
(0.1-1.9)
1.50
(0.7-17.6)
0.70
(0.1-1.4)
Chromium
(n=60) (n=32) (n=51) (n=30) (n=42) (n=23) (n=21) (n=8)
WB 0.10
(0.1-4.2)
0.10
(0.1-0.8)
1.20 a
(0.1-5.9)
0.10 a
(0.1-2.9)
0.90
(0.1-6.0)
0.40
(0.1-1.9)
1.10 a
(0.1-8.4)
0.55 a
(0.1-2.1)
SE 0.1
(0.1-2.7)
0.1
(0.1-2.9)
1.90 a
(0.1-8.8)
0.60 a
(0.1-4.9)
2.30 a
(0.1-10.2)
0.90 a
(0.1-2.9)
1.90 a
(0.9-14.4)
0.85 a
(0.1-3.4)
Values (μg/L) are given as the median (range). WB = whole blood, SE = serum. a Significant difference 
between RHA and THA (Mann-Whitney signed-rank).
Co whole blood and serum levels increased after implantation of an RHA (p<0.001) and a 
THA (p=0.015 (WB) and p=0.002 (SE)). Co concentrations were higher for HR compared 
to THA at 3, 6 and 12 months for whole blood (p<0.001, p=0.001, p=0.026) and serum 
(p<0.001, p<0.001, p=0.007). At 24 months Co levels stabilised and the initially statistically 
significant difference between HR and THA could no longer be detected for whole blood 
(p=0.082) and serum (p=0.53). Postoperative Cr levels of RHA patients increased compared 
to the pre-operative levels for whole blood and serum (p<0.001). The THA patients showed 
a solitary increase for serum (p<0.001), while whole blood concentrations remained stable 
(p=0.243). Cr concentrations were higher for RHA at 3, 6 and 24 months for whole blood 
(p<0.001, p<0.001, p=0.021), and at all follow­up intervals for serum (p<0.001).
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Figure 1 A Error­plot (median and IQR) cobalt concentrations in whole blood and serum in μg/L. 
B Error­plot (median and IQR) chromium concentrations in whole blood and serum in μg/L.
Whole blood versus serum
Demographics of specimen­specific patient data are given in Table 2. The mean difference 
between serum and whole blood was +0.13 μg/L for Co (95%­CI:0.03;0.22) and ­0.91 μg/L 
for Cr (95%­CI:­1.05;­0.77). There was a statistically significant difference between whole 
blood and serum levels for Co (p=0.01) and Cr (p<0.001). Despite this difference, Co and 
Cr levels in whole blood and serum were highly correlated: Co R=0.936 (p<0.001) and Cr 
R=0.937 (p<0.001).
A Bland­and­Altman analysis showed limits­of­agreement of +1.5 μg/L and ­1.25 μg/L 
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with a mean difference of +0.13 μg/L for Co (Figure 2A). This means that Co levels in whole 
blood are on average +0.13 μg/L higher compared to serum and that 95% of these differen-
ces between blood and serum levels appeared to be between +1.5 μg/L and ­1.25 μg/L. 
For Cr the correlation between whole blood and serum levels was obscured by an increase 
in difference at higher mean concentrations. There was a mean difference between whole 
blood and serum of ­0.91 μg/L with relatively wide limits­of­agreement between +0.95 μg/L 
and ­2.85 μg/L. The tendency of an increase in difference between whole blood and serum 
at higher mean concentrations is visualised by a diagonal trend in the Bland-Altman plot 
(Figure 2B). 
Figure 2 A Cobalt stan-
dard Bland-Altman plot.
B Chromium standard 
Bland-Altman plot. In both 
graphs the black line illu-
strates the mean difference 
between metal ion levels 
in serum and whole blood 
and the two gray parallel li-
nes illustrate subsequently 
indicate the 1.96 standard 
deviation of this difference 
or ‘limits-of-agreement’.
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We calculated a conversion formula for serum metal ion levels into whole blood metal ion le-
vels by regression analysis. The following formula was established for cobalt: Co whole blood 
= 0.34 + [0.88 * Co serum], and for chromium: Cr whole blood = 0.14 + [0.58 * Cr serum].
Figure 3 A Predicted co-
balt levels compared to 
the actual blood levels. 
B Predicted chromium 
levels compared to the 
actual blood levels. In 
both graphs the black line 
illustrates the mean diffe-
rence between predicted 
and real metal ion levels 
in serum and whole blood 
and the two gray parallel li-
nes illustrate subsequently 
indicate the 1.96 standard 
deviation of this difference 
or ‘limits-of-agreement’.
Validation of prediction model blood versus serum
In order to validate the conversion formula, we randomly divided our database in two. A 
similar regression analysis on half of the database provided a conversion formula which was 
subsequently tested on the second half of the database. The newly obtained conversion 
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formulae were Co whole blood = 0.29 + [0.89 * Co serum] and Cr whole blood = 0.21 + 
[0.54 * Cr serum]. Serum levels from the second half of the database were used to predict 
 whole blood levels, and compared to the actual measured values. The Bland-Altman test was 
computed as the difference between the measured and predicted value (Figures 3A and B). 
The mean difference be tween measured and predicted values of Co and Cr was 0.0 μg/L. 
Limits-of-agreement for the difference between predicted and measured Co whole blood le-
vels were +0.77 μg/L and ­0.84 μg/L. In relation to Cr these limits were +0.92 μg/L and ­0.98 
μg/L. There was no difference between predicted and actual measured whole blood values 
of Co (p=0.411) and Cr (p=0.561).
Discussion
The evaluation of metal ion levels is becoming increasingly important after a MoM hip arthro-
plasty and serves as an indicator of bearing performance and device safety.19 In this study, 
RHA revealed a higher initial increase in Co and Cr concentrations than a conventional MoM 
28mm THA. After a run-in phase, this difference in Co levels between the two groups resol-
ved, but Cr levels were still higher for the RHA group. Because Co is known to be a relatively 
toxic ion,13,22 it is important to note that Co levels decrease after a run-in phase of 12 months. 
It is clear from our observations that increased metal ion levels are not exclu sively seen 
in RHA patients, and over time metal ion levels after RHA may approach values following a 
MoM THA. These findings are consistent with previous reports; which suggest that after five 
years there is no difference in metal ion concentrations following large-diameter resurfacing 
and a small-diameter MoM THA.17
Unlike some reports following the use of a variety of RHA devices, the metal ion levels 
following both RHA and THA used in our study appeared to be rather low.16,17,19 Implant- 
related differences are present in metal ion release and this should be taken into account as 
one of the confounding factors in the interpretation of our results. Furthermore, it has to be 
recognised that the mechanism and source of metal debris may also be different for RHA 
compared to MoM THA. In general metal ions and particles are generated both by wear from 
the articulation and by corrosion. In addition to metal ion release from the bearings, a THA 
may create metal debris from the taper junction with the head. This may thus have influenced 
metal ion concentrations in peripheral blood in the THA group However, the source of metal 
ion release should not influence the relationship between metal ion levels in serum versus 
whole blood as evaluated in our study. Metal ion levels may be influenced by renal excretion, 
protein binding and transport, and extremely high levels of Co may occur in patients with 
renal dysfunction, and therefore MoM bea rings are contraindicated in these patients.23 High 
levels can also be related to other sources of metal ion release, such as mechanical heart 
valves, orthodontic implants, medical or nutritional supplements containing metal ion ‘equi-
valents’ or environmental and/or occupational sources of metal contamination. All patients in 
our study were carefully monitored for the potential presence of these other sources of metal 
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ions. These confounding factors should always be taken into consideration when confronted 
by high metal ion levels, and remain an obstacle in the interpretation of metal ion levels.
Regarding the differences between serum and whole blood, Co serum levels were slightly lo-
wer or equivalent to whole blood, which was represented by a mean difference of only +0.13 
μg/L. For Cr, serum levels were relatively high compared to  whole blood, indicated by a mean 
difference of ­0.91 μg/L. Our results correspond with earlier data from Walter et al, who found 
little difference between whole blood and serum for Co, but higher serum levels compared 
to whole blood for Cr.6 Studies that examine the difference between metal traces in whole 
blood and serum are rare. Daniel et al. studied the suitability of whole blood and serum for 
measurement of ion levels, but the limits-of-agreement between whole blood and serum for 
Co and Cr were relatively wide as compared to our data with +3.8 μg/L; ­2.2 μg/L for Co and 
+8.4 μg/L; ­4.2 μg/L for Cr.7 This finding may be explained by differences in collection and 
processing of the samples, and the fact that Daniel et al. studied a group of miscellaneous 
types of resurfacing implants each with unique metallurgy.24,25 
Daniel et al. suggested whole blood as a superior matrix over serum metal ion measu-
rements,7 but from our data we cannot recommend whole blood over serum or ‘vice versa’. 
From a practical point of view, the use of whole blood may be preferred, since whole blood 
can be sent to the laboratory without separation of serum, a step which can introduce pollu-
tion to the sample. The option of a conversion formula to extrapolate serum to whole blood 
metal ion levels is attractive for obvious reasons. Based on the wide limits-of-agreement 
of the Bland-Altman plot we do not believe that the two blood fractions can be used inter-
changeably. However, conversion between whole blood and serum remains possible. The 
conversion formulae, as provided in this study, can be used with limits-of-agreement that are 
within acceptable range (Figures 3A and B). For both metal ions the whole blood and serum 
levels could be predicted from one another with a prediction error below 1.0 μg/L. The pre-
diction error is obtained from testing on a homogeneous group of patients, and verification 
on a heterogeneous group might be helpful. The conversion formula is best used for the 
lower boundary of metal ion levels and may offer reassurance to the clinician in interpreting 
metal ion levels. The provided levels can subsequently be balanced to the upper accepta-
ble limits. Higher values cannot be predicted without accepting a greater prediction error, 
but we believe that prediction of these values from serum to whole blood is of less clinical 
significance since the values are usually already in the pathological range, and indicative of 
malfunctioning of the implant.
There are some weaknesses in our study. The number of available samples at 24 months 
was limited, which may have contributed to the observed non­significant difference in Co 
levels between both implants. Further follow-up of these patients will eventually resolve this. 
Co has a smaller variability compared to Cr, but is recognised to be more toxic both in par-
ticle and ion form. It is therefore important to follow Co ion levels closely. We also recognise 
some limitations in the conversion formulae presented. The conversion formula is particularly 
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valuable for the concentrations in the range of 2­5 μg/L, both because its prediction error 
is lowest in the lower range and because the lower values are of clinical importance for the 
evaluation of implant performance. Since the vast majority of metal ions should be below 
5 μg/L it may not be clinically relevant to be able to predict a serum or whole blood level 
knowing that it is already in the higher range. The formulae can be used for reassurance in 
clinical practice. A low serum level, for example, will never be correlated with a high whole 
blood level. Only one clinical sample (either whole blood or serum) can be used to conform 
to safety guidelines referring to serum or whole blood levels. 
It is extremely important in clinical practice to know the upper acceptable levels for metal 
ions. The best­defined reference values are the exposure equivalent of carcinogenic sub-
stances (EKA values)26 for industrial workers and the Mayo Medical Laboratories interpretive 
handbook.27 The upper limits are defined for Co at 5 μg/L in whole blood and for Cr at 17 
μg/L in erythrocytes (no whole blood upper limits reported).26 In addition to these reference 
values, De Smet et al. analysed metal ion levels in patients with a well-functioning versus a 
malfunctioning RHA and proposed that serum Co and Cr levels up to respectively 4.4 μg/L 
(odds ratio for revision 6.0) and 5.1 μg/L (odds ratio for revision 4.3) are acceptable as upper 
limits. Metal ion levels higher than twice these upper limits are very likely to be associated 
with poor clinical outcome.28 The median ion levels of our study are well below this limit, 
although a few outliers were still encountered. The North Tees group (UK) state that patients 
with Co values between 2­5 μg/L have to be followed clinically and patients with Co values 
above 5 μg/L have to be evaluated with cross­sectional imaging.29 In patients with clearly 
elevated levels, revision should be considered or anticipated.
We have summarised our results together with data from the literature in an attempt to pro-
duce some guidelines (Table 4) which may help the orthopaedic surgeon regarding the use 
and interpretation of metal ion levels in patients with a MoM hip arthroplasty. It is important to 
emphasise again that these guidelines can only be seen as an aid to the clinician in decision 
making and certainly not as an absolute reference tool. Numerous limitations exist, but since 
the topic of the interpretation of metal ion levels is becoming increasingly important we belie-
ve our study may help the clinician towards understanding of this difficult topic.
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Table 4 Practical guidelines for the interpretation of metal ion levels in patients with a MoM hip arthroplasty
Type of Analysis No superiority of whole blood or serum; whole blood may be favored for 
practical reasons depending on local preference
Inductively­coupled plasma mass spectrometer (ICP­MS) method of first 
choice
RHA versus THA a
Metal ion levels are significantly higher for RHA versus THA. This difference 
decreases after the run-in phase, in particular for cobalt
Metal ion measurement Serum ≠ whole blood
Toxicity: Cobalt > Chromium
Cobalt Serum > and < whole blood 
Co blood = Co serum + 0.13 µg/L (95%­CI:0.03;0.22)
Conversion formula (prediction error <1 µg/L):
Co whole blood = 0.34 + [0.88 * Co serum]
Chromium Serum (in general) > whole blood 
Cr blood = Cr serum ­ 0.91 µg/L (95%­CI:­1.05;­0.77)
Conversion formula (prediction error <1 µg/L):
Cr whole blood = 0.14 + [0.58 * Cr serum]
Confounding Factors Renal impairment
‘Contamination’ by nutritional supplements, medication, other metal implants
Implant type and positioning
High levels Associated with an increased risk of a malfunctioning implant.
Close monitoring is indicated with levels: 
- Cobalt serum concentration >4.4 µg/L
- Chromium serum concentration >5.1 µg/L
a This conclusion applies for the implants used in this study and may differ for other implants.
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Abstract
Forty-eight unilateral hip resurfacing arthroplasty patients were evaluated for cobalt and 
chromium levels. The metal ion trend of 42 well-functioning patients was compared with 6 
sub­optimal functioning patients. Median metal ion levels were significantly higher for the 
sub-optimal group. For the well-functioning implants, the percentage of patients with incre-
asing cobalt/chromium levels between two consecutive time-intervals (‘risers’) gradually de-
creased from 90/86% (0-3  months) to 22/22% (24-36 months). The percentage of patients 
with increasing metal ion levels was higher in the sub-optimal group. The median absolute 
increase of this ‘risers’ subgroup was significantly lower for the well­functioning group at 
12-24 months. Sub-optimal functioning MoM-implants have a different metal ion trend than 
well-functioning implants, a higher chance of ‘risers’ and a larger absolute increase in time. 
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Introduction
Hip resurfacing arthroplasty (RHA) is an attractive treatment option for young and active 
patients with osteoarthritis, however, over the last few years increasing concern has been 
raised. Exposure to metal ions over an extended period are a major cause of concern, as 
there are reports on hypersensitivity reactions, osteolysis and soft tissue reactions.1-3 In ad-
dition to these local effects, there is increasing evidence that elevated levels of metal ions, 
may have adverse long term systemic effects like polyneuropathy, cardiomyopathy and 
 hypothyroidism.4-5 
The uncertainty about the consequences of these elevated metal ion levels in most pa-
tients, together with the occasionally encountered serious adverse  events, has raised con-
cerns and tempered the use and acceptance of metal-on-metal (MoM) bearings. In respon-
se, the Medicines and Healthcare products Regulatory Agency (MHRA, UK) recommends in 
an official alert to control cobalt (Co) and chromium (Cr) blood levels at least once postope-
ratively and/or perform cross­sectional imaging if these levels are above 7 ppb (or μg/L).6 
Metal ion measurements have thereby become an important tool in the diagnostic work-up 
of a malfunctioning MoM implant and the orthopaedic surgeon is expected to know how to 
interpret them. 
In spite of abundant ongoing research on defining the best cut off level to differentiate be-
tween well-functioning and sub-optimal functioning implants, to date there is no consensus 
on which levels are acceptable.6,7 In addition to this confusion there is literature available on 
well-performing implants with relatively high levels of metal ions and malfunctioning implants 
with low values.8-14 In summary we must conclude that we do not fully understand the clinical 
significance of a single metal ion measurement and its interpretation. However, on the other 
hand clinicians are confronted with guidelines urging at least one metal ion analysis and with 
patients subsequently asking whether their values are too high or not. 
We hypothesize that the trend in these metal ion levels in time may be more informative 
then single measurements alone, since the latter frequently raise more questions then they 
answer. Several studies already reported on repeated metal ion measurements after RHA,15-18 
however, there are none with a specific trend evalua tion. The aim of this study was therefore 
to present a prospective follow-up of Co and Cr levels in a cohort of unilateral RHA’s and 
potentially identify differences in the trend characteristic in the short-term between patients 
with well versus sub-optimal functioning implants.
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Patients and methods
Study design 
Between May 2007 and June 2012 sixty patients with an RHA were prospectively followed in 
either a randomized controlled trial (RCT) comparing an RHA to a conventional MoM THA, or 
in a cohort of RHA patients.22,23 Approval for both RCT and cohort was obtained from the re-
gional ethics committee (LTC 419-071206). All patients agreed to sign an informed consent. 
All patients under the age of 65 were asked to participate in the ongoing RCT; patients who 
denied participation and had a profound preference for an RHA were followed in a separate 
cohort. 
Twelve patients were excluded from the study because of; bilateral RHA (n=7), missing 
metal ion measurements (n=4) and evident femoral loosening (n=1). The latter case was 
excluded because in this study we were interested in a possible difference in metal ion trend 
in patients with suboptimal clinical scoring and otherwise normal radiographs. Because the 
decision for revision in this patient was already made based on his evident radiographic 
loosening, the metal ion measurement may have biased our findings. This study will therefore 
present the results of 48 patients with a unilateral RHA and a minimum (and median) follow- 
up of 24 months. Based on their most recent Harris Hip Score (HHS) we divided the study 
patients in well and sub­optimal functioning. A HHS ≥90 was defined as ‘well­functioning’ 
(n=42), a HHS <90 was defined as ‘sub­optimal functioning’ (n=6). The clinical outcome was 
measured preoperatively and at 6, 12, 24 and 36 months by Oxford Hip Score (OHS), satis-
faction on visual analogue scale (VAS), University of California Los Angeles (UCLA) activity 
score and 12-item Short Form Health Survey (SF-12). In this study the outcome score at most 
recent follow-up was used.
Surgical technique
Preoperative digital templating for positioning of the implant was implemented in all patients. 
All operations were performed by three experienced hip surgeons through a posterolateral 
approach. The surgical technique has been described earlier.18,19 The resurfacing prosthesis 
was made of a cast, heat-treated solution-annealed Co-Cr alloy (Conserve® Plus; Wright 
Medical Technology, Arlington, Tennessee, USA; FDA approved). The femoral component 
was cemented and the hydroxyapatite (HA)-coated acetabular component, underreamed by 
1 mm, was press­fitted in the acetabulum. Antibiotic prophylaxis with Cephalosporin preope-
rative and 24 hours postoperative, periarticular ossification prophylaxis by three days of Di-
clophenac, and thrombosis prophylaxis with Nadroparine during hospital admittance and 
six weeks after were given. Patients were rehabilitated with immediate unrestricted weight 
bearing according to patient’s tolerance.
Metal ion blood levels
Blood samples were collected and assessed on Co and Cr serum concentrations pre- 
operatively and at consecutive time intervals until 36 months postoperatively (3, 6, 12, 24 and 
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36 months). Blood samples were collected in metal-free vacutainers and taken using a stan-
dardized technique to minimize the risk of contamination: a plastic intravenous cannula was 
inserted, the metal needle removed and the first 5 mL blood was discarded to eliminate metal 
contamination. Serum blood tubes were stored at 4°C, send the same day to the laboratory 
of Toxicology of the University Hospital Ghent (Belgium) and analyzed within seven days. 
Metal ion analysis
The metal ion levels in serum were determined using an inductively-coupled plasma mass 
spectrometer (ICP-MS). The trend line of median values was calculated, and presented in 
Table 2 and plotted in Figure 2. To obtain a ‘percentage of patients with an increase in their 
metal ion level’ we determined at each time-interval between subsequent analyses whether 
Co or Cr concentration for each patient increased, stabilized or decreased. This way for 
each time interval between two analyses the percentage of ‘risers’ could be calculated. This 
metal ion increase percentage is graphically presented in Figure 3. In addition, the actual 
‘quantitative increase’ was also calculated for each time interval by taking the median value 
of the elevation in metal ion level for this subgroup of ‘risers’. The quantitative increase of both 
Co and Cr in the subgroups of ‘risers’ for both groups of well and sub-optimal functioning 
patients is presented in Table 3.
Statistical analysis
Metal ion data distributions were asymmetric and therefore expressed as a group median 
with range. Symmetrical data are represented by a mean and standard deviation (SD). The 
following formal null hypothesis was used: there is no difference in metal ion trend between 
patients with a well- or sub-optimal functioning hip resurfacing. To test this null hypothesis 
the Mann-Whitney U test was used. Concerning study characteristics no a priori power ana-
lysis could be performed and combined with the small number of patients in the sub-optimal 
functioning group, this study can be considered an exploratory trial. Differences were consi-
dered statistically significant at p<0.05. All statistical analyses were performed using SPSS 
software (Version 18.0).
Results
Patient characteristics are presented in Table 1: age, BMI, gender en peroperative factors 
were comparable between the two groups. Clinical outcome scores were plotted against 
Co values per time interval in Figure 1. The clinical outcome scores show, in addition to the 
expected significant difference in HHS (<0.001), a significant difference in OHS (p=0.008), 
UCLA activity score (p=0.012) and SF­12 (p=0.002), all in favor of the well­functioning im-
plants. There is a trend for less VAS satisfaction in de sub-optimal functioning group, but this 
was not significant (p=0.069). 
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Table 1 Patient characteristics and clinical outcome scores, values are median (range)
Well-functioning
(n=42)
Sub-optimal functioning
(n=6)
p-value
Patient characteristics
Gender (women/men) 16/26 3/3 0.581
Mean BMI (SD) 26.3 (2.9) 24.3 (3.5) 0.121
Age at operation in years 55.1 (34-65) 56.5 (44-64) 0.524
Diagnosis (OA/CHD) a 41/1 5/1 0.105
Femoral head size 49 (42-54) 48 (42-52) 0.558
Clinical outcome at latest follow-up
HHS 100 (91-100) 78 (59-89) <0.001
OHS 13 (12-27) 21 (13-25) 0.008
VAS Satisfaction 94 (62-100) 68 (30-100) 0.069
UCLA Activity score 8 (3-10) 5.5 (3-8) 0.012
SF-12 Total score 110 (71-117) 89 (81-103) 0.002
a OA = osteoarthritis; CHD = congenital hip dysplasia.
Figure 1 Representation of the median clinical outcome scores (left y-axis) and cobalt concentration 
(right y­axis) per time interval per group. WF = Well­functioning group; SF = Sub­optimal functioning 
group; SF­12 = 12­item short form health survey; HHS = Harris hip score; VAS = Satisfaction on visual 
analogue scale; OHS = Oxford hip score; UCLA = University of California Los Angeles activity score.
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Trend in metal ion levels
pre-operative median metal ion concentrations were 0.1 µg/L for both metal ions (Co and Cr) 
in both groups. Both well-functioning and sub-optimal implant groups show stable median 
Co concentrations from 3 to 36 months (p=0.436; p=0.062), but significant differences oc-
cur between the groups. From three months on the median Co concentrations significantly 
differ between groups with higher levels in the sub-optimal functioning group (Table 2). At 
24 months the median Co concentration, for the well-functioning group, is 0.95 µg/L (0.1-9.3; 
42 patients) versus 6.2 µg/L (2.0-29.30; 6 patients) for the sub-optimal functioning group 
(p<0.001); at 36 months 0.85 µg/L (0.1-7.0; 18 patients) versus 3.65 µg/L (0.1-21.2; 6 pa-
tients) respec tively (p=0.015) (Table 2, Figure 2). 
Table 2 Median metal ion concentrations (range)
Well-functioning Sub-optimal functioning p-value
Cobalt
pre­operative (n=42/6) 0.10 (0.1-1.0) 0.10 (0.1-2.6) 0.305
3 months (n=42/6) 0.90 (0.1-2.2) 1.90 (0.8-7.8) 0.012
6 months (n=42/6) 0.90 (0.1-5.7) 2.65 (0.5-5.6) 0.015
12 months (n=42/6) 0.80 (0.1-4.7) 3.40 (0.1-7.7) 0.029
24 months (n=42/6) 0.95 (0.1-9.3) 6.20 (2.0-29.3) <0.001
36 months (n=18/6) 0.85 (0.1-7.0) 3.65 (0.1-21.2) 0.015
Chromium
pre­operative (n=42/6) 0.10 (0.1-0.7) 0.10 (0.1-1.3) 0.637
3 months (n=42/6) 1.30 (0.1-3.5) 3.10 (0.7-6.1) 0.096
6 months (n=42/6) 1.45 (0.1-5.8) 4.15 (0.1-7.2) 0.047
12 months (n=42/6) 1.70 (0.1-4.9) 4.15 (0.7-10.2) 0.024
24 months (n=42/6) 1.70 (0.6-13.3) 4.70 (2.9-17.5) 0.001
36 months (n=18/6) 1.70 (0.5-8.5) 4.30 (0.6-16.0) 0.022
For Cr both groups (well and sub-optimal functioning) also show stable median Cr concentra-
tions from 3 up to 36 months (p=0.059 and p=0.417) with differences between the groups. At 
six months (and further) the differences between the two groups for median Cr concentrations 
are significant, again with higher levels in the sub­optimal functioning group (Table 2). At 24 
months the median Cr concentration is 1.7 µg/L (0.6-4.9; 42 patients) versus 4.7 µg/L (2.9-
17.5; 6 patients) (p=0.001), and at 36 months 1.7 µg/L (0.5­8.5; 18 patients) versus 4.3 µg/L 
(0.6­16.0; 6 patients) for the well versus sub­optimal functioning group respectively (p=0.022) 
(Table 2, Figure 2).
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Figure 2 Median Co (black) and Cr (grey) serum concentrations in µg/L for the well-functioning (straight 
line) and sub-optimal functioning (dashed line) implants.
Figure 3 Metal ion increase percentage of patients with increasing Co (black) or Cr (grey) concentrations in 
serum, for the well-functioning (straight line) and sub-optimal functioning (dashed line) implants.
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Percentage of patients with increasing metal ion levels
Figure 3 shows the percentage of patients who have increasing Co or Cr concentrations at 
each interval between two subsequent measurements. For the  well-fun c tioning implants, the 
percentage of increasing Co levels between two time intervals gradually decreased from 
90% for 0-3 months, to 22% for 24-36 months; for Cr these percentages were respectively 
86% and 22%. The trend for sub- optimal functioning implants revealed higher percenta-
ges of increasing metal ions between time-intervals with a peak difference between the two 
groups at 12-24 months; increasing Co values in 80% and 40% for Cr (Figure 3). 
Quantitative increase
The median absolute increase in the subgroup of patients with an increase in their metal ion 
levels (‘risers’) for each time-interval of the well-functioning group from 0 to 36 months are 
shown in Table 3. For Co these median values at several time- intervals lies between 0.30 and 
0.80 µg/L and for Cr between 0.55 and 1.50 µg/L. On the other hand, for the ‘risers’ in the 
sub-optimal functioning group a median increase from preoperative to 24 months of Co lies 
between 0.40 and 6.65 µg/L and of Cr between 0.10 and 11.60 µg/L (Table 3). The highest 
median increase for the sub-optimal functioning group occurs at the 12 to 24 months interval, 
for Co 6.65 µg/L (2.9­23.7) and Cr 11.60 µg/L (11.0­12.2). This was significantly different for 
both metal ions (Co p=0.002; Cr p=0.009) as compared to the median increase for the risers 
from the well-functioning group at the same 12 to 24 months interval.
Table 3 Median elevation of metal ion concentrations of rising cases only (range)
Well-functioning Sub-optimal functioning p-value
Cobalt
0-3 months 0.80 (0.1-2.1) 2.10 (0.6-7.7) 0.049
3-6 months 0.30 (0.1-5.1) 0.75 (0.2-3.3) 0.411
6-12 months 0.50 (0.1-3.3) 1.10 (0.4-2.7) 0.305
12-24 months 0.70 (0.1-4.6) 6.65 (2.9-23.7) 0.002
24-36 months 0.75 (0.4-1.2) 0.40 (0.4-0.4) 0.400
Chromium
0-3 months 1.50 (0.4-3.4) 2.40 (0.6-6.0) 0.297
3-6 months 0.55 (0.1-3.8) 1.35 (0.9-4.3) 0.012
6-12 months 0.70 (0.1-3.0) 0.90 (0.2-3.2) 0.642
12-24 months 0.80 (0.1-8.9) 11.6 (11.0-12.2) 0.009
24-36 months 0.70 (0.1-1.9) 0.10 (0.1-0.1) 0.267
84
Chapter 6
Discussion
In this study the metal ion trend of well- versus potentially malfunctioning unilateral resur-
facing implants is presented. The interpretation of metal ions focused on, besides individual 
metal ion trend, on the odds of a metal ion increase at each time- interval and the absolute 
quantitative value of a specific increase. 
Although we already know which Co and Cr levels are of clinical concern,  there is no 
consensus which absolute cut off levels should be used. In spite of the recognized rela-
tionship between elevated Co and Cr blood levels and malfunctioning implants, there is 
limited knowledge on the range of acceptable metal ion concentrations and where toxicity 
is introduced. Research so far concludes that Co concentrations higher than 19 µg/L and Cr 
concentrations higher than 17 µg/L were likely to be associated with metallosis at revision 
surgery.9 De Smet et al. proposed (AAOS poster, 2010) that serum Co and Cr levels up to 
respectively 4.4 µg/L and 5.1 µg/L are acceptable as upper limits. Hart et al. defined a thres-
hold level of 7 µg/L for both Co and Cr20 (which the UK MHRA adopted for their safety alert of 
April 2010)6 and recently lowered it to a cut off level of 4.97ppb.7 All these previous studies 
focus on attempts to formulate a recommendation based on single metal ion measurement. 
Several studies found high blood metal ion levels at the intermediate term and correlated this 
with increased wear.8,9,11-13 On the contrary, others reject this correlation and the use of metal 
ion measurements as solitary screening tool or surgical trigger.10,14 The divergent results of 
all these studies emphasize the need for a different use and interpretation of metal ions. We 
feel that better information about implant functioning may be obtained from repeated metal 
ion measurements and trend evaluation. For example, in our opinion a single measurement 
Co level of 5 µg/L at 12 months raises more questions than it answers. An additional 24 
months measurement of 3 µg/L would be rather reassuring, while 6 µg/L would indicate a 
potentially malfunctioning implant. Although there are no reports of test retest variation from 
metal ion measurements by ICP-MS, it is the authors opinion that an increase of 1 µg/L after 
24 months would be a reason for concern and an indication for repeated measurements or 
other investigations.
The chronological follow-up of metal ion concentrations of the well-functioning implants ex-
hibits a mild increase in Co and Cr levels up to 12 months. Subsequently, the median metal 
ion values remain at an acceptable and relatively low level until the end of follow-up at 36 
months. These low median metal ion concentrations are in agreement with several other stu-
dies, as is the ‘running-in phase’ of the metal ions until six to twelve months with stabilizing 
values thereafter.11,17,18 However, the 12 and 24 months median Co and Cr concentrations of 
the well-functioning patients in our study are three to six times lower than the ones reported 
by Allen et al. and deSouza et al.15,16 The reason for this difference is not clear, however this 
might be implant or surgical technique related.13 The chronological metal ion trend for the 
potentially malfunctioning implants differed significantly from the well­functioning group with 
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higher levels at all times. As the range of both trend lines is wide, the interpretation of a single 
ion measurement might still be difficult when it is positioned within both trend lines. In such 
cases interpretation may become more reliable with a second measurement and knowledge 
about the odds of increasing levels in time and acceptable increase limits. 
From three months on, the odds of an increase in Co and Cr concentration decreases 
for both groups. Although both groups show a comparable course of this metal ion increase 
percentage, the 12-24 months interval shows a greater percentage of increasing values for 
the sub-optimal functioning group (Figure 3). Since this group was relatively small, this high 
percentage of ‘risers’ was not significantly different and only a trend can be concluded at 
this point. This trend might be indicative for a transition point of Co and Cr concentrations in 
serum at 12 months. If metal ion levels increase structurally after 12 months, this might be 
an indication of increasing wear and a potentially malfunctioning implant. When looking at 
the ac tual quantitative amount of increase in Co or Cr concentration, there was a significant 
difference between the groups. In well-functioning patients the median increase in metal ion 
concentrations, if present, was always below 1 µg/L for both metal ions. For patients from 
the sub­optimal group the observed increase in metal ion levels was significantly higher, 
especially at the 12-24 months interval with median in crease values up to 6.65 µg/L (Co) and 
11.6 µg/L (Cr). Thus, the difference between the two groups lies, besides significantly higher 
median metal ion concentrations, in a trend towards higher odds for an increase together 
with a significant higher absolute increase for the sub­optimal functioning patients.
We recognize the limitations of our study. We only present a relative small group with a 
median follow-up of 24 months, with a maximum of 36 months. However, the failures related 
to high wear and therefore high metal ion concentrations seem to occur between 8 to 85 
months21 and thus short term follow-up studies are still appropriate since we are dealing 
with a problem of early failures. A HHS above 90 is considered an excellent result, therefore 
this was chosen as cut off point. There might unfortunately be test retest variations, how-
ever, according to two studies the intraclass correlation of the HHS are well over 0.75 and 
can therefore be considered excellent.22,23 We are interested if consecutive measurements 
in a bigger cohort will validate the conclusions from this exploratory study, however to date 
there are no reports on this specific matter. Furthermore it is recognized that test retest and 
design-related differences are present in metal ion release13 and we only studied a single 
resurfacing design. However, as we present a trend assessment, the in crease or decrease is 
more important than the absolute value of metal ion release and thus the potential influence 
of design specific differences is minimized. 
The evaluation of metal ion levels is becoming increasingly important after a MoM hip arthro-
plasty and serves as an indicator of bearing performance and device safety. Determination 
how to use and interpret Co and Cr concentration is essential for the general ortho paedic 
surgeon who will be confronted with the follow-up of patients with MoM implants. For well- 
functioning patients, it appears that the odds of an increase in metal ion levels is minimal after 
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two years. If an increase after six months is still encountered, the absolute value of this incre-
ase can be considered to be low (below 1 µg/L). On the contrary, for the sub-optimal functi-
oning patients we found a notably ‘different trend’ with significantly higher metal ion levels at 
all time-intervals, even after the running-in period. In addition, the odds of increasing metal 
ions levels were higher in this group, together with significantly higher absolute values of this 
increase from 12 to 24 months. Although one would prefer a longitudinal measurement of 
each individual patient, the widespread use is limited by the high costs of analysis. From the 
results of the trend evaluation in our study we recommend a low threshold for repeated metal 
ion measurement after the running-in period, as it can help to clarify if an implant is failing.
87
Is the metal ion trend predictive for MoM function?
6
References
1. Willert HG, Buchhorn GH, Fayyazi A, et al. Metal-on-metal bearings and hypersensitivity in pa-
tients with artificial hip joints. A clinical and histomorphological study. J Bone Joint Surg Am. 
2005;87(1):28-36.
2. Park YS, Moon YW, Lim SJ, Yang JM, Ahn G, Choi YL. Early osteolysis following second-generation 
metal-on-metal hip replacement. J Bone Joint Surg Am. 2005;87(7):1515-1521.
3. Pandit H, Glyn-Jones S, McLardy-Smith P, et al. Pseudotumours associated with metal-on-metal hip 
resurfacings. J Bone Joint Surg Br. 2008;90(7):847-851.
4. Ikeda T, Takahashi K, Kabata T, Sakagoshi D, Tomita K, Yamada M. Polyneuropathy caused by co-
balt –chromium metallosis after total hip replacement. Muscle Nerve. 2010;42(1):140-143.
5. Keegan GM, Learmonth ID, Case CP. Orthopaedic metals and their potential toxicity in the arthro­
plasty patient: A review of current knowledge and future strategies. J Bone Joint Surg Br. 2007;89-
B(5):567-573.
6. MHRA. Medical Device Alert: All metal-on-metal (MoM) hip replacements MDA/2012/008. 2012(28 
february 2012).
7. Hart AJ, Sabah SA, Bandi AS, et al. Sensitivity and specificity of blood cobalt and chromium me-
tal ions for predicting failure of metal-on-metal hip replacement. J Bone Joint Surg Br. 2011;93-
B(10):1308-1313.
8. Daniel J, Ziaee H, Kamali A, Pradhan C, McMinn D. What are the risks accompanying the reduced 
wear benefit of low­clearance hip resurfacing? Clin Orthop Relat Res. 2012;470(10):2800-2809.
9. De Smet K, De Haan R, Calistri A, et al. Metal ion measurement as a diagnostic tool to identify 
problems with metal-on-metal hip resurfacing. J Bone Joint Surg Am. 2008;90 Suppl 4:202-208.
10. Griffin WL, Fehring TK, Kudrna JC, et al. Are metal ion levels a useful trigger for surgical interven­
tion? J Arthroplasty. 2012;27(8 Suppl):32-36.
11. Heisel C, Silva M, Skipor AK, Jacobs JJ, Schmalzried TP. The relationship between activity and ions 
in patients with metal-on-metal bearing hip prostheses. J Bone Joint Surg Am. 2005;87(4):781-787.
12. Jacobs JJ, Skipor AK, Campbell PA, Hallab NJ, Urban RM, Amstutz HC. Can metal levels be used 
to monitor metal-on-metal hip arthroplasties? J Arthroplasty. 2004;19(8 Suppl 3):59-65.
13. Langton DJ, Joyce TJ, Jameson SS, et al. Adverse reaction to metal debris following hip resur-
facing: the influence of component type, orientation and volumetric wear. J Bone Joint Surg Br. 
2011;93(2):164-171.
14. Macnair RD, Wynn­Jones H, Wimhurst JA, Toms A, Cahir J. Metal ion levels not sufficient as a 
screening measure for adverse reactions in metal-on-metal hip arthroplasties. J Arthroplasty. 
2013;28(1):78-83.
15. Allan DG, Trammell R, Dyrstad B, Barnhart B, Milbrandt JC. Serum cobalt and chromium elevations 
following hip resurfacing with the Cormet 2000 device. J Surg Orthop Adv. 2007;16(1):12-18.
16. deSouza RM, Parsons NR, Oni T, Dalton P, Costa M, Krikler S. Metal ion levels following resurfacing 
arthroplasty of the hip: serial results over a ten-year period. J Bone Joint Surg Br. 2010;92(12):1642-
1647.
17. Isaac GH, Siebel T, Oakeshott RD, et al. Changes in whole blood metal ion levels following resur-
facing: serial measurements in a multi-centre study. Hip Int. 2009;19(4):330-337.
18. Smolders JM, Hol A, Rijnberg WJ, van Susante JL. Metal ion levels and functional results after 
either resurfacing hip arthroplasty or conventional metal-on-metal hip arthroplasty. Acta Orthop. 
2011;82(5):559-566.
19. Amstutz HC, Beaule PE, Dorey FJ, Le Duff MJ, Campbell PA, Gruen TA. Metal-on-metal hybrid sur-
88
Chapter 6
face arthroplasty. Surgical technique. J Bone Joint Surg Am. 2006;88(1_suppl_2):234-249.
20. Hart AJ, Skinner JA, Winship P, et al. Circulating levels of cobalt and chromium from metal-on-metal hip 
replacement are associated with CD8+ T-cell lymphopenia. J Bone Joint Surg Br. 2009;91(6):835-842.
21. Langton DJ, Jameson SS, Joyce TJ, Hallab NJ, Natu S, Nargol AVF. Early failure of metal-on- 
metal bearings in hip resurfacing and large-diameter total hip replacement. J Bone Joint Surg Br. 
2010;92-B(1):38-46.
22. Soderman P, Malchau H, Herberts P. Outcome of total hip replacement: a comparison of different 
measurement methods. Clin Orthop Relat Res. 2001(390):163-172.
23. Wright JG, Young NL. A comparison of different indices of responsiveness. J Clin Epidemiol. 
1997;50(3):239-246.
89
Is the metal ion trend predictive for MoM function?
6

7High incidence of pseudotumors after hip 
resurfacing even in low risk patients; results 
from an intensified MRI screening protocol
Walter van der Weegen
José M.H. Smolders
Thea Sijbesma
Henk J. Hoekstra
Koen Brakel
Job L.C. van Susante
Hip International 2013 Jun 4;3(23):243-249
92
Chapter 7
Abstract
We intensified our screening protocol for the presence of pseudotumors in a consecutive 
series of patients with a hip resurfacing arthroplasty (RHA), to establish whether we should 
be alert to the presence of ‘silent’ pseudotumors. Patients categorized with high risk (11 
hips) and low risk (10 hips) for pseudotumor development and a control group (23 hips) were 
screened with metal artifact reduction sequence (MARS) magnetic resonance imaging (MRI). 
The Anderson classification to grade any metal­on­metal (MoM) disease present on MARS­
MRI images was used. In 15 out of 44 MRI scans pseudotumors were observed (34.1%), of 
which six were graded with mild (13.6%), eight with moderate (18.2%) and one with severe 
MoM disease (2.3%). Twelve pseudotumors were present in asymptomatic patients (27.3%). 
Metal ion levels were normal in 80% of the MARS-MRI screened patients. As a consequence 
of our intensified screening protocol, one patient was revised for pseudotumor formation and 
another patient was scheduled for revision. Silent pseudotumors were observed in all three 
groups. Before our intensified screening protocol was initiated, no pseudotumors were en-
countered in our cohort of 289 RHA’s. We concluded that clinical outcomes and plain radio-
graphs for screening MoM patients underestimates the presence of pseudotumors in MoM 
patients. The true clinical relevance of these pseudotumors is still unclear. 
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Introduction
Metal-on-metal (MoM) bearings have been widely used in hip arthroplasty. Al though wear 
rates are low, these bearings still release cobalt (Co) and chromium (Cr) particles which may 
result in a periprosthetic soft tissue reaction, requiring revision surgery.1,2 This periprosthetic 
soft tissue damage, known as adverse reaction to metal debris (ARMD) compromises aseptic 
lymphocytic vasculitis-associated lesions (ALVAL), metallosis and pseudotumor formation.3 
Revision surgery for pseudotumors is sometimes difficult and post­revision surgery clinical 
outcomes are less satisfying.4 The reported incidence of pseudotumors varies, depending 
on patient characteristics, type of follow-up and implant design features.5,6 Earlier MoM hip 
arthroplasty studies relied on clinical outcome scores and radiographs of large case series 
to report on good implant performance and excellent functional outcomes.7-9 
Recently published data, however, report on a much higher incidence of pseudo tumors 
in patients with MoM implants after all patients have been screened for the presence of these 
adverse peri-prosthetic reactions with metal artifact reduction sequence (MARS) magnetic 
resonance imaging (MRI) or ultrasound.10,11 Suspicion arises that there may be a relatively 
large number of ‘silent’ pseudotumors present in otherwise well-functioning implants. There 
is reason to believe that the occurrence of pseudotumors is not solely observed with mal-
positioned implants with relatively high metal ion levels and poor clinical outcome.11 From this 
growing unease we decided to intensify our screening protocol for the presence of pseudo-
tumors in a consecutive series of patients with RHA. The aim of this study was to clarify 
whether we should be alert to the presence of ‘silent’ pseudotumors in our cohort of hip res-
urfacing patients. According to previously defined patient and implant characteristics,6,11 we 
categorized high and low risk patients for pseudotumor development, together with a non- 
stratified control group. Subsequently, in all three groups MARS­MRI screening for pseudo-
tumors was performed. 
Patients and methods
Patients
Between September 2004 and September 2010 we included 298 consecutive RHA procedu-
res (240 patients) in a prospective cohort study. Females <60 years of age and males <65 
years of age were the primary candidates for RHA if diagnosed with end stage osteoarthritis 
and had an active lifestyle. Older patients with sufficient bone quality and an active lifestyle 
were considered for RHA on an individual basis. Dual energy X-ray absorptiometry was used 
to exclude patients with osteoporosis. Patients with renal failure, femoral cysts, avascular 
necrosis (AVN) of the femoral head and female patients trying to conceive were also exclu-
ded. Procedures were followed in accordance with the ethical standards of the responsible 
committee on human experimentation and with the Helsinki Declaration of 1975, as revised 
in 2000. After informing the patient on the expected benefits and risks associated with RHA, 
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informed consent on the surgery procedure and on study participation was obtained. Our 
study was approved by the Institutional Review Board (IRB nr. 08.013, 18th December 2008). 
Implant system
All procedures were performed by one of two experienced hip arthroplasty surgeons (TS, 
HH). The ReCap hip resurfacing system (Biomet Inc, Warsaw, USA) was implanted by a pos-
terolateral approach. The press­fit acetabular component and the cemented femoral compo-
nent are manufactured from ‘as-cast’ cobalt-chro mium (Co-Cr-Mo) with a high carbon con-
tent (>0.2%) without any heat treatment. The acetabular outside is a full hemisphere design 
and has four pairs of small fins for initial rotational stability. It has a titanium porous plasma 
spray surface coating facilitating bone ingrowth. The system offers 2 mm increment sizing. 
The surgical technique has been described earlier by Gross and Liu.12 All patients received 
antibiotic prophylaxis with a Cephalosporin pre-operatively and 24 hours post-opera tively, 
three days of Indometacin for periarticular ossification prophylaxis, Diclophenac for pain 
management and thrombosis prophylaxis with Dalteparine 5000 units for six weeks postope-
ratively. Patients were rehabilitated with immediate unrestricted weight bearing according to 
the patient’s tolerance. All bilateral procedures were staged interventions with at least a three 
month interval.
Table 1 Patient characteristics, values are median (min-max)
High risk ARMD Low risk ARMD Routine FU group
Patients/hips 11/12 10/10 19/22
Male/female 0/11 10/0 16/3
Femoral component size in mm (median) 46 (44-50) 52 (50-56) 52 (46-54)
Cup inclination angle 60° (55-70) 41° (35-44 ) 51.5° (36-64)
Bilateral MoM 5 0 3
HHS score 89 (79-95) 89 (83-91) 80 (48-91)
HHS pain score (none/slight/moderate) 7/2/2 10/0/0 9/8/3
Age in years 53.1 (41-61) 54 (40-66) 54 (28-69)
Follow up in years 3.8 (1-7) 4.5 (2.3-6.9) 4.0 (1.6-6.9)
Study design
To evaluate the occurrence and incidence of pseudotumor formation we defined three diffe-
rent groups of patients. The first group had a perceived high risk for pseudo tumor formation 
based on gender, component size and cup inclination  angle.6,11,13 Cup inclination angle was 
measured on the latest available standard anteroposterior radiograph using earlier descri-
bed methods.14 Eventually we allocated eleven female patients with a cup inclination angle 
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>45° and a femoral component size <50 mm to this ‘high risk’ group. Five patients in this 
group had bilateral RHA; one patient fulfilled all high risk criteria bilaterally, four patients only 
unilaterally, and therefore twelve hips were included in the high risk group for MARS-MRI 
screening. The ‘low risk’ group consisted of ten asymptomatic male patients with a unilate-
ral RHA, cup inclination angle <45° and femoral component size >50 mm. The third group 
consisted of 19 patients (22 hips) who, regardless of risk factors, were scheduled for routine 
follow-up between November 2011 and May 2012 and acted as a ‘control’ group without risk 
stratification (Table 1). 
In all three groups, blood serum samples were collected and assessed on Co and Cr con-
centrations. Samples were collected in metal­free vacutainers; the first 5 mL blood was dis-
carded to eliminate metal contamination from the needle. Tubes were stored at 2-8°C and 
sent to an external laboratory (Ziekenhuis Groep Twente, Hengelo, Netherlands) for analy-
sis. The metal ion levels in whole blood were determined using Atomic Absorption Spectro-
photometry (AAS) analysis. Co levels were classified according to guidelines by the Dutch 
Orthopaedic Society15 with normal Co <40 nmol/L, slightly elevated 40-85 nmol/L, elevated 
85-170 nmol/L and extremely elevated >170 nmol/L. All MARS-MRI examinations were per-
formed on a 1,5T MRI (Philips Medical Systems, Best, Netherlands). Scan parameters are 
listed in Table 2. 
Table 2 MARS-MRI details
Coronal
PDW
Coronal
STIR
Transverse
PDW
Transverse Sagittal 
STIR
TE (ms) 30 40 30 40 40
TR (ms) 3000 8645 3576 105000 9570
TI (ms) 130 130 130
Slice thickness 2.5 2.5 3 3 3
FOV (mm) 230 x 197 230 x 198 240 x 199 280 x 198 230 x 230
Matrix 328 x 220 256 x 168 344 x 198 280 x 152 256 x 189
BW (HZ/pixel) 435 437 437 435 438
Coil Sense body 
16 ch
Sense body 
16 ch
Sense body 
16 ch
Sense body 
16 ch
Sense body 
16 ch
All MARS­MRI images were judged by an experienced musculoskeletal radiologist (KB) and 
validated by a second musculoskeletal radiologist (RH), who were both unaware of the clini-
cal status of the patients. We used the description by  Matthies et al. of a pseudotumor being 
a sterile inflammatory lesion found in the soft tissues surrounding a MoM hip arthroplasty.16 
Grading of MARS­MRI findings was based on the method described by Anderson et al. 
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( Table 3).17 Since Harris hip scores (HHS),18 Oxford hip scores (OHS)19 and anteroposterior 
and lateral radiographs were collected yearly as part of routine follow-up, these were avail-
able for all patients. The OHS results were calculated using the original scoring system (12 
points being best possible score, 60 points being the worst possible score).
Table 3 Anderson classification for MoM disease on MARS-MRI17
Grade Description Criteria
A Normal or 
acceptable
Normal post-op appearances including seromas and small haematomas.
B Infection Fluid­filled cavity with high signal T2 wall; inflammatory changes in soft 
tissues, ± bone marrow oedema.
C1 Mild 
MoM disease
Periprosthetic soft tissue mass with no hyperintense T2W fluid signal or fluid­
filled peri­prosthetic cavity; either less than 5 cm maximum diameter.
C2 Moderate 
MoM disease
Peri­prosthetic soft tissue mass/fluid­filled cavity greater than 5 cm diameter 
or C1 lesion with either of following: (1) muscle atrophy or edema in any 
muscle other than short external rotator or (2) bone marrow edema: 
hyperintense on STIR.
C3 Severe 
MoM disease
Any of the following: (1) fluid­filled cavity extending through deep fascia, (2) 
a tendon avulsion, (3) intermediate T1W soft tissue cortical or marrow signal, 
(4) fracture.
Statistical analysis
Descriptive statistics were used to compare the three study groups. Metal ion data distribu-
tions were asymmetric and are expressed as a group median with range. Symmetrical data 
are represented by a mean and standard deviation (SD). The significant level is defined 
as p≤0.05 in this study. A post hoc analysis was used to measure the statistical power of 
the observed difference in pseudotumor occurrence between groups. SPSS software (SPSS 
Statistics, version 17.0, IBM Corporation, Somers USA) was used for all statistical analyses.
Results
Patient characteristics are shown in Table 1. Before the intensified screening protocol was 
implemented, no pseudotumors had been detected in our cohort of 298 RHA’s. With the 
MARS-MRI screening completed, pseudotumors were observed in all three groups (Table 4). 
The risk for pseudotumor development in the high risk group was 0.45, 0.33 in the low risk 
group and 0.30 in the control group. However, the statistical power to detect a true signifi-
cant difference in risk ratios between groups was low (p=0.11). Overall, in 15 cases of the 44 
MARS-MRI available for analysis, pseudotumor formation had occurred. In total 29 MARS-
MRI images were classified as grade A, none as grade B, six as grade C1, eight as grade 
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C2 and one grade as C3. In contrast to the MARS-MRI images, the Co levels were normal 
in 80% of the patients. Two patients had slightly elevated metal ion levels, four patients had 
elevated levels and two patients had extremely elevated levels. The median Co level for all 
patients was 24 nmol/L (min-max 11-1897 nmol/L). 
Table 4 Incidence and characterization of pseudotumor formation and cobalt levels (min-max)
High risk ARMD Low risk ARMD Routine FU group
Patients/hips 11/12 10/10 19/22
Pseudotumor 5 3 7
Grade C1/C2/C3 2/2/1 3/0/0 1/6/0
Pseudotumor size in cm (mean) 5.2 (1.9-10.5) 3.3 (1.8-5.0) 4.4 (1.9-8.0)
Cobalt in nmol/L (median) 27 (19-1897) 18 (11-36) 24 (12-407)
Out of the 15 pseudotumors which were observed on MARS-MRI, there were 12 silent pseu-
dotumors. These patients did not complain of any pain or other symptoms and had excellent 
clinical outcome scores (HHS >90, Oxford Hip Score <16) with normal radiographs.
One female patient from the high risk group with severe MoM disease underwent revision 
surgery, and one male patient from the control group with moderate MoM disease is sche-
duled for revision. The revised patient had bilateral RHA: seven years after implantation on 
her right, six years on her left side. There was no pseudotumor observed on her right side 
but on her left side she had a pseudotumor measuring 105 mm craniocaudal, 71 mm antero-
posterior and 80 mm mediolateral (Figure 1). 
Figure 1 Large fluided filled cyst 
left hip, indicating Anderson grade 
C2 MoM disease. 
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Her Co level was extremely elevated (1897 nmol/L). Her HHS score was 91 points and she 
never complained of pain after RHA. She did however regularly noticed squeaking on the left 
side, something we had not observed in any other patient from our series. Both cups had a 
steep inclination angle (left 70°, right 59°). During revision surgery a large fluid filled cyst was 
excised, extending from the lateral side to the anterior part of the hip joint.
Discussion
In our study group of patients with a Recap RHA the prevalence of pseudotumors appeared 
to be high, with pseudotumor occurrence even in the group defined as having a low risk for 
ARMD. With an established pseudotumor incidence of 34.1 percent in this concise explora-
tory study group, we can expect another 87 pseudo tumors using an intensified MARS­MRI 
screening protocol on our entire group of 298 resurfacing hip arthroplasties. Of these 87 
pseudotumors, an expected 17 would classify as a grade C2 or C3 pseudotumor with an 
increased revision risk. 
As confirmed by other authors, pain was not a very useful indicator for pseudo tumor 
occurrence.20,21 Compared to the extent of damage noticed on MARS-MRI and at revision 
surgery, one has to wonder by which mechanism pseudotumors develop relatively pain free. 
Mild symptoms and relatively low metal ion levels can contribute to the difficulty of convin-
cing patients to have their RHA revised. How ever, recent media attention about the negative 
effects of MoM bearings has scared many MoM patients, who even ask for revision surgery 
in absence of any symptoms. 
Although several authors report on pseudotumor rates, the number of studies using other 
imaging modalities than plain radiographs to detect pseudotumor occurrence is very limited. 
High rates of pseudotumor occurrence have been found in other studies which used MARS-
MRI or computer tomography (CT) scanning. Wynn-Jones reported a similar pseudotumor 
rate of 36% using the ASR resurfacing device.21 Compared to MoM hip resurfacing, higher 
pseudotumor rates are reported for MoM total hip arthroplasty. Mistry et al. reported a 58.3% 
pseudotumor rate using the Ultima TPS design20 and Bosker et al. found a 39% pseudotumor 
rate in MoM THA patients who received the M2a-Magnum femoral head and ReCap aceta-
bular component.10 Langton et al. described a 13.6% revision rate for ARMD with the ASR 
design, but use of MRI or CT scanning was not reported in this paper.6 Malviya et al. found 
a pseudotumor incidence of just 0.15% using the BHR resurfacing device, although it is not 
clear from his paper if all patients routinely were scanned using MARS-MRI.22
To our knowledge, there are no other studies which have investigated the prevalence 
of pseudotumors with this particular RHA design using imaging modalities other than plain 
radiographs. The studies by Baad- Hansen et al. and Gagala et al. were limited to 23 and 
25 RHA patients respectively with a maximum follow-up of 24 months.23,24 Gross and Liu re-
cently published a case series of 740 consecutive procedures with the ReCap RHA design 
with a follow-up of seven years maximum.25 The reported Kaplan­Meier survivorship with any 
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 revision as an end point was 96.4% at seven years, with only two revisions (0.3%) for adverse 
wear. Follow-up was limited to clinical outcomes and plain radiographs, but as the possibility 
of more adverse wear failures was acknowledged by the authors, they started taking metal 
ion samples routinely.
There remains uncertainty on the risk factors for pseudotumor formation with current MoM 
hips. Studies have suggested that edge-loading resulting from adverse cup orientation and 
implant design leads to a higher wear of the components and subsequently increases blood 
metal ion levels.26,27 Clinical studies and reports from arthroplasty registers also implicate 
smaller components in connection with increased metal ion levels.13,28 Based on these fin-
ding, the use of MoM prostheses is supported for appropriately trained surgeons who select 
appropriate patients.29 Recently, studies have debated risk factors for pseudotumor forma-
tion. Kwon et al. and Mistry et al. showed that pseudotumors can be observed in asymptoma-
tic patients with well-positioned and well-functioning prostheses.11,20 Recently, Matthies et al. 
reported that pseudotumors are common in well-positioned MoM prosthesis.16 These results 
are confirmed by our study in which pseudotumors were commonly found in asymptomatic 
patients with well-positioned, large components. This suggests that development of pseudo-
tumors is more likely to be dependent on patient susceptibility than on factors such as com-
ponent size, component positioning or implant design. The risk for pseudotumor formation is 
higher for any patient with any MoM prosthesis than previously thought.
Until now, clinical signs, radiographic evaluation and metal ion levels have been used to 
identify patients at risk for pseudotumor formation. The best protocol for detecting pseudo-
tumors is not yet defined, but ultrasound scans, CT or MARS­MRI scans are commonly used. 
Our study indicates that follow-up methods of clinical outcomes and radiographs underes-
timate the prevalence of pseudotumors after MoM RHA. Moreover, metal ion levels alone 
are also not sufficient to detect all cases of ARMD. Our findings, especially those from the 
low risk ARMD group, have prompted us to start using MARS-MRI scans for our whole MoM 
cohort. Our findings suggest that radiographic screening with MARS­MRI, CT or ultrasound 
on all patients with a hip resurfacing might be the only option to discover the real magni tude 
of pseudotumor formation after MoM arthroplasty.
There are several limitations of our study. Most importantly, the number of patients is 
small since we report on an exploratory study at this stage. In spite of this limited number 
of patients we still feel the need to report on our preliminary findings of the high number of 
pseudotumors found on MARS-MRI even in low risk patients with few or no symptoms. In our 
study group, there were quite a few patients with a steep cup inclination angle, which is con-
sidered the only risk factor for ARMD by some authors.30 However, despite the fact that we 
differentiated amongst other factors between high and normal cup inclination, we still found 
pseudotumors with normally inclined cups. 
We believe that conventional radiological and clinical follow-up together with metal ion 
analyses will underestimate the true prevalence of MoM­disease. An intensified screening 
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protocol for pseudotumors with MRI, CT scan or ultrasound is likely to become unavoidable. 
There is no consensus yet on the clinical relevance of pseudotumors and it may be possi-
ble that only some become problematic.  There is increasing evidence that the incidence of 
pseudotumor formation with large dia meter (>36 mm) MoM may be higher than assumed so 
far and the use of these implants has been suspended in the Netherlands.
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Abstract
We undertook a randomized prospective follow-up study of changes in peri-prosthetic bone 
mineral density (BMD) after hip resurfacing and compared them with the results after total 
hip replacement. A total of 59 patients were allocated to receive a hip resurfacing (n=29) 
or an uncemented distally fixed total hip replacement (n=30). The BMD was prospectively 
determined in four separate regions of interest (ROI) of the femoral neck and in the calcar 
region corresponding to Gruen zone 7 for the hip resurfacing group and compared only to 
the calcar region in the total hip replacement group. Standardized measurements were per-
formed pre-operatively and after 3, 6 and 12 months. The groups were well matched in terms 
of gender distribution and mean age. The mean BMD in the calcar region increased after 
one year to 105.2% of baseline levels in the resurfaced group compared with a significant 
decrease to 82.1% in the total hip replacement group (p<0.001) by 12 months. For the resur-
faced group, there was a decrease in bone density in all four ROI of the femoral neck at three 
months which did not reach statistical significance and was followed by recovery to baseline 
levels after 12 months. Hip resurfacing did indeed preserve BMD in the inferior femoral neck. 
In contrast, a decrease in the mean BMD in Gruen zone 7 followed uncemented distally fixed 
total hip replacement. Long term follow­up studies are necessary to see whether this benefit 
in preservation of BMD will be clinically relevant at future revision surgery.
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Introduction
One of the most common sequelae of total hip arthroplasty (THA) is periprosthetic bone loss. 
Stress shielding is an important cause of this phenomenon according to the principles of 
Wolff’s law.1-3 Such bone loss is clinically relevant as it may result in peri-prosthetic fractures 
and loosening or migration of the implant. 
Hip resurfacing arthroplasty is an option for the treatment of arthritis of the hip in young 
and active patients. This procedure preserves the femoral neck and part of the head and 
does not invade the femoral canal, thus preserving bone stock. The loading patterns in the 
femoral neck after hip resurfacing seem to mimic the natural situation,4,5 although stress 
shielding seems to occur in the femoral neck according to finite element models.6,7 Narro-
wing of the femoral neck has been described as a radiological feature following hip resurfa-
cing arthroplasty,8,9 and might represent adaptive remodelling to stress shielding. However, 
the literature to date is inconclusive on this subject. 
One of the theoretical advantages of hip resurfacing is preservation of the femoral neck 
which would simplify future revisions in these young patients. However, for this to be true, 
the preserved bone of the femoral neck needs to be durable and not susceptible to gradual 
decline. Loss of bone stock in the femoral neck may then predispose to critical narrowing of 
the neck and to peri-prosthetic fractures. If this transpired the assumed advantages of hip 
resurfacing would be limited.
Dual energy X-ray absorptiometry (DEXA) is a reliable method of evaluating changes in 
bone mineral density (BMD) and can be applied to the femoral neck.10 Accordingly it can be 
used to assess the evolution of changes in BMD after hip resur facing. Earlier studies using 
DEXA have shown an increase in BMD in Gruen zone 711 after hip resurfacing arthroplasty, 
whereas a decrease in BMD in this zone has been observed after conventional THA.3,12 How-
ever, these studies were performed with early DEXA equipment and today more sensitive 
software can detect BMD changes in well defined and smaller region of interest (ROI) in the 
femoral neck. Also, these studies were cohort series and a truly randomized comparison 
between THR and hip resurfacing arthroplasty for changes in BMD has not been previously 
described. 
We have performed a prospective randomized controlled trial of hip resurfacing arthrop-
lasty compared with metal-on-metal uncemented THA during which we evalu ated changes 
in BMD in several ROI in the femoral neck and proximal femur for the resurfacing procedure 
and the corresponding region of the calcar in THA.
Patients and methods
The study was designed following a power analysis based on the work of Lian et al.13 The 
minimum number of participants needed in each group to obtain a power of 80% with a 
significance level of p<0.05, was determined as 34, with a calculated difference of 2.98% 
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(SD 6.14) in BMD ratio. 
Figure 1 Consort diagram showing patient selection (THA = total hip arthroplasty).
Between June 2007 and December 2008, 75 patients were randomly assigned to receive 
one of two hip implants, either a hip resurfacing arthroplasty (Conserve® Plus, Wright Medical 
Technology, Arlington, Tennessee) or a THA (Zweymüller® Metasul®, Zimmer Orthopaedic, 
Warsaw, Indiana) (Figure 1). Consecutive randomization was employed using a computer- 
generated variable block schedule. The randomization list was generated by an indepen-
dent statistician and the resulting treatment allocations were stored in sealed opaque enve-
lopes. Randomization occurred prior to surgery. Due to the nature of the procedure both the 
patient and the surgeon could not be blinded to the eventual type of implant but neither the 
patient nor the surgeon could influence the randomization process. Patients were informed 
in detail about the randomization procedure and accepted the assigned implant in all cases. 
They were aged between 35 and 65 years old and needed a primary hip replacement be-
cause of arthritis, congenital hip dysplasia or posttraumatic arthritis. Patients were excluded 
if they had a previous history of infection of the hip or other sites, a hip fracture, avascular 
necrosis with collapse of the femoral head, rapid progressive bone resorption, levels of BMD 
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indicating osteoporosis of the involved hip, or renal failure. Two patients were excluded after 
randomization for hip resurfacing since during the operation anatomical deformities were 
encountered which precluded this procedure and a THA was carried out. Of the randomized 
patients, 59 had a minimum follow-up of three months. The 29 patients in group A received 
a resurfacing implant and 30 in group B, an uncemented THA. There were no significant 
differences between the groups for age and gender (Table 1). The body mass index (BMI) of 
group A was significantly lower than in group B (Student’s t­test, p=0.048), but this difference 
was small and considered clinically irrelevant. 
Approval from the regional ethics committee from the Radboud University Nijmegen Me-
dical Centre was obtained and all patients provided informed consent. 
Table 1 Clinical details of the patients in both groups 
Group A (RHA) Group B (THA) p-value
Number of patients (hips) 29 30
Mean follow-up in months (range) 17.3 (4.4-31.3) 16.0 (4.2-27.8) 0.585 b
Gender (women:men) 15:14 11:19 0.299 c
Mean body mass index (SD) 26.0 (2.7) 28.2 (5.3) 0.048 d
Mean age at operation in years (range) 54.8 (24 - 65) 56.6 (37-65) 0.440 d
Diagnosis (OA/AVN/CHD) a 27/1/1 29/0/1 0.713 e
Mean blood loss in mL (range) 258.7 (100-600) 286.4 (100-900) 0.596 d
Mean operating time in minutes (SD) 75.1 (10.4) 54.6 (12.9) <0.001 b
a OA = osteoarthritis; AVN = avascular necrosis; CHD = congenital hip dysplasia b Student’s t-test; 
c Fisher’s exact probability test; d Mann-Whitney U test; e Kruskal­Wallis test
Surgical technique
Pre-operative digital templating for positioning of the implant (Easyvision, Philips Medical 
Systems, Eindhoven, the Netherlands) was carried out in all patients. All operations were 
carried out by one author (JVS) and two other experienced hip surgeons through a postero-
lateral approach. In group A, the Conserve® Plus resurfacing arthroplasty was implanted with 
both components made of a cast, heat-treated solution- annealed cobalt-chrome alloy. The 
femoral component was cemented with low-viscosity cement after preparation of the femoral 
head with multiple subchondral anchor holes, and the hydroxyapatite (HA)-coated acetabu-
lar component  under­reamed by 1 mm was press­fitted into the acetabulum. The surgical 
technique has been described in detail before.14 Cementing around the stem of the femoral 
component was avoided. 
In group B, an uncemented grit-blasted titanium alloy Zweymüller® tapered stem and a 
threaded acetabular component were implanted. As this trial was designed to minimize con-
founding variables, a metal-on-metal bearing was also used for THA with a Metasul 28 mm 
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diameter modular head and a Metasul lined acetabular component. Both groups received 
identical prophylaxis against infection, periarticular ossification and venous thrombosis du-
ring the hospital admission and for six weeks after operation. Patients mobilised without any 
weight-bearing restriction according to their tolerance. 
The BMD was measured by DEXA (Lunar Prodigy, GE Healthcare, Little Chal font, United 
Kingdom) with the software package Encore 2007 version 11.30.062. Measurements were 
performed two weeks pre-operatively and then at three, six and 12 months after surgery. Sin-
ce the actual ROI could only be defined after implantation of the hip components, these ROI 
were imported from the three-month DEXA scan to the pre-operatively DEXA scan in order 
to measure baseline BMD levels in the absence of the implant. The patients were positioned 
supine on the examination table with their feet attached to a positioning device to obtain a 
standardised reproducible 20° of internal rotation. Mortimer et al. found that a range of 15° 
internal to 15° external rotation yields a precision of 1.7%.15 The software used in our study 
was designed to measure the periprosthetic BMD in five ROI in the proximal femur in group 
A and one ROI (Gruen zone 7) in group B with a mean entrance skin dose of 37 mSv per 
patient (Figure 2). 
Figure 2 Templated example of the measurement of bone mineral density in: A the five separate region 
of interest (ROI) in hip resurfacing arthroplasty; B in total hip arthroplasty; C a diagrammatic representa-
tion of distribution of the areas of interest.
Tests using phantoms have shown that our DEXA scans are accurate for the determination 
of peri-prosthetic BMD with an error below 1%.10 In addition, precision and reproducibility 
of the DEXA measurements for each ROI were assessed on 15 patients (eleven male, four 
female, eight hip resurfacing arthroplasty and seven THA) with a mean age of 53 years (34 
to 63). They underwent two sequential DEXA examinations of the involved hip, taken on the 
same day and measured twice by two independent laboratory assistants, with repositioning 
between each scan. The precision error was then expressed as the coefficient of variation 
percentage and calculated according to Aldinger et al.16 The precision in our study (Table 2) 
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was adequate and consistent with the literature.16,17 Additional quality controls for the DEXA 
equipment were undertaken daily according to the manufacturer’s guidelines to verify the 
stability of the system. No change was observed during the entire study period.
Table 2 Percent coefficient of variation (CV%) in ROI 1 to 5
ROI 1 2 3 4 5 Mean (SD)
CV% 1.2 2.1 2.0 2.7 3.5 2.3 (0.7)
Statistical analysis
The BMD data were normally distributed and the differences in each ROI between the two 
groups pre-operatively and at each follow-up were analysed using a Student’s t-test. The 
change of the BMD in each ROI over each observation period was assessed by repeated 
analysis of variance (ANOVA) for the two groups. For purposes of clarity the mean change 
in BMD is described as the percentage relative to the pre-operative mean value. Differences 
were considered statistically significant with a p­value <0.05. All statistical analyses were 
performed using SPSS software version 15.0.1 (SPSS Inc., Chicago, Illinois).
Results
The patient characteristics are presented in Table 1. As expected, the mean operating time 
for group A was significantly longer than for group B (Student’s t­test; p<0.001), demonstra-
ting the inherent technical difficulty of the resurfacing procedure. There was no significant dif-
ference in pre-operative mean BMD at ROI 5 which matched Gruen zone 711 for resurfacing 
compared with THA (Student’s t­test; p=0.785) (Table 3). The mean BMD ratios obtained du-
ring the 12-month follow-up, compared with the mean baseline levels, are shown in Table 4. 
Table 3 Mean (SD) bone mineral density (g/cm2) for each group at each study interval
Pre-operative 3 months 6 months 12 months
Group A (RHA) n=29 n=29 n=27 n=20
Group B (THA) n=30 n=30 n=28 n=20
ROI 1 Group A 0.88 (0.32) 0.82 (0.29) 0.85 (0.28) 0.93 (0.29)
ROI 2 Group A 1.32 (0.33) 1.31 (0.35) 1.33 (0.35) 1.35 (0.36)
ROI 3 Group A 0.92 (0.31) 0.88 (0.27) 0.90 (0.28) 0.95 (0.28)
ROI 4 Group A 1.28 (0.25) 1.27 (0.25) 1.29 (0.24) 1.34 (0.25)
ROI 5 Group A 1.87 (0.32) 1.92 (0.41) 1.97 (0.39) 1.97 (0.40)
ROI 5 Group B 1.90 (0.39) 1.67 (0.39) 1.57 (0.43) 1.53 (0.40)
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Table 4 Mean (SD) bone mineral density ratio (%) for each group at each study interval
Pre-operative 3 months 6 months 12 months
Group A (RHA) n=29 n=29 n=27 n=20
Group B (THA) n=30 n=30 n=28 n=20
ROI 1 Group A 100 94.1 (10.4) 97.3 (10.9) 101.3 (10.9)
ROI 2 Group A 100 98.5 (9.8) 100.2 (9.2) 100.9 (7.7)
ROI 3 Group A 100 92.0 (8.0) 95.0 (7.6) 96.6 (7.8)
ROI 4 Group A 100 99.0 (6.1) 100.2 (5.6) 100.5 (4.7)
ROI 5 Group A 100 103.5 (10.0) 105.2 (9.2) 105.2 (9.7)
ROI 5 Group B 100 88.8 (12.7) 84.0 (15.0) 82.1 (14.6)
After resurfacing the BMD values of ROI 1, 2 and 4 revealed a slight, non­significant de­
crease in BMD during the first three months (Student’s t­test; ROI 1 p=0.486, ROI 2 p=0.955, 
ROI 4 p=0.774), together with a subsequent restoration to the baseline pre­ perative values 
at 12 months (Figure 3). In contrast, in ROI 3 of the tip of the peg of the resurfacing arthro-
plasty, a significant decrease to 92% of the baseline values (ANOVA; p<0.001) was observed 
at three months which remained 96.6% (ANOVA; p=0.046) of the mean pre­operative value 
at 12 months. 
Figure 3 Graph of the mean 
bone mineral density ratio as 
a proportion of the pre-ope-
rative baseline values (100%) 
for all region of interest (ROI) 
in resurfacing hip arthro-
plasty (RHA) and total hip 
arthroplasty (THA).
Due to the nature of a resurfacing arthroplasty compared to a THA, only BMD values of ROI 
5 representing Gruen zone 7 were available for both implants. The mean BMD ratio in ROI 
5 increased to 105.2% of the pre-operative mean values after resurfacing within six months 
(ANOVA; p=0.012), while in the same ROI the mean BMD ratio for THA decreased signifi-
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cantly to 82.1% (ANOVA; p<0.001). The actual decrease of 17.9% of the mean BMD ratio in 
Gruen zone 7 for the THA group was most marked in the first six months after surgery and 
remained stable thereafter. This pattern of difference in BMD changes between the two im-
plants in ROI 5 persisted at one year, with a further reduction in the mean BMD ratio for the 
THA group which remained significantly different from the findings in the resurfacing arthro­
plasty patients (Student’s t-test; p<0.001).
Discussion
This prospective randomized controlled study indicates that the normal load transfer through 
the femoral neck is maintained or restored after hip resurfacing arthro plasty and there is an 
increase in desnity in the proximal femur. In contrast the BMD was reduced after the unce-
mented THA used in this study. 
These results are in accordance with earlier case control studies, which also reported an 
increase of BMD in the calcar region to 105% at 12 months3,12 and 111% at 24 months in a 
resurfacing group,3 and a decrease of 17% in a THA group. However, both earlier studies 
were non-randomized case control series with the potential for bias in patient selection. In 
addition, the studies were small and the metal-on-metal HA-bearing was compared with a 
ceramic-on-polyethylene bearing couple. Our patients were randomized, producing com-
parable groups with similar demographics (Table 1) and bearing couples. The more recent 
DEXA software package used in our study permitted smaller ROI to be examined with greater 
accuracy, as indicated by the low coefficient of variation (Table 3). 
The literature is inconclusive regarding the extent to which stress-shielding affects the 
proximal femoral bone stock after resurfacing.4-8,18 The data from our randomized controlled 
trial clearly indicate preservation of BMD in the femoral neck after resurfacing arthroplasty 
and a significant increase of BMD in Gruen zone 7. In the control group of uncemented 
THA’s a significant decrease of the BMD in Gruen zone 7 was identified. This loss of BMD 
in the proximal femur is a consequence of stress­shielding in distally fixed uncemented 
THA’s.1,2,5,19-22 It has to be recognised that the choice of implant plays an important role in 
the progress of depletion of peri­prosthetic bone stock and thus may have influenced the 
observed changes in BMD in our study. However, since earlier studies3,12 with different types 
of resurfacing arthroplasty report similar changes, it appears that evidence is accumulating 
for true preservation of bone density after this procedure. 
We have evidence that BMD recovers in the proximal femur after resurfacing arthroplasty, 
which might be important at a future revision. We recognise the limitations of this study as the 
follow-up is short. Accordingly, caution must be observed in extrapolating the results at one 
year of an operation designed to last many years. The significant decrease of ROI 3 might 
be iatrogenic as the drill hole for the RHA peg extends beyond the peg itself. We looked at 
a range of aetiologies for the arthritis of the hip but could not perform any analysis of the 
subgroups as most patients had osteoarthritis. 
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Abstract
A randomized controlled trial was performed to evaluate acetabular bone mineral density 
(BMD) changes after hip resurfacing (RHA) versus an established conventional total hip 
arthroplasty (THA). A total of 71 patients were allocated randomly to receive either an RHA 
press­fit Co­Cr cup (n=38) or a THA with a threaded titanium cup and polyethylene­ metal­
inlay insert (n=33). The BMD in five separate periacetabular regions of interest (ROI) was 
prospectively quantified pre­operative until 24 months. We conclude that, in contrast to our 
hypothesis, periacetabular BMD was better preserved after RHA than after placement of a 
conventional THA. Long term follow­up studies are necessary to see whether this benefit 
in bone preservation sustains over longer time periods and whether it is turned into clinical 
benefits at future revision surgery.
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Introduction
One of the biggest concerns in total hip arthroplasty is long­term acetabular fixation and 
preservation of bone stock. According to the Swedish hip register 65% of all re-operations 
are because of an acetabular component revision.1 A thirty year follow-up of the Charnley 
arthroplasty by Callaghan et al.2 shows that revision of the cup is three times more common 
than stem revision. Polyethylene wear of acetabular components is a key factor in the deve-
lopment of periprosthetic osteolysis.3,4 Periprosthetic osteolysis with loosening of the socket 
frequently opposes the orthopedic surgeon with challenging acetabular bone defect recon-
structions. 
Metal-on-metal (MoM) hip arthroplasty was introduced as an alternative to overcome 
poly ethylene wear related prosthetic failure. Proposed advantages are a reduction of wear, 
a subsequent lower incidence of periprosthetic osteolysis and eventually improved prosthe-
tic survival.5 On the other hand, a resurfacing hip prosthesis needs a rigid and thick shell 
press­fit socket. Such a relatively thick and rigid socket makes the implant stiffer and more 
susceptible to localized bone resorption caused by stress shielding behind the implant.6 
These press­fit cups transmit forces sideways to the peripheral cortical bone which induces 
stress shielding and a subsequent decrease of the cancellous bone mineral density (BMD) 
behind the cup.7-9 
The main theoretical benefit of resurfacing is the bone­preserving nature of the technique 
on the femoral side, however, when stress shielding results in osteolysis behind the cup, this 
benefit would be ineffective, if not detrimental. Finite element analyses predict medial bone 
loss up to 50% caused by stress shielding, and a bone gain near the prosthetic rim of press-
fit cups (which is the main loading site of the pelvis).10 Clinical dual energy X-ray absorp-
tiometry (DEXA) studies on metal­on­poly (MoP) conventional THA confirm these results.11,12 
Little is known about periprosthetic acetabular BMD changes around MoM implants and res-
urfacing hip arthroplasty (RHA) in particular. So far, only one study evaluated the acetabular 
BMD after RHA.13 In that study the periacetabular BMD was evaluated one year after an RHA 
and compared to the BMD in the contralateral non-operated hip, no prospective changes in 
BMD were recorded in this study. 
A randomized comparison between RHA and conventional THA for periacetabular BMD 
changes has not been previously reported. For this reason, we performed a prospective 
randomized controlled trial of an RHA versus a conventional MoM THA and evaluated BMD 
changes in five periprosthetic regions of interest (ROI) of the acetabulum. We hypothesized 
that due to stress shielding behind the RHA cup a more profound BMD decrease would be 
encountered as compared to an establish ed threaded conventional THA cup.
Materials and methods
This randomized study was designed to compare, amongst other outcome parameters, the 
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periprosthetic BMD changes in the acetabulum of patients who received an RHA against 
a conventional uncemented MoM THA. The BMD of the femoral side of these patients has 
already been reported by our group,14 we now present a further recruitment of patients.
From June 2007 till January 2010 82 patients were randomly assigned to receive one of 
the two hip implants types (RHA versus THA) (Figure 1). 
Figure 1 Consort statement: flowchart of participants throughout the study.
A computer-generated variable block schedule was used for randomization. The randomi-
zation list was generated by an independent statistician and the resulting treatment alloca-
121
Periacetabular BMD changes after resurfacing and total hip arthroplasty
9
tions were stored in sealed opaque envelopes. Randomization occurred at the outpatient 
consultation by the orthopedic surgeon at the time of planning the hip arthroplasty. Patient 
and the surgeon could not be blinded for the eventual type of implant,  neither could they 
influence the randomization outcome. The criteria for inclusion were patients under 65 years, 
who needed a primary hip replacement for osteoarthritis. Patients were excluded if they had 
(previous) infection of the hip or other sites, hip fracture, avascular necrosis with collapse, 
osteoporosis, neoplasm, or renal failure. Inclusion and subsequent follow-up of patients is 
summarized in the consort statement (Figure 1).
Five patients (three RHA, two THA) were lost to follow­up; directly after operation (n=2), af-
ter 12 months (n=1) and after 24 months (n=2). Three patients (one RHA, two THA) did not 
participate in all follow-up moments because of revision after 24 months, one patient passed 
away. One RHA was revised for unexplained pain and subtle signs of a periprosthetic ad-
verse reaction to metal debris (ARMD) on MRI scan, in two patients with a THA a relatively 
simple insert exchange was performed for recurrent dislocation. Seventy-one patients had a 
follow-up of 12 months; 38 RHA patients, and 33 THA patients, 51 patients had a follow-up 
of 24 months.  There were no significant differences between both groups for age, gender 
and BMI (Table 1). Approval from the regional ethics committee from the Radboud University 
Nijmegen Medical Centre was obtained (LTC 419- 071206). All patients agreed to sign an in-
formed consent form. The study was performed in compliance with the Helsinki declaration, 
and is registered in EudraCT (2006-005610-12). 
Table 1 Clinical details of the patients in both groups 
RHA
(n=38)
THA
(n=33)
p-value
Gender (women:men) 17:21 13:21 0.637 a
Mean BMI (SD) 26.1 (3.1) 28.0 (5.1) 0.083 b
Median acetabular cup size (range) 54 (48-60) 64 (58-68) <0.001 c
Median age at operation in years (range) 57.5 (40.7) 59.1 (27.8) 0.475 c
Diagnosis (OA/AVN/CHD) * 35/1/2 32/0/2 0.639 d
Median blood loss in mL (range) 300 (100-600) 250 (100-900) 0.993 c
Mean operating time in minutes (range) 75.0 (40) 54.0 (45) <0.001 b
* OA = osteoarthritis; AVN = avascular necrosis; CHD = congenital hip dysplasia. a Fisher’s exact 
probability test, b Student’s t-test, c Mann-Whitney U test, d Kruskall­Wallis test.
Surgical technique 
Pre-operative digital templating (Easyvision, Philips Medical Systems, Eindhoven, the 
Netherlands) for positioning of the implant was carried out for all patients. All surgeries were 
carried out by one of the authors (JvS) and two other experienced hip surgeons through 
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a posterolateral approach. In the RHA group a resurfacing prosthesis was implanted with 
both components made of a cast, heat-treated solution-annealed Co–Cr alloy (Conserve® 
Plus; Wright Medical Technology, Arlington, Tennessee, USA) (Figure 2). The femoral com-
ponent was cemented with low-viscosity cement after preparation of the femoral head with 
multiple subchondral anchor holes, the 6-mm hydroxyapatite (HA)-coated acetabular com-
ponent was pressfitted in the acetabulum (underreamed by 1 mm). The surgical technique 
has been described earlier.15 In the THA group, an uncemented grit-blasted titanium alloy 
Zweymüller® tapered stem was press­fitted in the femoral canal and a threaded solid backed 
titanium acetabular component was screwed in the acetabulum without additional screw 
fixation (Figure 3). 
Figure 3 Alloclasic Zweymüller® CSF with Metasul 
inlay; Zimmer Orthopaedics, Warsaw, Indiana, USA.
Figure 2 Conserve® Plus hip resurfacing; Wright 
Medical Technology, Arlington, Tennessee, USA.
As this trial was designed to minimize confounding variables, a metal-on-metal  bearing was 
also used for the THA together with a metal 28-mm head (Alloclasic Zweymüller® CSF with 
Metasul® inlay; Zimmer Orthopaedics, Warsaw, Indiana, USA). Both groups received iden-
tical antibiotic prophylaxis with Cephalosporin pre-operative and 24 hours postoperative, 
three days of Diclophenac for periarticular ossification prophylaxis, and thrombosis prophy-
laxis with Fraxiparine until six weeks postoperative. Patients were rehabilitated with imme-
diate unrestricted weight  bearing according to patient’s tolerance.16 
Bone densitometry 
BMD measurements and software have been described previously by our group.14 Briefly, 
the BMD was measured by DEXA (Lunar Prodigy, GE Healthcare, United Kingdom) with 
software package 13.60.033. Measurements were performed two weeks pre-operatively and 
then at 3, 6, 12 and 24 months after surgery. The patients were positioned supine with their 
feet attached to a positioning device to obtain a standardized reproducible 20° of internal 
rotation. Mortimer et al.17 found that a range of 15° internal to 15° external rotation yields a 
precision of 1.7%. Five ROI were carefully defined, modified from the regions defined by 
Wilkinson et al. (Figure 4).18
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Figure 4 Typical example of the measurement of BMD in the separate ROI’s by DEXA of RHA (A) and 
THA (B).
For each patient standardized analysis of each ROI was obtained using the manu facturers 
metal exclusion software. Since the ROI could only be defined after implantation of the hip 
arthroplasty, these ROI’s were imported in the pre-operatively available DEXA scan to measu-
re baseline BMD levels in the absence of the implant. Tests using phantoms have shown that 
DEXA is accurate for the determination of periprosthetic BMD with an error below 1%.19 In ad-
dition, precision and reproducibility of the DEXA measurements for each region in this study 
were assessed on fifteen patients (eleven male, four female; eight RHA and seven THA) with 
a mean age of 53 years (range 34–63). They underwent two sequential DEXA examinations 
of the involved hip, taken on the same day and measured twice by two independent labora-
tory assistants, with repositioning between each scan. The precision error was expressed as 
the coefficient of variation percentage, calculated according to Aldinger et al.20 The precision 
in our study (Table 2) was adequate and consistent with the literature.18,20,21 Additional quality 
controls for the DEXA equipment were undertaken daily according to the manufacturer’s 
guidelines to verify the stability of the system. No change was observed during the entire 
study period. 
Table 2 Percent coefficient of variation (CV%) in ROI 1 to 5
ROI 1 2 3 4 5 Mean (SD)
CV% 1.3 2.2 3.0 4.0 2.5 2.6 (0.9)
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Statistical analysis 
We conducted a power analysis based on the article of Lian et al.22 The minimal number of par-
ticipants needed in each group, to obtain a power of 80%,was determined at 34 patients,with 
a calculated difference of 2.98 percent (SD 6.14) in mean relative BMD. All BMD data were 
normally distributed and the differences in each ROI between the two groups pre-operati-
vely and at 3, 6, 12 and 24 months after surgery were analyzed using a Student’s t-test. The 
change of the BMD in each ROI over each observation period was assessed by repeated 
analysis of variance for the two groups. To compare the changes between the time intervals, 
the mean relative BMD as a percentage of the baseline value (presented as 100%) was cal-
culated. All normally distributed data are expressed as group means±SD. When not normally 
distributed a median and a range are given. Differences were considered statistically signi-
ficant at p<0.05 All statistical analyses were performed using SPSS software (version 18.0). 
Results
Patient characteristics are presented in Table 1. The mean operating time for the RHA group 
was significantly longer than for the THA group (p<0.001), demonstrating the inherent technical 
difficulty of the resurfacing procedure. The acetabular cup of the THA was significantly bigger 
than the RHA (p<0.001). Pre­operatively the BMD of ROI 3 (caudal zone) significantly differed 
between the two study groups with a higher BMD in the RHA group (p=0.006) (Table 3).
Table 3 Mean BMD (in g/cm2) (SD) for both groups in the postoperative period
Time 
(months)
Cranial Medial Caudal
ROI 1 ROI 5 ROI 2 ROI 4 ROI 3
RHA
(n=35) 0 1.78 (0.24) 1.71 (0.31) 2.01 (0.29) 1.48 (0.48) 1.48 (0.47) a
(n=38) 3 1.73 (0.29) 1.70 (0.36) 1.54 (0.35) 1.39 (0.52) 1.48 (0.47) a
(n=38) 6 1.76 (0.30) 1.72 (0.34) 1.53 (0.37) a 1.39 (0.52) 1.45 (0.45) a
(n=38) 12 1.75 (0.33) 1.72 (0.36) 1.57 (0.41) a 1.39 (0.49) 1.53 (0.51) a
(n=26) 24 1.77 (0.41) 1.73 (0.37) 1.54 (0.45) b 1.40 (0.54) b 1.45 (0.57) a
THA
(n=32) 0 1.78 (0.33) 1.76 (0.39) 2.03 (0.35) 1.34 (0.60) 1.19 (0.35) a
(n=33) 3 1.67 (0.29) 1.64 (0.35) 1.46 (0.29) 1.23 (0.56) 1.08 (0.35) a
(n=33) 6 1.63 (0.32) 1.67 (0.38) 1.35 (0.28) a 1.25 (0.54) 1.07 (0.31) a
(n=33) 12 1.61 (0.37) 1.61 (0.37) 1.31 (0.27) a 1.21 (0.57) 1.07 (0.27) a
(n=25) 24 1.60 (0.35) b 1.60 (0.39) b 1.34 (0.29) b 1.24 (0.46) b 1.05 (0.24) a,b
a Significant difference between RHA and THA (p≤.05). b Significant difference against baseline at re­
peated measures within each ROI (p≤0.05).
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There were significant differences between the two groups in mean relative BMD. Twelve 
months after surgery the mean relative BMD was significantly higher for RHA in all ROI’s ex-
cept for ROI 4 (p=0.028, p=0.001, p=0.040, p=0.293, and p=0.006, for ROI’s 1, 2, 3, 4 and 
5 respectively). At 24 months a significantly higher mean relative BMD still existed for ROI’s 
1, 2 and 5 (p=0.030, p=0.046, p=0.013). In ROI’s 1 and 2 there was also a difference at 6 
months in favor of RHA (p=0.017, p=0.018). The pattern of postoperative BMD decrease in 
ROI 2 was similar in both groups (Figure 5) with a steep decline in BMD from baseline till the 
first evaluation at 3 months. 
A difference of 13.6% between the two groups in mean relative BMD was obtained for the 
caudal ROI 3, at 12 months. In this region the BMD increased up to 105% for RHA versus a 
decrease up to 91% for THA (p=0.040). At 24 months there were only significant differences 
between RHA and THA in ROI’s 1, 2 and 5; 7.9% (p=0.030), 10.4% (p=0.046) and 8.1% 
(p=0.013) respectively, in favor of RHA. 
Figure 5 Graph of the mean 
relative BMD change, as per-
centage of pre-operative ba-
seline values with error bars 
indicating one standard devi-
ation for all ROI of RHA (black 
line) versus THA (gray line).
A Cranial to the acetabular 
cup ROI 1.
B Cranial to the acetabular 
cup ROI 5. 
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Figure 5 (continued) 
C Medial to the acetabular 
cup ROI 2. 
D Medial to the acetabular 
cup ROI 4. 
E Caudal to the acetabular 
cup ROI 3.
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Discussion
This prospective randomized controlled study shows that after an RHA both cranial ROI’s 
remained stable around baseline levels whereas for one cranial ROI the BMD decreased 
significantly after THA. As for the two medial ROI’s, the BMD decreased significantly for both 
implants (p<0.05), in one of these ROI’s this difference was in favor of the RHA group. BMD 
remained stable in the caudal ROI for RHA, whereas a significant decrease was found in the 
caudal ROI for THA. 
These results suggest that, unlike our hypothesis, the acetabular bone was be tter preser-
ved after the RHA with the rigid press­fit cup. The observed decrease in BMD medial to the 
cup (ROI’s 2 and 4) of 23% and 8.5% for RHA and 32% and 3% for THA at 24 months are 
in concordance with earlier literature on BMD changes after press­fitted cups of a conven-
tional THA. In clinical12,23,24 and finite element10,25 studies a 5% to 50% decrease was found 
in the ROI medial to the acetabular cup. The BMD preservation of RHA patients was most 
profound cranial to the cup (ROI’s 1 and 5) for RHA patients. This is in accordance with the 
recent report from Yahia et al.13 where similar results were found two years postoperative. In 
contrast to other studies, where a 3% to 35% decrease of cranial acetabular BMD was seen 
after the placement of a press­fit cup,7,9,23,26,27 we only found a significant decrease for one 
of the two cranial ROI’s in the THA group. As confirmed in other studies we found the most 
rapid changes in BMD in the first six months after surgery, but (smaller) BMD changes still 
occurred until 24 months.27-29
Wear and osteolysis are probably the most important factors that limit the survival of 
metal-on-poly THA. The articulation of the metal ball against the poly ethylene cup of the ace-
tabular component creates polyethylene wear debris. The macro phage-mediated response 
to these implant-derived particulate debris and probably other stimuli, results in local osteo-
clastic bone resorption.30 Using a metal-on-metal  bearing might prevent this wear-induced 
osteolysis, but does not overcome stress shielding and subsequent adaptive remodelling. 
Stress shielding is a major reason for periprosthetic bone loss after THA, because of chang-
es in load distribution as a consequence of the rigidity of an implant.7,25 Theoretically, the 
 thicker and stiffer press­fit acetabular cup of an RHA may increase periacetabular bone 
stress shielding.7-9,13,29 The rationale behind differences in stress shielding for press­fit or 
threaded cups is based on the elasticity modulus, whereas titanium is half as stiff as  cobalt–
chromium–molybdenum alloy (modulus of elasticity 114 vs. 214 GPa). There fore, one would 
expect that the stiffer and more robust monoblock cobalt-chromium shell would show more 
bone loss because of increased stress shielding as shown ‘in vitro’.7 We found the oppo-
site, the monoblock shell preserved relatively more cranial acetabular bone compared to 
the titanium threaded cup. Possibly the differences in modulus of elasticity between the two 
bearings in vivo were insufficient to effect the same quantitative changes in the BMD over the 
two years of the study. In our observations, that overall more BMD decline was encountered 
for THA patients as compared to RHA, we also have to realize that firm conclusions can only 
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be drawn for the implants used in our study. The use of a metal-on-metal bearing with the 
THA may for example have stiffened the acetabular component leading to more profound 
stress shielding and BMD decline. On the other hand we do feel that this potential influence 
may have been minimal. What we know from our clinical data of these patients is that RHA 
patients reach a higher activity level then patients with a conventional THA,31 this might be 
a possible confounder. This higher post operative activity level may have contributed to a 
reduced postoperative bone loss in the RHA group.32 On the other hand the encountered 
difference in activity score in favor of RHA patients was only limited and we do not feel that 
the difference in BMD  changes from can be explained by this phenomenon.
A remarkable finding in our study is the major decrease of BMD within the first 3 months of 
ROI 2 in both groups, whereas in other clinical studies11,23 a more gra dual medial BMD loss 
between 5% and 17% until one year postoperative has been described. All these studies, 
however, have their baseline measurements one to six weeks postoperative and therefore 
all measurements on BMD were performed on the postoperative situation with the implant in 
situ. One of the strengths of our study was the use of serial BMD measurements which are 
recorded truly against the pre-operative baseline values, unlike the study of Yahia et al.11,13 
who compared with the contralateral non-operated side only at one time interval. We believe 
that the steep decline in BMD in the medio-cranial ROI 2 between the pre-operative situation 
and 3 months after surgery can simply be explained iatrogenic by subchondral reaming 
and bone removal at the time of implantation and not by stress shielding. There are some 
remarkable findings in ROI 3 as well. At first, we found a lower pre­operative BMD for the THA 
patients. We do not have an explanation for this difference, as all other patient characteristics 
appeared to be matched after randomization. It could have had an influence on the results 
as there is a significant relationship between periprosthetic femoral bone loss and the pre­ 
operative BMD.28 Secondly, at 12 months we found an increase in BMD to 105% for RHA, this 
can be explained by an outlier of 260%. Without this outlier the mean relative BMD would be 
100%. Lastly, at all time intervals the standard deviation in ROI 3 of the RHA groups is almost 
twice as large compared to THA. The reason might be the difficulty of ROI analysis, although 
the coefficient of variation is only 3%, which is relatively low. 
Limitations of this study consist of the fact that patients and reviewing surgeons were not 
blinded. However, we do not see how these two factors can be overcome and are convinced 
that this has not biased our results. In RHA patients the cup size used appeared to be sig-
nificantly larger than for THA patients. This can be explained by the fact that the acetabular 
preparation was different between the RHA and THA socket. In the THA group a threaded 
conical cup was screwed in the acetabular socket which mandated removal of a relatively 
large amount of subchondral acetabular bone. This difference in acetabular preparation and 
cup size between groups is a confounding factor that theoretically may have affected the 
subsequently observed change in periprosthetic BMD for both implants, however, we feel 
that since our change in BMD is recorded against pre­operative baseline levels this influence 
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can only be very limited. In addition the software used to calculate the actual change in BMD 
did correct for the iatrogenic bone removal and thus a potential influence from this pheno-
menon on our results was also avoided. Another limitation is the presentation of the results 
up to two years, whereas stress shielding is a process of years. Therefore we will continue to 
follow these patients in time, as these data are part of a larger randomized trial on this matter. 
On the other hand, we know from the literature that a decrease in BMD after various types of 
arthroplasty mainly occurs during the first two years.28,29 Additionally, although DEXA remains 
a safe and reliable method to evaluate changes in BMD,19 the method only measures BMD 
and does not discriminate cancellous from cortical bone, and it is a two-dimensional projec-
tion instead of a three-dimensional measurement which can be performed with computed 
tomography. 
Protection of bone stock after hip arthroplasty is important, especially for the relatively young 
population, since revision surgery is likely to occur. In this study we focused on periprosthetic 
BMD changes in the acetabulum after a bone-preserving RHA and the potential pitfall of gra-
dual bone resorption due the effects of an acetabular cup implantation. We found that after 
placement of a thick press­fit resurfacing cup the supposed decrease of BMD seems not to 
be as critical as indicated in some finite element studies.10 
We can conclude that, on the short term, an RHA press­fit cup does not lead to more 
decline in periprosthetic BMD as compared to an established conventional threaded titanium 
acetabular component. The RHA used in this study thus appears to be relatively bone pre-
serving, also on the acetabular side, however stress shielding is a process of years and this 
follow-up so far is limited to 24 months. RHA  therefore does not appear to be more suscep-
tible for periprosthetic acetabular bone loss from stress shielding as compared to an esta-
blished titanium threaded shell with a well­defined clinical track record. Similar findings were 
already recorded by us for the femoral side14 and thus we believe that it is safe to conclude 
that RHA is indeed bone preserving on both the acetabular and the femoral sides. How ever, 
as these results are different from our hypothesis, clinical and biomechanical studies are 
necessary to assess why bone preservation is better around the RHA compared to the con-
ventional THA. A better understanding of periprosthetic bone remodeling may lead to further 
improvements of hip replacement implants.
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Chapter 10
Summary
Total hip arthroplasty (THA) is a very successful treatment for end-stage osteoarthritis of the 
hip. There is a trend towards increasing hip replacement surgeries,1 not only because of an 
increasing number of patients with osteoarthritis of the hip, but because the lower age limits 
are also stretched. The working age patient (with high hip activity demands) with end- stage 
osteoarthritis demands to be treated with the same successful treatment as the older age 
group. Unfortunately, these younger patients are very likely to outlive a conventional metal- 
on-polyethylene (MoP) THA because of polyethylene wear and related consequences. This 
is the rationale behind the search for other bearing materials, and the revival of the me-
tal-on-metal (MoM) implants. MoM hip resurfacing (RHA) is an old concept, with an improved 
design and metallurgy (since the 1990s and 2000s). MoM bearings claims to be more wear 
resistant, and are therefore expected to show less osteolysis and aseptic loosening. The 
overall aim of this thesis was to obtain an objective comparison between RHA and THA and 
confirm or reject the proposed (dis)advantages of RHA with respect to clinical outcome, me-
tal ion and bone mineral density evolution. This chapter will summarize the outcomes after 
RHA, which will be discussed following the seven aims laid out in Chapter 1.
To determine the single surgeon learning curve of RHA
From a surgical perspective, hip resurfacing is a more demanding procedure than THA. 
Component positioning is a factor under the surgeon’s control and, in particular, acetabular 
position is an important determinant of the ten year survivorship.2,3 Pitfalls are a relatively 
steep cup position and a femoral component position in the posterior one-third of the col-
lum. A poor cup orientation can lead to edge loading (a phenomenon whereby the femoral 
component comes into contact with the edge of the acetabular component), and as a con-
sequence increased wear and metal debris accumulation. According to retrieval studies, 
the latter can lead to pseudotumor formation, which is four times more likely with a cup not 
positioned in the safe zone.4 
To determine whether a learning curve was present, the radiological results of the first 
forty patients who underwent RHA in our clinic (divided in four subsequent cohorts of ten pa-
tients), were studied. The results are presented in Chapter 2. For each patient six established 
radiographic parameters on implant positioning5 were measured on the pre-operative plan-
ning template with the optimal implant posi tioning. These parameters were compared with 
those of the actual implant posi tioning on postoperative standardized radiographs. In the last 
cohort, on average 10 min shorter operation time was needed compared to the first cohort 
(p<0.013). The optimal radiological position of an RHA is less than fifty degrees of acetabular 
abduction and a slightly valgus orientation central in the collum of the femoral component. 
The subsequent four cohorts showed a trend towards a less steep cup placement, a pro-
gressive valgus orientation of the stem and a highly reproducible cup-head angle. In each 
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subsequent cohort the difference was reduced between the pre-operative planned position 
and the final postoperative implant position. A clear trend towards optimal stem positioning 
in the central third of the femoral neck in two radiographic planes was detected throughout 
the four cohorts. A reproducible optimal implant position was achieved within forty patients, 
if performed by an experienced hip surgeon, and proves to be an acceptable learning curve 
for RHA.
To compare RHA and 28-mm MoM THA with regard to short-term metal ion evolu-
tion, functional results and complications
The short-term results of the randomized controlled trial (RCT) between the Conserve® Plus 
RHA (Wright Medical Technology, Arlington, Tennessee, USA) and Zweymüller® Classic Me-
tasul® THA (Zimmer Orthopaedics, Warsaw, Indiana, USA) are presented in Chapter 3. From 
June 2007 till January 2010 seventy-one patients were randomized for either implant (38 
RHA; 33 THA) and forty patients had a follow-up of at least 24 months (19 RHA, 21 THA) at 
the time of this manuscript. Patient characteristics were comparable, except for operation 
time, which was longer for the RHA patients (p<0.001). The main reason for hip replacement 
was end-stage osteoarthritis. As expected, in both groups the functional outcome scores 
improved significantly after surgery. RHA patients scored at 12 months significantly higher 
on University of California Los Angeles (UCLA) activity score (8 vs 7) and Visual Analogue 
Scale (VAS) satisfaction (95 vs 85) and at 24 months on UCLA (8 vs 7) and Oxford Hip Score 
(OHS) (13 vs 16). Chromium whole blood levels in the unilateral patients were significantly 
higher for RHA (p<0.001), whereas cobalt concentrations were comparable to those in THA. 
At 24 months median chromium concentrations were 1.2 µg/L (0.1-2.3) vs 0.5 µg/L (0.1-2.1), 
for cobalt this was 1.2 µg/L (0.5-2.2) vs 0.9 µg/L (0.1-2.7) for RHA and THA respectively. In 
the THA group there were three patients with recurrent dislocation, two of them had a simple 
cup insert exchange. No dislocations occurred in the RHA group. One RHA was revised for 
early aseptic loosening because of avascular necrosis of the femoral head; the cobalt level 
in this patient prior to revision was 2.3 µg/L. 
Cobalt and chromium levels correlate with linear and volumetric wear of the femoral com-
ponent.6,7 High metal ion concentrations can be caused by continuous elevated wear as 
a result of edge loading from a steep acetabular positioning or a lower coverage angle 
design.6,8 Excessive release of cobalt and chromium particles may result in Aseptic Lympho-
cytic Vasculitis-Associated Lesions (ALVAL), metallosis and pseudotumor formation, all also 
known under the collective term Adverse Reaction to Metal Debris (ARMD), requiring revision 
surgery.9-11 The reported incidence of pseudotumors varies, depending on type of follow-up, 
patient characteristics, and implant design features. This is discussed in Chapter 7. In nei-
ther group there was suspicion for pseudotumor formation at the time of latest follow-up. It 
has to be noted however that cross-sectional imaging screening on the presence of pseudo-
tumor formation was not part of this RCT. After the run-in phase four unilateral (three RHA, 
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one THA) and one bilateral (RHA) implants were considered extreme outliers, all with good 
clinical scores. Median metal ion levels were higher for the RHA patients, but remained below 
the proposed non-deviant limit of 2 µg/L for unilateral implants.12 OHS, VAS satisfaction and 
UCLA activity score showed to be somewhat higher in the short-term for RHA patients. How-
ever, despite randomization, pre-operative UCLA activity levels were also in favor of RHA.
To assess whether a profound patient preference for RHA did influence clinical 
outcome and patient satisfaction
Patient satisfaction plays a vital role in outcome scores. A stable, well-positioned implant 
with low wear characteristics can still be classified a failure if the patient is not satisfied. 
Postoperative patient satisfaction is influenced by pre­operative expectations. Prior to even-
tual randomization for the RCT, patients were well informed about the known advantages and 
disadvantages at the outpatient department. However, randomizing for either RHA or THA in 
a period when RHA was marketed as ‘sport prosthesis’ and the ideal solution for the young 
and/or active patient proved extremely difficult. Patients base their perceptions and expecta-
tions, which can be totally inconsistent with known published results, on other sources than 
their orthopedic surgeon.13 Certain patients proved to have an extremely high preference for 
RHA and did not want to participate in the RCT. These patients were followed in a separate 
cohort of RHA patients with an identical follow-up protocol as the RCT. The differentiation be-
tween the cohort (preference) and RCT (randomized) patients was their explicit preference 
for RHA or not. This gives the opportunity to identify whether preference bias of these cohort 
patients positively or negatively influenced postoperative satisfaction and clinical results. 
The results of the comparison between 22 cohort patients and 28 RCT patients with an 
RHA are presented in Chapter 4. Both groups had twelve months postoperative a high VAS 
satisfaction; 97/100 for the preference patients and 93/100 for the randomized patients. Har-
ris Hip Score (HHS), OHS and UCLA activity score re vealed a similar significant improve-
ment up to twelve months (p<0.001). Regarding the Short-Form-12 (SF-12), the preference 
patients scored pre­operatively lower on the mental subscale (p=0.03) and showed a greater 
increase after twelve months compared to the randomized patients (p=0.03). An influence of 
preference on patient satisfaction and early clinical outcome after RHA could not be objecti-
fied. This contradicts a meta­analysis which did find an influence of preference on treatment 
effect size, which was hypothesized to rely on better compliance and motivation.14 Patient 
compliance might be worse when not receiving the preferred treatment if the treatment proto-
cols differ in medication, rehabilitation or adverse effects, this is not applicable for either hip 
replacement where patients received an identical rehabilitation protocol. 
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To determine the interchangeability and provide a conversion formula between 
serum and whole blood metal ion measurements
The evaluation of metal ion levels is becoming increasingly important after a MoM hip re-
placement and serves as an indicator of bearing performance and device safety.15 Metal ion 
measurements have become an important tool in the diagnostic work-up of a malfunctioning 
MoM implant and the orthopedic surgeon is expected to know how to interpret them. For the 
assessment of metal ion levels in patients with a MoM hip prosthesis various matrices, such 
as whole blood, serum and urine can be used. There is no consensus on the best surrogate 
measure of metal ion exposure, both serum and whole blood measurements are used. 
In Chapter 5 the interchangeability of serum and whole blood metal ion measure ments 
was analyzed. This chapter provides also a guideline for interpretation of metal ion analysis 
in clinical practice based on 343 specimens from 60 RHA and 32 THA patients, respecti-
vely. The median metal ion levels were below 2 µg/L. Cobalt and chromium levels were in 
accordance with Chapter 2 significantly higher for RHA versus THA, although the differences 
decrease after the run-in phase. In accordance with Daniel et al. no direct interchange ability 
between whole blood and serum levels was found.16 The mean difference between blood 
and serum values was +0.13 µg/L for cobalt and -0.91 µg/L for chromium. The formula to 
convert serum into whole blood values was 0.34 + [0.88 * Co serum] for cobalt and 0.14 + 
[0.58 * Cr serum] for chromium, both with an acceptable prediction error less than ±1.0 µg/L. 
No recommendation for the use of whole blood over serum or vice versa can be given, for 
practical reasons whole blood may be favored. For the interpretation of metal ion concen-
trations it is important to be aware of renal impairment, implant design and positioning, and 
contamination by nutritional supplements, medication or other metal implants. With regard to 
implant design it is of paramount importance to define which implant brand and category of 
MoM hip implant it concerns: a MoM hip resurfacing, a large-diameter-head (LDH) MoM THA 
(greater than 36 mm diameter) or a small-diameter-head (SDH) MoM THA. These different 
implant designs have a different metal ion release pattern,10,17,18 the successes and failures 
cannot be lumped together. 
To assess the difference in trend evolution of metal ions after well and sub-optimal 
functioning RHA
To date there is no consensus on which levels are acceptable as cut off level to differentia-
te between well-functioning and sub-optimal functioning implants.19,20 In spite of abundant 
ongoing research upper metal ion concentration limits are ill defined. The Mayo Medical La-
boratories interpretive handbook, addresses 5 µg/L as upper limits for cobalt in whole blood 
and 17 μg/L in erythrocytes for chromium.21 In our guideline the values of De Smet et al. were 
adopted as upper acceptable limits; 4.4 μg/L for cobalt (odds ratio for revision 6.0) and 5.1 
μg/L for chromium (odds ratio for revision 4.3).22 The Medicine and Healthcare products Re-
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gulatory Agency (MHRA) recommends to check cobalt and chromium blood levels at least 
once postoperatively and perform cross-sectional imaging if these levels are above 7 ppb 
(ppb corresponds to μg/L).20 The Dutch Orthopaedic Society advices that 2­5 μg/L should 
result in an outpatient visit; 5­10 μg/L mandates cross­sectional imaging for ARMD; greater 
than 10 μg/L is an alarm signal and revision surgery should be considered with patient com-
plaints and cross-sectional imaging taken into account. Despite these guidelines, there are 
uncertainties about the consequences of prolonged elevated metal ion levels in patients and 
at what level the occasionally encountered events will occur. In addition to this confusion 
there is literature available on well-performing implants with relatively high levels of metal ions 
and malfunctioning implants with low values.6,7,23-27 
At this moment, the clinical significance of a single metal ion measurement and its inter-
pretation is not fully understood. The hypothesis was that the evolution of metal ion levels 
might be more informative than the currently demanded single measurements alone. The aim 
of this study presented in Chapter 6 was therefore to present a prospective follow-up of Co 
and Cr levels in a cohort of 48 unilateral RHA’s and potentially identify differences in the trend 
characteristic in the short-term between patients with well versus sub-optimal functioning 
implants. Based on the most recent postoperative functional outcome score — Harris Hip 
Score (HHS), 0 is the worst and 100 the best outcome — the patients were divided in well and 
sub­ optimal functioning. A HHS greater than or equal to 90 was defined as ‘well­ functioning’ 
(n=42), a HHS smaller than 90 was defined as ‘sub­optimal functioning’ (n=6). The cobalt 
and chromium levels and individual trends were analyzed in these patients with a median 
follow­up of 24  months. The median cobalt and chromium concentration are significantly 
higher for the sub-optimal group, at 24 months 0.95 µg/L (0.1-9.3) vs 6.2 µg/L (2.0-29.3) 
and 1.70 µg/L (0.6-13.3) vs 4.70 µg/L (2.9-17.5), respectively. The percentage of well-func-
tioning patients with increasing cobalt and chromium levels between two consecutive time- 
intervals (risers) gradually decreased from 90/86% (0-3 months) to 22/22% (24-36 months). 
The percentage of risers was higher in the sub-optimal group, in particular at 12-24 months. 
The median absolute increase of the subgroup of risers was significantly lower for the well­ 
functioning group at 12-24 months; 0.70 µg/L (0.1-4.6) vs 6.65 µg/L (2.9-23.7) for cobalt and 
0.80 µg/L (0.1-8.9) vs 11.6 µg/L (11.0-12.2) for chromium. It was concluded that sub-optimal 
functioning MoM implants have a different metal ion trend than well-functioning implants, a 
higher percentage of ‘risers’ and a larger absolute increase per interval. 
From these results a low threshold for repeated metal ion measurement is recommended 
(in particular cobalt, as this is the most toxic), in addition to patient complaints, physical 
examination and cross-sectional imaging, it can help to clarify if an implant is failing. For 
example, a single measurement Co level of 5 μg/L at 12 months is considered a borderline 
concentration. In a patient without complaints, an additional concentration at 24 months of 
3 μg/L would be quite reassuring (as it proves decreasing metal ion concentrations), where­
as a concentration of 6 μg/L would indicate a potential malfunctioning implant. For well­ 
functioning patients, it appears that an increase in metal ion levels is minimal after two years. 
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If metal ion levels increase structurally after 12 months, this might be an indication of increas-
ing wear and a potentially malfunctioning implant. Consecutive measurement after one year 
and a trend assessment can help in decision- making about revision surgery in patients with 
mild symptoms and borderline metal ion levels (4-5 µg/L).
To determine the rate of silent pseudotumors in a cohort of hip resurfacing patients
The characteristics associated with a malfunctioning MoM implant and adverse reaction to 
metal debris (ARMD) include high or rising metal ions, a steep cup positioning and com-
plaints. Currently, clinical signs, conventional radiographic evaluation and metal ion levels 
are mandated in guidelines to identify patients at risk. If these characteristics are aberrant, 
cross-sectional imaging by ultrasound, CT or Metal Artifact Reduction Sequence (MARS) 
MRI scan should be performed to detect pseudotumors. The sensitivity and specificity of 
the clinical characteristics are not indisputably established yet. It is suggested, that cross- 
sectional imaging on all patients with a MoM hip implant might be the only option to discover 
the real magnitude of pseudotumor formation after MoM arthroplasty. However, the clinical 
implications of the presence of pseudotumors are still unclear. 
Anticipating this possible upcoming screening for all patients, the screening protocol for 
the presence of asymptomatic pseudotumors in a cohort of 289 RHA’s was intensified.28 The 
aim of this study was to clarify whether one should be alert to the presence of silent pseudo-
tumors (pseudotumors in asymptomatic patients) in our cohort of hip resurfacing patients. 
Before the intensified screening protocol was initiated, no pseudotumors were suspected 
in the cohort of 289 RHA’s based on the available clinical scoring and conventional radio-
graphs. In Chapter 7 the occurrence of a pseudotumor on MARS­MRI in a high risk (n=11, 
12 hips), low risk (n=10, 10 hips) and routine follow­up group (n=19, 22 hips) is described. 
Female patients with a cup inclination angle greater than 45° and a femoral component size 
smaller than 50 mm were allocated to the high risk group. The low risk group consisted of 
asymptomatic male patients with a unilateral RHA, cup inclination angle smaller than 45° 
and femoral component size greater than 50 mm. The risk for pseudotumor development in 
the high, low and control group was 0.45, 0.33 and 0.30 respectively, and did not show sig-
nificant differences between the groups. In 15 of the screen ed hips (34.1%) pseudotumors 
were observed, of which six were graded mild, eight moderate and one severe MoM disease. 
27.3% of the pseudotumors could be regarded silent, this occurred regardless of risk group. 
In 80% of the screened patients metal ion levels were normal (below 40 nmol/L). Evaluation 
of clinical outcome, plain radiographs and metal ion levels underestimate the presence of 
pseudotumors in MoM patients and are not sensitive enough to detect all cases of ARMD. In 
conclusion, without cross-sectional imaging less pseudotumors are diagnosed and reported. 
There is, however, no consensus yet on the clinical relevance and consequences of pseudo-
tumor formation.
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To compare bone mineral density evolution after RHA and a 28-mm MoM THA
RHA is promoted as a femoral bone preserving implant. Protection of femoral and acetabu-
lar bone stock after RHA is important, especially for the relatively young population, since 
revision surgery is likely to occur. Bone loss prior to revision creates more complicated and 
complex revision surgery and a lower survival rate of the implants after revision. A potential 
pitfall of RHA might be gradual bone resorption at the femoral calcar and at the medial aceta-
bular wall due to stress shielding. To determine femoral and acetabular bone mineral density 
changes after RHA compared with a 28-mm MoM THA a randomized controlled study with 
DEXA was performed and described in Chapter 8 and Chapter 9. DEXA measurements 
were made pre-operative, at 3, 6, 12 and 24 months with mean relative bone mineral density 
(BMD) calculated as a percentage of pre-operative (baseline) values. 
In Chapter 8 the results of consecutive standardized DEXA scans up to 12  months after 
RHA (n=20) and THA (n=22) are presented. BMD was measured in the calcar region (Gruen 
zone 7) in both groups and four additional measurements of femoral regions of interest (ROI) 
in the RHA group. RHA did indeed preserve bone mass in the femoral neck. The mean 
rela tive BMD of the calcar significantly increased to 105.2% (p=0.012) for RHA versus a 
de crease to 82.1% (p<0.001) for THA, one year after implantation. The difference between 
groups was significant (p<0.001). In the four additional femoral ROI, an initial early non­ 
significant de crease in bone density after RHA was followed by recovery to baseline levels 
after 12 months. 
In Chapter 9 the results are presented of BMD measurements of the acetabulum up to 
24 months after RHA press­fit cobalt­chromium cup (n=38) and THA threaded titanium cup 
with poly­ethylene­metal­inlay (Metasul) insert (n=33). The BMD in five separate acetabular 
periprosthetic ROI was prospectively quantified, which could be divided in two cranial, two 
medial and one caudal ROI. Our hypothesis was that periacetabular BMD would be better 
preserved after THA than after placement of a RHA. After an RHA both cranial ROI’s remain-
ed stable around baseline levels (ROI 1 98.7%; ROI 5 101.9%) whereas after THA the cranial 
ROI 1 showed a significant BMD decrease (ROI 1 90.8% (p<0.001); ROI 5 93.8% (p=0.055)). 
As for the two medial ROI’s, the BMD decreased significantly for RHA to 77.7% and 91.5% 
and THA to 67.3% and 97.0% (ROI 2 and 4 respectively) (p<0.05), in one of these ROI’s this 
difference was in favor of the RHA group. BMD remained stable in the caudal ROI 3 for RHA 
at 99.8%, whereas a significant decrease was found for THA at 93.5% (p<0.001). Unlike the 
hypothesis, the acetabular bone was better preserved after the rigid press­fit cup RHA. The 
observed decrease in BMD medial to the cup (ROI 2 and 4) of 23% and 8.5% for RHA and 
32% and 3% for THA at 24 months are in concordance with earlier literature on BMD changes 
after conventional THA with press­fit cups. An RHA press­fit cup does not lead to more decli-
ne in periprosthetic BMD as compared to an established conventional threaded titanium ace-
tabular component. However, this is debatable if bigger acetabular cups are implanted with 
RHA (and therefore more acetabular bone is resected) in order to match the corre sponding 
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diameter of the femoral component.29-31 On the femoral side a more natural loading is proven 
after RHA, whereas bone diminution occurred after a conventional uncemented THA. In the 
short term in the femur and the acetabulum, RHA is more bone mineral density preserving 
compared to THA.
Discussion
As RHA is a (re-introduced) new concept and design for hip replacement it is important to 
compare its results with the gold standard, the THA. For this thesis, a randomized controlled 
trial was performed to provide an objective clinical comparison between RHA and THA, to 
increase the current level of evidence in literature, and to assess whether hip resurfacing 
would meet its expectations. Based on the results of this thesis it can be concluded that 
RHA does meet the expectations concerning bone mineral density, clinical outcome at short-
term and stability. The RHA preserves the femoral head and conserves more femoral and 
acetabular bone mineral density compared to THA at clinical relevant locations, like cranial 
and medial to the acetabular cup and the femoral calcar. Clinical outcome scores and sa-
tisfaction prove to be good to excellent after RHA in our short-term study. OHS, UCLA Acti-
vity and VAS satisfaction scored significantly higher compared to THA at some time points. 
However, despite randomization the RHA patients also had a higher UCLA activity score 
at the pre­operative stage, thus one can argue whether this benefit is clinically significant. 
The difference in patient satisfaction and early clinical outcome between THA and RHA can, 
according to our preference study, not be attributed to the fact that patients might have recei-
ved their preferred (RHA) implant. RHA proves to be the more stable implant, no dislocations 
were encountered compared to three dislocation in the THA group. With regard to metal ion 
levels, RHA initially produces higher cobalt and chromium levels than 28-mm MoM THA; 
at 24 months this difference was only significant for the chromium levels. Median metal ion 
levels remain, for the unilateral implants, below 2 µg/L. 
Based on the current literature and registry studies the ideal candidate for RHA is male, less 
than 55 years of age, has a femoral head size greater than 50 mm, a BMI smaller than 35 kg/
m2 and osteoarthritis as primary diagnosis.32-35 Male RHA patients with a femoral head size 
greater than 50mm have a ten year revision rate of 5.1%.35 When comparing RHA and the 
conventional MoP THA (regarded as the gold standard) for a male patient, below 55 years of 
age, with osteoarthritis, the ten year revision rates are 6.1% for RHA and 9.3% for MoP THA. 
Based on the Australian registry the RHA meets the NICE criteria (joint replacement 10-year 
survival greater than or equal to 90%) easily when implanted in young, preferably male (or 
female with femoral head size over 50mm) patients with osteoarthritis.35 It has to be noted 
that this successful 10 year follow-up is only available for two resurfacing brands (Conserve® 
Plus and Birmingham Hip Resurfacing (BHR)) and for a selected groups of ideal patients as 
described above.
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Registry data apply to the merged results of different types of RHA and MoM THA implants and 
there is increasing evidence that results differ between different manufacturers. The initial release 
of the BHR on the market was tightly controlled, with selected surgeons and emphasis on the 
need for good surgical techniques and patient selection. The positive biomechanical, hip simu-
lator and clinical (from designing surgeons) results of the BHR, drew the attention of other ma-
nufacturers keen to be part of the metal-on-metal revolution.36 Manufacturers in Europe and the 
United States all developed their own MoM hip implant systems, and each available device has a 
different combination of modifications of the original design features.6,37 Design features thought 
to influence wear are 1) the use of as cast versus forged material, 2) varying heat treatments of 
the components, 3) the radial clearance, 4) the arc of acetabular coverage, and 5) the angle of 
function of the femoral component.6 Some designs, with low wear properties in vitro, proved 
to be extremely sensitive to sub-optimal acetabular positioning with high wear rates in a large 
number of patients as a consequence. Larger sizes of different designs seem more resistant to 
sub-optimal positioning.6 In addition, large- diameter-head (LDH) MoM THA’s show substantial 
higher and clinical concerning levels of metal ion levels compared to RHA and one should not 
lump the results of LDH MoM THA together with the RHA. 
When the MoM devices were launched in Europe the regulatory parties placed these 
hip implants into a category of devices that required only hip simulator testing (an in vitro 
biomechanical cyclic loading process of the prosthesis) since the concept was considered 
only an extension of an earlier approved design. Several competing companies could thus 
quickly release their own MoM implant, since no clinical testing was mandatory to allow the 
release for commercial use. In the USA, the FDA considered the MoM THA components to 
be like other heads, cups, and stems already in use and declared they could be cleared 
through a 510(k) process. Therefore, again no clinical studies were required to show how 
LDH MoM heads worked when coupled with a modified stem.36 Stimulated by the relative 
‘easy’ approval and urged by receiving the return on their investment, the MoM implants were 
introduced rather quick onto the market by the manufacturers. The competition for market 
share resulted in an aggressive marketing campaign aiming at patients and surgeons. These 
circumstances resulted in a too fast global introduction of these new MoM implants, without 
data of long­term clinical results and identification of all possible complications.
At present, there are worldwide increasing concerns about these MoM implants. These con-
cerns focus on relatively high revision rates, pseudotumor formation and potential metal ion 
toxicity. There is clear evidence that the risk for these problems varies between different 
types of MoM implants and this applies both for differences in type of MoM implant (LDH-
THA versus RHA) and brand. On the other hand, no type or brand of these MoM implants is 
entirely free of these concerns. National guidelines from regulatory bodies and orthopedic 
societies differ throughout the world in their advice concerning MoM hip implants. These 
guidelines vary from attentiveness to restraints to prohibition, concerning specific designs or 
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all MoM prosthetic systems.12,20,38 Despite the apparent need, a uniform international consen-
sus is lacking. The problem of MoM hip replacement and the encountered adverse events 
are complicated, and research sometimes raises more questions than it answers. Another 
complicating factor is the number of involved parties consisting of patients, surgeons, manu-
facturers, researchers, regulatory bodies and notified bodies, each with their own interest, 
responsibility and involvement in the MoM hip implant problem. At a national level, encoun-
tered complications and concerns in literature, ask for a clear policy on MoM hip implants. 
In 2012, forced or not by the public opinion, it was decided to impose a time-out for all MoM 
hip replacements (including RHA and irrespective of implant brand) with a femoral head size 
greater than or equal to 36mm in the Netherlands.12 With respect to the increasing revision 
rates and commonly encountered complications after LDH MoM THA, this seems a justified 
decision. However, considering RHA, it may be that we are ‘throwing the baby out with the 
bath water’ by banning all brands of the RHA for all patients as well. On the other hand, dis-
tinct clinically relevant benefits of RHA over THA could not be proven by this thesis and many 
uncertainties persist with respect to MoM related problems. Both warrant a time-out of its 
use. The Australian registry reports on revision and survival data according to implant design 
and category, which may gives the possibility of distinguishing between failing and surviving 
RHA and MoM THA designs in the future.35 Already the differences between the well and non- 
functioning designs and MoM categories become increasingly clear. When RHA’s are com-
pared to LDH MoM THA’s, the ten year revision rates are 9.1% and 20.3%  respectively.35 This 
might, in time, give the opportunity to allow certain RHA implants, which perform according 
to the NICE criteria in the national registries and do not show unacceptable adverse events 
in clinical trials. It may be reasonable to allow those RHA implants, in a controlled setting in a 
very specific group of patients; male under 55 years of age, with a femoral head size greater 
than 50 mm, a BMI smaller than 35kg/m2 and osteoarthritis as primary diagnosis. 
This thesis has concentrated on patients receiving a single brand of RHA (Conserve® Plus; 
Wright Medical) and all patients were operated by a limited number of experienced hip sur-
geons. There is clear evidence that the chance of a MoM related problem differ between 
different RHA brands, and that more concerns are related to the LDH MoM THA concept 
as compared to RHA. While reading the results of this thesis one has to realize that these 
two factors may very well be responsible for the relatively good results presented. These 
results may be applicable for the type of implant used in this study and are most likely not to 
be generalized to all MoM implants. In addition, the studies of this thesis present data from 
short­term follow­up and longer follow­up will be necessary to draw firm conclusions. In the 
meantime, patients will be followed with great care. Metal ions blood levels, DEXA analysis 
and functional outcome scores are included in the standard follow-up protocol; currently 
nearly all of the patients are beyond the 3 year follow-up and no clear shift in outcome or revi-
sion has been encountered yet. In accordance to the guidelines from the Dutch Orthopaedic 
Association the use of RHA in our clinic has been abandoned; whether this proclaimed time-
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out is temporarily or permanent is not clear yet. For the near future cross-sectional imaging is 
planned with MARS-MRI on all the patients from the RCT and cohort of RHA as further clari-
fication of the incidence of silent pseudotumors is important. To date, there is no consensus 
on the incidence of pseudotumors after different types of MoM implants and above all there 
is no consensus on whether these silent pseudotumors are clinically relevant or insignificant. 
As the hype of MoM hip replacement has past and turned into a national professional allergy 
against MoM articulation, it is time to consolidate the successes and abandon the failures of 
MoM hip replacement in clinical practice. Therefore, re search to further identify the causative 
factors behind these failures and successes remains of major importance. Prolonged fol-
low-up of patients with MoM implants will help to determine to which extend there is a place 
for RHA and/or LDH MoM THA’s in a selected group of patients using a selection of currently 
available implants. 
Future research should probably focus on elucidation of consequences of prolonged 
exposure to high metal ion levels, determination of triggering factors of an ARMD in the 
human body, the clinical significance of asymptomatic pseudotumors and clinical outcomes 
after RHA revisions. Intensified and prolonged follow­up of the patients with a MoM implant 
throughout the world will help clarify these issues and to establish whether the current debate 
on MoM bearing concerns will justify further use or not.
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Chapter 11
Samenvatting
Nederland kent 238.00 mensen coxartrose (artrose van de heup). Jaarlijks komen hier 27.000 
nieuwe gevallen bij. Coxartrose kan ernstige beperkingen in het dagelijks functioneren ver-
oorzaken en de artrosepatiënt kan hierdoor van zijn omgeving en de gezondheidszorg af-
hankelijk worden. Indien pijnstilling en fysiotherapie niet effectief zijn in het reduceren van 
klachten bij invaliderende coxartrose kan een heupprothese worden overwogen. De totale 
heupprothese (THP) is een zeer succesvolle behandeling voor eindstadium coxartrose en 
werd door Learmonth zelfs ‘de operatie van de eeuw’ genoemd. Het is dus niet verwonderlijk 
dat in de loop der jaren het aantal heupvervangende operaties toegenomen is. Deze trend 
wordt niet alleen veroorzaakt door de vergrijzing en de daarbij behorende toenemende in-
cidentie van coxartrose, ook worden de onderste leeftijdsgrenzen voor heupprothesiologie 
verruimd. De jongere patiënt (onder de 60 jaar) met eindstadium coxartrose wil graag de-
zelfde succesvolle behandeling als de oudere coxartrosepatiënt. Deze jongere patiënten 
hebben echter een grote kans om hun conventionele metaal-op-polyethyleen-heupprothese 
(MoP-THP) te overleven. De oorzaak hiervan is polyethyleenslijtage en de daaraan gerela-
teerde gevolgen zoals loslating van de prothese, pijn en/of instabiliteit. Dit is de achterlig-
gende gedachte in de zoektocht naar alternatieve materialen voor de heuparticulatie, en de 
opleving van metaal-op-metaal-implantaten (MoM). Heupresurfacing (RHA) is reeds een oud 
concept, maar sinds de jaren 90 en 00 is het design en het metaalbewerkingsproces door-
ontwikkeld en verbeterd. De MoM-gewrichtsoppervlakten zouden hierdoor slijtvaster zijn en 
minder osteolyse en aseptische loslating veroorzaken. Het algemene doel van dit proefschrift 
is de RHA en THP objectief te vergelijken met betrekking tot klinische resultaten,  samen met 
het beloop in de tijd van metaalionenconcentraties in bloed en botdichtheidsveranderingen. 
Bepalen van de leercurve van een individuele chirurg voor de plaatsing RHA 
Een RHA is een complexere ingreep dan een conventionele THP. De juiste acetabulaire cup-
positie is bovendien een belangrijke factor voor de tienjaarsoverleving van een prothese en 
volledig afhankelijk van de kunde van de chirurg. Valkuilen in de positionering van een RHA 
zijn een steile cupplaatsing en plaatsing van de steel in de posterieure derde van het collum. 
Een slechte cuporiëntatie kan leiden tot edge loading (een fenomeen waarbij de femorale 
component in contact komt met de rand van de acetabulaire component), met als gevolg 
verhoogde slijtage en lokale ophoping van metaalpartikels. Volgens retrieval studies (studies 
waarbij gereviseerde componenten worden onderzocht) kan dit laatste leiden tot pseudo-
tumorvorming. Als de cup niet juist gepositioneerd is, is deze kans viermaal groter.
Om het verloop van de leercurve te onderzoeken werden de radiologische resultaten van de 
eerste veertig RHA-patiënten (verdeeld over vier cohorten van tien patiënten) in het Zieken-
huis Rijnstate beoordeeld. De resultaten van dit onderzoek worden in Hoofdstuk 2 gepresen-
teerd. Zes vooraf vastgestelde radiologische parameters voor de implantaatpositie werden 
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op de preoperatieve planning (met daarop de optimale oriëntatie) gemeten. Deze parameters 
werden vergeleken met de uiteindelijke positie op de gestandaardiseerd genomen postope-
ratieve röntgenfoto. In de laatste cohort was gemiddeld tien minuten minder operatietijd 
nodig ten opzichte van de eerste cohort (p<0,013). De optimale röntgenologische plaatsing 
van een RHA is minder dan vijftig graden abductie van de cup en een femorale component 
centraal in het collum met lichte valgus. De opeenvolgende cohorten lieten per cohort een 
minder steile cupplaatsing, een progressieve valgus en een grote reproduceerbaarheid van 
de cup-kop-hoek zien. In de opeenvolgende cohorten nam het verschil tussen de positie op 
de preoperatieve planning en de definitieve postoperatieve positie af. Er was ook een duide-
lijke verbetering zichtbaar naar de optimale femorale positionering in de centrale derde van 
de femorale hals in twee radiologische vlakken. De optimale prothese- oriëntatie met een gro-
te reproduceerbaarheid werd door een ervaren heupchirurg binnen veertig patiënten bereikt.
Vergelijken van RHA en 28-mm-MoM-THP met betrekking tot de kortetermijn-
resultaten van metaalionenverloop, functionele uitkomsten en complicaties
De kortetermijnresultaten van de gerandomiseerde klinische studie (RCT) naar de Con-
serve® Plus RHA (Wright Medical Technology, Arlington, Tennessee, USA) en Zweymüller® 
Classic Metasul® THP (Zimmer Orthopaedics, Warsaw, Indiana, USA) worden gepresenteerd 
in Hoofdstuk 3. Van juni 2007 tot januari 2010 werden 71 patiënten gerandomiseerd voor 
een van beide implantaten (38 RHA, 33 THP), veertig patiënten hadden ten tijde van pu-
blicatie van het artikel een follow-up van ten minste 24 maanden (19 RHA, 21 THP). Beide 
groepen waren vergelijkbaar met betrekking tot geslacht, leeftijd, body mass index (BMI) 
en bloedverlies tijdens de operatie. De operatietijd was echter langer voor de RHA-pati-
enten (p<0,001). Zoals verwacht verbeterden postoperatief de functionele uitkomstmaten 
significant in beide groepen. RHA­patiënten scoorden na 12 maanden significant beter op 
de University of California Los Angeles-activiteitsscore (UCLA; 8 versus 7) en Visual Ana-
logue Scale-tevredenheid (VAS; 95 versus 85). Na 24 maanden werd er ook een verschil 
gezien in UCLA-activiteitsscore (8 versus 7) en Oxford Hip Score (OHS; 13 versus 16). De 
preoperatieve UCLA-activiteitsscores waren ondanks randomisatie echter ook beter voor de 
RHA- patiënten. De volbloedconcentraties van de unilateraal geïmplanteerde RHA-patiënten 
waren voor chroom significant hoger (p<0,001), terwijl de kobaltconcentraties vergelijkbaar 
waren met die van de THP-patiënten. Na 24 maanden was de mediane chroomconcentratie 
1,2 µg/L (0,1-2,3) versus 0,5 µg/L (0,1-2,1) voor respectievelijk RHA en THP, voor kobalt was 
dit 1,2 µg/L (0,5-2,2) versus 0,9 µg/L (0,1-2,7). Ten aanzien van complicaties werden in de 
THP-groep drie patiënten met recidiverende heupluxaties gezien, twee van hen kregen een 
eenvoudige cupinsertwissel. Eén RHA-patiënt werd gereviseerd ten gevolge van een vroege 
aseptische loslating door een avasculaire necrose van de femurkop; voorafgaand aan de 
revisie was de kobaltconcentratie 2,3 µg/L. 
Kobalt­ en chroomconcentraties correleren met lineaire en volumetrische slij tage van 
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de femorale component. Hoge metaalionenconcentraties kunnen veroorzaakt worden door 
een continu verhoogde metaalionenafgifte door slijtage ten gevolge van edge loading. Dit 
ontstaat als gevolg van een steile acetabulaire cuporiëntatie of een resurfacingdesign met 
een kleinere overdekkingshoek. Extreme afgifte van kobalt- en chroompartikels kunnen lei-
den tot aseptic lymphocytic vasculitis-associated lesions (ALVAL), metalose en pseudotu-
morvorming. De verzamelnaam voor deze bevindingen is adverse reaction to metal debris 
(afweerreacties op metaalpartikels; ARMD), waarvoor revisiechirurgie noodzakelijk is. De 
gerapporteerde incidentie van pseudotumoren varieert en is afhankelijk van type diagnos-
tiek, patiëntkarakteri stieken en implantaatdesign. Dit wordt tevens in Hoofdstuk 7 bespro-
ken. Tijdens de recentste follow-up was er in geen van beide groepen een verdenking op 
pseudotumorvorming. Hierbij moet aangemerkt worden dat gestandaardiseerde cross-sec-
tionele beeldvorming naar pseudotumorvorming geen deel uitmaakte van deze RCT. Na een 
run-in-periode van 12 maanden werden de metaalionenconcentraties van vier unilaterale 
(drie RHA, één THP) en één bilaterale (RHA) prothese aangemerkt als extreme uitbijters (een 
afwijking meer dan drie keer de interkwartielrange vanaf het hoogste kwartiel), Alle patiënten 
hadden goede klinische scores. De mediane metaalionenconcentraties waren hoger voor de 
RHA-patiënten, maar bleven wel onder de niet-afwijkende waarde van 2 µg/L voor unilaterale 
implantaten. OHS, VAS-tevredenheid en UCLA-activiteitsscore van de RHA-patiënten toon-
den op korte termijn een beter resultaat. 
Vaststellen of een uitgesproken voorkeur voor RHA de postoperatieve uitkomsten 
en tevredenheid kan beïnvloeden
Patiëntentevredenheid speelt een belangrijke rol in postoperatieve uitkomstscores. Een sta-
biel, goed gepositioneerde prothese met geringe slijtage kan bijvoorbeeld worden aange-
merkt als een mislukking wanneer de patiënt niet tevreden is. Postoperatieve tevredenheid 
van de patiënt wordt deels beïnvloed door de preoperatieve verwachtingen. Voorafgaand 
aan de inclusie en randomisatie voor de RCT werden de patiënten goed geïnformeerd over 
de reeds bekende voor- en nadelen van een RHA. Echter, randomisatie voor RHA dan wel 
THP in een periode waarin de heupresurfacing werd gepromoot als ‘sportheup’ en de ideale 
oplossing voor de jonge en/of actieve patiënt bleek zeer moeizaam. Patiënten baseren hun 
percepties en verwachtingen, die volledig in strijd kunnen zijn met resultaten uit de literatuur, 
op andere bronnen dan hun orthopedische chirurg. Bepaalde patiënten bleken zo’n sterke 
voorkeur voor RHA te hebben dat zij niet wilden deelnemen aan de RCT. Deze patiënten wer-
den gevolgd in een separaat cohort van RHA-patiënten met identieke follow-up als de RCT. 
De differentiatie tussen de cohortpatiënten (voorkeursgroep) en RCT-patiënten (randomisa-
tiegroep) was hun expliciete voorkeur voor RHA of niet. Hierdoor kon worden vastgesteld 
of de voorkeurs bias van deze cohortpatiënten de postoperatieve tevredenheid en klinische 
resultaten positief beïnvloedt. 
De resultaten van de vergelijking tussen 22 cohortpatiënten en 28 RCT- patiënten met 
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een RHA worden gepresenteerd in Hoofdstuk 4. Beide groepen hadden twaalf maanden 
postoperatief een hoge VAS-tevredenheid: 97/100 voor de voorkeursgroep en 93/100 voor 
de randomisatiegroep. HHS, OHS en UCLA toonden voor beide groepen een vergelijkbare 
verbetering na twaalf maanden (p<0,001). Met betrekking tot de SF-12 scoorde de voor-
keursgroep preoperatief lager op de mentale score (p=0,03) en in vergelijking met de rando-
misatiegroep verbeterde zij na twaalf maanden significant meer (p=0,03). De invloed van 
voorkeur op patiënttevredenheid en vroege klinische uitkomsten na RHA kon niet worden 
aangetoond. Dit spreekt een meta-analyse tegen die wel een invloed vond van voorkeur 
op het effect van de behandeling, hypothetisch op basis van meer therapietrouw en mo-
tivatie van de patiënten. De therapietrouw zou slechter kunnen zijn wanneer patiënten niet 
hun voorkeursbehandeling zouden krijgen en de behandelingsprotocollen verschillen met 
betrekking tot medicatiegebruik, rehabilitatie en bijwerkingen. Dit is niet van toepassing op 
heupvervanging waarbij alle patiënten een identieke postoperatieve behandeling krijgen.
Bepalen of de metaalionenconcentraties in serum en volbloed uitwisselbaar zijn en 
een omrekenformule opstellen
De evaluatie van metaalionenconcentraties na een MoM-heup prothese wordt steeds belang-
rijker en wordt gebruikt als indicator van het functioneren en de veiligheid van de prothese. 
Van de orthopedisch chirurg wordt verwacht dat hij/zij behoort te weten hoe de waarden 
geïnterpreteerd dienen te worden. Voor de beoordeling van metaalionenconcentraties bij 
patiënten kunnen verschillende matrices worden gebruikt, onder andere bloed en 24-uurs 
 urine, waarbij analyse van bloed te voorkeur heeft. Er bestaat nog geen consensus welke 
meting in bloed het beste de metaalionenblootstelling in het lichaam weergeeft, zowel serum 
als volbloed kunnen worden gebruikt.
In Hoofdstuk 5 wordt de uitwisselbaarheid van serum- en volbloed-metaal ionenmetingen 
geanalyseerd op basis van 343 specimens van 60 RHA en 32 MoM-THP-patiënten. Dit 
hoofdstuk bevat ook een richtlijn voor de interpretatie van een metaalionenanalyse in de 
klinische praktijk. De mediane metaalionenconcentraties lagen onder de 2 µg/L. Kobalt­ en 
chroomconcentraties waren, in overeenstemming met Hoofdstuk 2, significant hoger voor 
RHA dan voor THP, hoewel de verschillen afnamen na de run-in-periode. Conform Daniel et 
al. is er geen directe uitwisselbaarheid tussen volbloed- en serumconcentraties gevonden. 
Het gemiddelde verschil van kobalt- en chroomconcentraties tussen volbloed en serum is 
respectievelijk +0.13 µg/L en -0.91 µg/L. De conversieformule voor serum- naar volbloed-
waarden is: kobalt volbloed = 0.34 + [0.88 * kobalt serum] en chroom volbloed = 0.14 + 
[0.58 * chroom serum], met een acceptabele foutmarge van ± 1.0 µg/L. Op basis van onze 
studie kan geen aanbeveling worden gegeven of volbloed boven serum geprefereerd kan 
worden, of vice versa. Vanwege praktische redenen zou volbloed volgens sommige studies 
de voorkeur hebben. Voor de interpretatie van metaalionenconcentraties is het belangrijk om 
op de hoogte te zijn van nier functiestoornissen, het design en (mal-)positie van de  prothese, 
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contaminatie door voedingssupplementen, medicijnen of andere metalen implantaten. Met 
betrekking tot het implantaat is het belangrijk te bepalen welk merk en categorie MoM- 
implantaat het betreft: MoM-heupresurfacing, een large-diameter-head-MoM-THP (>36mm) 
of een small­diameter­head­MoM­THP (≤36mm) (LDH­MoM­THP). Deze verschillende im-
plantaatontwerpen hebben een ander metaalionenafgiftepatroon en het succes en het falen 
van de verschillende categorieën kunnen niet worden gegeneraliseerd. 
Vaststellen of er een verschil is in trend van metaalionenconcentraties tussen goed 
en slecht functionerende RHA-prothesen
Tot op heden bestaat er geen consensus over welk afkappunt gebruikt moet worden om 
onderscheid te maken tussen goed en slecht functionerende implantaten. Ondanks een 
overvloed aan studies zijn de bovengrenzen van metaalionenspiegels slecht gedefinieerd. 
Het Mayo Medical Laboratories-handboek geeft voor kobalt in volbloed als bovengrens 5 
µg/L en 17 µg/L voor chroom in erytrocyten. Voor onze richtlijn is de waarde van De Smet et 
al. overgenomen als uiterst aanvaardbare bovengrens voor een goed functionerend MoM- 
implantaat; 4,4 µg/L voor kobalt (odds ratio van 6,0 voor revisie) en 5,1 µg/L voor chroom 
(odds ratio van 4,3 voor revisie). De MHRA adviseert kobalt en chroom ten minste eenmaal 
postoperatief in het bloed te bepalen en cross-sectionele beeldvorming (echo, CT, MRI) 
te verrichten indien deze waarden groter zijn dan 7ppb (ppb komt overeen met µg/L). De 
Nederlandse Orthopedische Vereniging (NOV) adviseert dat een waarde tussen de 2-5 µg/L 
moet leiden tot een poliklinische beoordeling, bij 5-10 µg/L is nader onderzoek met MRI, CT 
of echo geïndiceerd. Een waarde groter dan 10 µg/L is een alarmsignaal waarbij, in combi-
natie met de klachten en resultaten van het beeldvormende onderzoek, besloten kan worden 
tot een revisieoperatie. Ondanks deze richtlijnen heerst er onduidelijkheid wat de gevolgen 
zijn van langdurig verhoogde metaalionenspiegels bij patiënten en bij welke waarden na-
delige effecten kunnen optreden. Bovendien is er uit literatuur bekend dat er goed functi-
onerende implantaten met relatief hoge metaalionenspiegels zijn en slecht functionerende 
implantaten met lage spiegels, wat de onduidelijkheid voedt.
Op dit moment is de klinische betekenis en interpretatie van een enkele metaalionen-
meting onduidelijk. De onderzochte hypothese was dat de evolutie van metaalionenconcen-
traties informatiever is dan de huidige vereiste enkelvoudige meting. Het doel van de studie, 
gepresenteerd in Hoofdstuk 6, was een prospectieve follow-up van kobalt- en chroomcon-
centraties in een cohort van 48 unilaterale RHA’s te presenteren en de verschillen in metaal-
ionentrend op de korte termijn tussen goed versus suboptimaal functionerende patiënten te 
identificeren. Op basis van de recentste postoperatieve functionele uitkomstmaat — HHS, 
waarbij 0 de slechtste en 100 de beste uitkomst is — werden de patiënten verdeeld in goed 
en suboptimaal functionerende groepen. Een HHS≥90 werd gedefinieerd als goed functio-
nerend (n=42), een HHS<90 als sub­optimaal functionerend (n=6). De metaalionenspiegels 
en individuele trends werden geanalyseerd met een mediane  follow-up van 24 maanden. 
155
Nederlandse samenvatting en discussie
11
De mediane kobalt­ en chroomconcentraties waren significant hoger voor de suboptimale 
groep op 24 maanden: 0,95 µg/L (0,1-9,3) versus 6,2 µg/L (2,0-29,3) voor kobalt en 1,70 
µg/L (0,6-13,3) versus 4,70 µg/L (2,9-17,5) voor chroom. Het percentage goed functione-
rende patiënten met stijgende kobalt- en chroomconcentraties tussen twee opeenvolgende 
tijdsintervallen (stijgers) neemt geleidelijk af van 90/86% (0-3 maanden) naar 22/22% (24-36 
maanden). De mediane absolute toename van de subgroep van stijgers was significant lager 
voor de goed functionerende groep dan voor de suboptimaal functionerende groep in de 
periode van 12 tot 24 maanden: 0,70 µg/L (0,1-4,6) versus 6,65 µg/L (2,9-23,7) voor kobalt 
en 0,80 µg/L (0,1-8,9) versus 11,6 µg/L (11,0-12,2) voor chroom. Concluderend; suboptimaal 
functionerende MoM-implantaten hebben een andere trend van metaalionenspiegels dan de 
goed functionerende implantaten, een hoger percentage stijgers en een grotere absolute 
toename per tijdsinterval. 
Naar aanleiding van deze resultaten adviseren wij om laagdrempelig een metaalionen-
meting te herhalen, in het bijzonder kobalt, aangezien dit het meest toxische van de twee is. 
In aanvulling op anamnese, lichamelijk en beeldvormend onderzoek kan een opeenvolgen-
de meting duidelijkheid geven over het al dan niet falen van een implantaat. Het navolgende 
voorbeeld illustreert dit: een enkele kobaltmeting van 5 µg/L op 12 maanden kan als grens-
waarde worden gezien. Bij een patiënt zonder klachten is een concentratie van 3 µg/L op 
24 maanden geruststellend (aangezien het een daling betreft), terwijl een concentratie van 
6 µg/L kan wijzen op een potentieel disfunctionerend implantaat. Bij de goed functionerende 
patiënten wordt twee jaar na implantatie zelden nog een stijging van de metaalionenconcen-
traties gezien. Indien metaalionenconcentraties na 12 maanden structureel stijgen kan dit 
een teken zijn van toenemende slijtage en een potentieel disfunctionerend implantaat. Op-
eenvolgende metingen na een jaar en een trendbeoordeling kunnen helpen in de besluitvor-
ming rond revisieoperaties bij patiënten met milde symptomen en metaalionengrenswaarden 
(4-5 µg/L).
Beoordelen van het voorkomen van stille pseudotumoren in een cohort van heup-
resurfacing-patiënten
Lichamelijke klachten, een steile cuppositionering en/of hoge dan wel stijgende metaal-
ionenconcentraties kunnen kenmerkend zijn voor een slecht functionerend MoM-implan-
taat en indicatief voor ARMD. Op dit moment wordt in richtlijnen onderzoek naar klinische 
symptomen, conventionele röntgenfoto’s en metaalionenmetingen geadviseerd om patiën-
ten met een slecht functionerend implantaat te identificeren. Als voorgenoemde kenmerken 
afwijkend zijn, moet cross-sectionele beeldvorming (zoals echo, CT of een metal artefact 
reduction  sequence-MRI (MARS-MRI) verricht worden om een eventuele pseudotumor te 
detecteren. De sensitiviteit en specificiteit van de klinische kenmerken zijn echter nog niet 
vastgesteld. Er wordt tevens gesuggereerd dat cross-sectionele beeldvorming van alle pa-
tiënten met een MoM-heupprothese de enige mogelijkheid is om de volledige omvang van 
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pseudotumorvorming na een MoM-implantaat vast te stellen. Daarnaast zijn de klinische 
implicaties van de aanwezigheid van pseudotumoren ook nog onduidelijk.
Vooruitlopend op een mogelijke toekomstige screening van alle patiënten werd het scree-
ningsprotocol voor de aanwezigheid van asymptomatische pseudotumoren in een cohort van 
289 RHA’s geïntensiveerd. Het doel van deze studie was om te bepalen of men alert dient te 
zijn op de aanwezigheid van stille pseudotumoren (pseudotumoren bij volledig asymptoma-
tische patiënten) bij heupresurfacing-pa tiënten. Voordat het geïntensiveerde screeningspro-
tocol van start ging, was, gebaseerd op de beschikbare klinische scores en conventionele 
röntgenfoto’s, geen van de 289 RHA’s verdacht op de aanwezigheid van een pseudotumor. 
In Hoofdstuk 7 wordt de aanwezigheid van pseudotumorvorming op MARS-MRI in een hoog-
risicogroep (n=11, 12 heupen), een laagrisicogroep (n=10, 10 heupen) en routine­ follow­up­
groep (n=19, 22 heupen) beschreven. De hoogrisicogroep bestond uit vrouwelijke patiënten 
met een acetabulaire inclinatie groter dan 45° en een femorale diameter kleiner dan 50 mm. 
De laagrisicogroep bestond uit asymptomatische mannelijke patiënten met een unilaterale 
RHA, acetabulaire inclinatie kleiner dan 45° en femorale diameter groter dan 50 mm. Het risi-
co op pseudotumorvorming in de hoogrisico-, laagrisico- en controlegroep was respectieve-
lijk 0,45, 0,33 en 0,30; hierbij werden geen significante verschillen tussen de groepen gezien. 
Bij 15 heupen (34,1%) werd pseudotumorvorming vastgesteld, volgens de Anderson- 
classificatie werden er zes als licht, acht als matig en één als ernstige MoM­ziekte geclas-
sificeerd. 27,3% van de pseudotumoren trad op bij asymptomatische patiënten en werd 
beschouwd als een stille pseudotumor, er was hierbij geen correlatie met de risicogroep. 
In 80% van de gescreende patiënten waren de metaalionenconcentraties normaal (kleiner 
dan 40 nmol/L). Evaluatie van alleen klinische resultaten, röntgenfoto’s en metaalionen-
concentraties onderschatten de aanwezigheid van pseudotumorvorming bij patiënten met 
een MoM-implantaat en zijn niet gevoelig genoeg om alle gevallen van ARMD detecteren. 
Concluderend: zonder cross-sectionele beeldvorming worden er minder pseudotumoren ge-
diagnosticeerd en gerapporteerd. Er is echter geen consensus over de klinische relevantie 
en gevolgen van pseudotumorvorming.
Vergelijken van botdichtheidsveranderingen na RHA en 28-mm-MoM-THP
Een van de belangrijkste kenmerken van RHA is het femorale botbehoud door het ontwerp 
waarbij de eigen femurkop bedekt wordt met een metalen kap. Bescherming van de femora-
le en acetabulaire botmassa na een RHA is belangrijk, vooral voor de relatief jonge patiënt, 
aangezien er bij hen een grote kans is op toekomstige revisieoperaties. Bestaand botverlies 
kan leiden tot ingewikkelde en gecompliceerde reconstructies tijdens revisiechirurgie en een 
lagere overleving van de implantaten na revisie. Een potentiële valkuil van RHA kan geleide-
lijke botresorptie ter plaatse van de femorale calcar zijn en de mediale acetabulaire wand als 
gevolg van stress-shielding (afname in botdichtheid door afname van de normale belasting 
in het bot ten gevolge van een implantaat). Om de femorale en acetabulaire botdichtheids-
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veranderingen na RHA in vergelijking met een 28-mm-MoM-THP te beoordelen werd een 
RCT met dual-energy Xray absorptiometry (DEXA) uitgevoerd, beschreven in Hoofdstuk 8 en 
Hoofdstuk 9. De DEXA-metingen werden pre-operatief en na 3, 6, 12 en 24 maanden uitge-
voerd, waarbij de gemiddelde relatieve botdichtheid berekend werd als een percentage van 
de preoperatieve waarde (die op 100% werd gesteld).
In Hoofdstuk 8 worden de resultaten van de opeenvolgende gestandaardiseerde DEXA-
scan tot 12 maanden postoperatief na RHA (n=20) en THP (n=22) gepresenteerd. De bot-
dichtheid werd bij beide groepen ter plaatse van de calcar (Gruen zone 7) gemeten en bij 
de RHA-patiënten werden vier extra femorale regions of interest (ROI) gemeten. Bij RHA kon 
de botdichtheid in de femurhals behouden worden. De gemiddelde relatieve botdichtheid 
ter plaatse van de calcar nam een jaar na RHA significant toe tot 105,2% (p=0,012) versus 
een daling tot 82,1% (p<0,001) voor de THP-groep. Het verschil tussen de groepen was 
significant (p<0,001). In de overige vier femorale metingen wordt initieel een niet­significante 
afname van de botdichtheid gezien, gevolgd door een herstel tot op preoperatief niveau na 
12 maanden.
In Hoofdstuk 9 worden de resultaten van de botdichtheidsmetingen van het acetabulum 
tot 24 maanden na de RHA­press­fit­kobalt­chroom­cup (n=38) en THP­titanium­schroefcup 
met Metasul­insert (een metaal­inlay in een polyethyleen liner) (n=33) gepresenteerd. De 
botdichtheid in vijf acetabulaire periprothetische zones werd prospectief gestandaardiseerd 
geanalyseerd; deze zones konden onderverdeeld worden in twee craniale (ROI 1 en 5), twee 
mediale (ROI 2 en 4) en een caudale zone (ROI 3). In tegenstelling tot onze hypothese werd 
de periacetabulaire botdichtheid beter behouden na RHA dan na plaatsing van een con-
ventionele THP. Na een RHA bleven beide craniale zones rond de uitgangswaarden stabiel 
(ROI 1 98,7%; ROI 5 101,9%), terwijl na THP de craniale zone 1 een significante afname in 
botdichtheid toonde (ROI 1 90,8% (p<0,001); ROI 5 93,8% (p=0,055)). Ten aanzien van de 
twee mediale zones was er een significante botdichtheidsafname in beide groepen: RHA tot 
77,7% en 91,5% en THP tot 67,3% en 97,0% (ROI 2 en 4) (p<0,05), in zone 2 is het verschil 
in het voordeel van RHA. De botdichtheid bleef in de caudale zone 3 voor RHA stabiel op 
99,8%, terwijl er een significante afname werd gevonden voor THP tot 93,5% (p<0,001). In 
tegenstelling tot de hypothese bleef het acetabulaire bot beter behouden ondanks de stijve 
press­fit RHA­cup. De waargenomen afnames van de botdichtheid mediaal van de cup (ROI 
2 en 4) van 23% en 8,5% voor RHA en 32% en 3% voor THP na 24 maanden zijn in over-
eenstemming met eerdere literatuur over botdichtheidsveranderingen na conven tionele THP 
met press­fit­cups. Een press­fit­RHA­cup leidt derhalve in deze studie niet tot een grotere 
afname van periprothetisch botdichtheid vergeleken met een gevestigde schroefcup. Dit re-
sultaat is echter discutabel indien grotere acetabulaire cups moeten worden geïmplanteerd 
bij RHA (en dus meer acetabulair bot verwijderd wordt) om te passen bij de overeenkomstige 
femorale diameter. Aan de femorale zijde wordt na RHA een natuurlijkere belasting gezien, 
terwijl er botdichtheidsverlies optreedt na een conventionele ongecementeerde THP. Op de 
korte termijn is er in deze studies na RHA een groter behoud van botdichtheid gezien in 
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 zowel het femur als het acetabulum, in vergelijking met THP. 
Discussie
Heupresurfacing (RHA) is een (geherintroduceerd) nieuw concept en design voor heup-
prothesiologie en het is derhalve belangrijk om de resultaten te vergelijken met de gouden 
standaard, de totale heupprothese (THP). Voor dit proefschrift werd onder andere een ge-
randomiseerde studie tussen RHA en THP verricht voor een objectieve vergelijking van klini-
sche uitkomsten, voor het vergroten van het niveau van bewijs in de huidige literatuur en om 
te onderzoeken of heupresurfacing voldoet aan de geopperde (hoge) verwachtingen. Geba-
seerd op de resultaten van dit proefschrift kan geconcludeerd worden dat RHA voldoet aan 
de verwachtingen met betrekking tot botdichtheid, klinische uitkomsten en stabiliteit op de 
korte termijn. Een RHA behoudt de femurkop en conserveert meer botdichtheid rondom de 
prothese dan de THP in klinisch relevante zones van acetabulum, zoals craniaal en me diaal 
van de cup en de femorale calcarzone. Klinische uitkomstmaten en patiënttevredenheid zijn 
goed tot uitstekend na RHA in onze kortetermijnstudie. De scores van OHS, UCLA- 
activiteitsscore en VAS­tevredenheid waren significant hoger na RHA dan na THP op sommi-
ge tijdpunten. Ondanks randomisatie hadden de RHA-patiënten echter reeds preoperatief 
een hogere UCLA-activiteitsscore, dus is het de vraag of het postoperatieve voordeel klini-
sche betekenis heeft. Het verschil in patiënttevredenheid en vroege klinische uitkomstmaten 
tussen RHA en THP kan, volgens onze voorkeursstudie, niet worden toegeschreven aan het 
feit dat patiënten mogelijk hun implantaat van voorkeur (RHA) kregen. De RHA blijkt ten  slotte 
ook het stabielere implantaat te zijn. In de RHA-groep werden geen dislocaties gevonden, in 
de THP-groep drie. De metaalionenconcentraties kunnen bij metaal-op-metaalprothesen een 
reden van zorg zijn. In onze studies blijven de mediane metaalionenconcentraties echter 
laag, voor de unilaterale implantaten onder de 2 µg/L. In de RHA-groep is er initieel een sig-
nificant hogere afgifte van kobalt en chroom dan in de 28­mm­MoM­THP­groep. Na 24 maan-
den is dit alleen nog significant verschillend voor de chroomwaarden. 
Gebaseerd op de huidige literatuur en nationale implantaatregisters zijn de criteria voor een 
ideale kandidaat voor een RHA: mannelijk geslacht, jonger dan 55 jaar, een femorale dia-
meter groter dan 50 mm, een BMI kleiner dan 35 kg/m2 en primaire coxartrose. Mannelijke 
RHA-patiënten, ongeacht leeftijd, met een femorale diameter groter dan 50 mm hebben een 
tienjaars-revisiepercentage van 5,1%. Wanneer het revisiepercentage van RHA vergeleken 
wordt met de gouden standaard – de conventionele metaal-op-polyethyleen-THP voor een 
mannelijke patiënt, jonger dan 55 jaar met primaire coxartrose – is dit na tien jaar 6,1% 
voor de RHA en 9,3% voor de THP. Gebaseerd op het Australische implantaatregister vol-
doet RHA ruim aan de NICE-criteria (overlevingspercentage van een implantaat groter dan 
of gelijk aan 90% na tien jaar) wanneer het geplaatst wordt in jonge mannen (of vrouwen 
met een femorale diameter groter dan 50 mm) met primaire coxartrose. Er moet hierbij op-
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gemerkt worden dat deze succesvolle tienjaars-follow-up alleen beschikbaar is voor twee 
resur facingmerken (Conserve® Plus en de Birmingham Hip Resurfacing (BHR)) en voor een 
selecte groep van ideale patiënten zoals beschreven.
In de registers worden de resultaten van de verschillende soorten RHA- en MoM-THP- 
implantaten samengevoegd weergegeven. Er is echter steeds meer bewijs dat de resul-
taten variëren tussen de verschillende merken c.q. fabrikanten. De introductie van de BHR 
op de markt werd streng gecontroleerd, met geselecteerde chirurgen en de nadruk op de 
noodzaak van de juiste chirurgische techniek en selectie van patiënten. De succesvolle re-
sultaten van de BHR in biomechanische, heupsimulator studies en klinische studies (van 
designer surgeons, chirurgen die bij de ontwikkeling van de prothese betrokken zijn) trok de 
aandacht van andere fabrikanten die graag deel uit wilden maken van de metaal-op- metaal-
revolutie. Fabrikanten in Europa en de Verenigde Staten ontwikkelden hun eigen MoM-
heup implantaten, met in elk ontwerp een wisselende combinatie van aanpassingen aan de 
 oorspronkelijke ontwerpkenmerken. Kenmerken van de RHA waarvan gedacht wordt dat ze 
de slijtage positief dan wel negatief beïnvloeden zijn: 1) het gebruik van gegoten (as cast) 
versus gesmeed materiaal, 2) verschillende hittebehandelingen van de componenten, 3) de 
afstand tussen de twee articulerende oppervlakten (radial clearance), 4) de mate van aceta-
bulaire overdekking van de femorale component en 5) de functionele hoek van de femorale 
component. Sommige ontwerpen, met lage slijtage-eigenschappen in vitro, blijken zeer ge-
voelig te zijn voor suboptimale positionering in vivo, met extreem hoge slijtage waarden tot 
gevolg bij grote aantallen patiënten. Grotere maten van bepaalde ontwerpen lijken juist weer 
ongevoelig voor suboptimale positionering. Daarnaast vertonen de grote diameter (groter 
dan 36 mm) LDH-MoM-THP aanzienlijk hogere en klinisch zorgelijke metaalionenwaarden in 
vergelijking met RHA en men moet de resultaten van deze LDH-MoM-THP niet samenvoegen 
met die van de RHA.
Toen de MoM-implantaten in Europa geïntroduceerd werden, werden ze door de reguleren-
de partijen in de categorie prothesen geplaatst die alleen een heupsimulatortest (in vitro 
biomechanisch cyclisch belasten van de prothese) vereiste, aangezien het concept werd 
beschouwd als een uitbreiding van eerder goedgekeurde ontwerpen. Verschillende con-
currerende ondernemingen konden snel hun eigen MoM-implantaat op de markt brengen, 
zonder dat klinische studies verplicht waren om commercieel gebruik toe te staan. In de 
Verenigde Staten beschouwde de Food and Drugs Administration (FDA) de componenten 
van de LDH-MoM-THP gelijk aan andere kopjes, cups en stelen die reeds in gebruik wa-
ren en verklaarde dat ze op basis hiervan goedgekeurd konden worden (een zogenaamd 
510(k) proces). Derhalve waren er ook hier geen klinische studies nodig om te bewijzen hoe 
de LDH­MoM­koppen werkten wanneer ze gecombineerd werden met een gemodificeerde 
steel. Mede mogelijk gemaakt door de relatief ‘gemakkelijke’ goedkeuring en onder druk van 
hun investeringen introduceerden de fabrikanten de MoM-implantaten snel op de markt. De 
concurrentie om marktaandeel resulteerde in een agressieve marketingcampagne gericht 
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op patiënten en chirurgen. Dit resulteerde in een te snelle wereldwijde introductie van deze 
nieuwe MoM­implantaten zonder gegevens over langdurige klinische resultaten en identifi-
catie van alle mogelijke complicaties.
Op dit moment is er wereldwijd een toenemende bezorgdheid over de MoM-implantaten. De 
zorgen richten zich op relatief hoge revisiepercentages, pseudotumorvorming en mogelijke 
metaalionintoxicatie. Er zijn duidelijke aanwijzingen dat het risico op deze problemen tussen 
verschillende soorten MoM-implantaten verschilt. Dit geldt zowel voor verschillen in type im-
plantaat (LDH-THP versus RHA) als voor de verschillende merken. Geen enkel type of merk 
MoM-prothese is geheel vrij van zorg. Nationale richtlijnen van de regelgevende instanties 
en orthopedische verenigingen verschillen in hun adviezen met betrekking tot MoM-heupim-
plantaten. Deze richtlijnen variëren van aandacht voor het probleem tot inperkingen in het 
gebruik tot aan een expliciet verbod, van bepaalde specifieke typen tot alle MoM­implanta-
ten. Ondanks de duidelijke behoefte ontbreekt een uniforme internationale consensus. De 
problemen van de MoM-heupprothese en de gevonden bijwerkingen zijn ingewikkeld en 
onderzoek roept soms nog meer vragen op dan dat het beantwoordt. Een andere complice-
rende factor is het aantal betrokken partijen, bestaande uit patiënten,  chirurgen, fabrikanten, 
onderzoekers, regelgevende instanties en keuringsinstanties, elk met hun eigen belangen, 
verantwoordelijkheden en betrokkenheid bij het MoM-implantaat-probleem. Op nationaal ni-
veau vragen de complicaties en gesignaleerde problemen in de literatuur om een duidelijk 
beleid inzake de MoM-heupimplantaten. In 2012 werd in Nederland, al dan niet gedwongen 
door de publieke opinie, besloten om een time-out op te leggen voor alle MoM-heupimplan-
taten met een heupkop-diameter groter dan of gelijk aan 36 mm (inclusief RHA en merk-
onafhankelijk). Met betrekking tot de toenemende revisiepercentages en veelvoorkomende 
complicaties na LDH-MoM-THP lijkt dit een zeer terechte beslissing. Men kan zich, met het 
oog op RHA, echter afvragen of we nu de baby weggooien met het badwater door een 
verbod op álle merken van de RHA voor álle patiënten. Aan de andere kant kan in dit proef-
schrift geen uitgesproken klinisch relevante voordelen van RHA ten opzichte van THP bewe-
zen worden en blijven er nog veel onzekerheden bestaan aangaande de MoM- gerelateerde 
problemen. Beide rechtvaardigen een time-out van het gebruik van MoM-implantaten. Met 
het oog op de toekomst geeft het Australische register de mogelijkheid revisie- en overle-
vingspercentages type­ en merkspecifiek te beoordelen. Dit geeft de mogelijkheid om on-
derscheid te maken tussen falende en succesvolle RHA- en MoM-THP-ontwerpen. De ver-
schillen tussen de goed en slecht functionerende ontwerpen en MoM-categorieën worden 
momenteel al steeds duidelijker. Wanneer RHA wordt vergeleken met LDH-MoM-THP is er 
een tienjaars-revisiepercentage van 9,1% versus 20,3%. Dit kan, mettertijd, de mogelijkheid 
geven om bepaalde RHA-implantaten toe te laten, als ze voldoen aan de NICE-criteria in 
de nationale registers en in klinische studies geen onaanvaardbare bijwerkingen hebben. 
 Redelijkerwijs kunnen die RHA-implantaten in een gecontroleerde setting worden toegela-
ten, in een zeer specifieke groep patiënten: mannen jonger dan 55 jaar, met een heupkop­ 
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diameter groter dan 50 mm, een BMI kleiner dan 35 kg/m2 en primaire coxartrose. 
Dit proefschrift heeft zich geconcentreerd op patiënten met een specifiek RHA­merk (Con-
serve® Plus; Wright Medical) en alle patiënten werden geopereerd door een beperkt aantal 
ervaren heupchirurgen. Er zijn duidelijke aanwijzingen dat de kans op een MoM-gerelateerd 
probleem verschilt tussen de verschillende merken van RHA en dat er meer problemen zijn 
die gerelateerd zijn aan het LDH-MoM-THP-concept dan aan het RHA-concept. Tijdens het 
lezen van de resultaten van dit proefschrift moet men zich realiseren dat deze factoren ver-
antwoordelijk kunnen zijn voor de gepresenteerde, relatief goede resultaten. Deze resultaten 
kunnen waarschijnlijk niet worden gegeneraliseerd naar alle MoM-implantaten. Bovendien 
geven de studies in dit proefschrift de resultaten weer na kortetermijnfollow-up en zal een 
langere follow-up nodig zijn om harde conclusies te trekken. In de tussentijd zullen deze pa-
tiënten met grote zorg vervolgd worden. Metaalionen in het bloed, DEXA-analyse en functio-
nele uitkomstscores zijn opgenomen in het standaard follow-up-protocol. Momenteel zijn 
bijna alle patiënten voorbij de driejaars-follow-up en worden er geen duidelijke verschuivin-
gen in resultaten of revisiepercentages gezien. In overeenstemming met de richtlijnen van 
de Nederlandse Orthopaedische Vereniging is er afgestapt van het gebruik van RHA in onze 
kliniek. Of deze time-out tijdelijk of permanent is, is nog niet duidelijk. Voor de nabije toe-
komst staat beeldvorming met MARS-MRI bij alle RCT- en cohortpatiënten gepland, aange-
zien het concretiseren van de incidentie van stille pseudotumoren op dit moment belangrijk 
lijkt te zijn. Tot op heden is er geen overeenstemming over de incidentie van pseudotumoren 
na verschillende soorten MoM-implantaten. Ook de consensus over de vraag of deze stille 
pseudotumoren klinisch relevant zijn ontbreekt.
Nu de hype van de MoM-heupimplantaten overgegaan is in een nationale professionele 
afkeer van MoM-articulaties, is het tijd om de successen in de klinische praktijk te besten-
digen en de mislukkingen af te wijzen. Daarom is onderzoek naar verdere identificatie van de 
oorzaken achter deze mislukkingen en successen van groot belang. Langdurige follow-up  in 
een geselecteerde patiëntengroep met een kleine selectie van de momenteel beschikbare 
MoM-implantaten zal helpen om te bepalen in welke mate er plaats is voor RHA en/of LDH-
MoM-THP.
Toekomstig onderzoek zou zich moeten richten op het scheppen van meer duidelijk-
heid over de gevolgen van langdurige blootstelling aan hoge metaal ionenspiegels, bepaling 
van de provocerende factoren van ARMD in het menselijk  lichaam, de klinische betekenis 
van asymptomatische pseudotumoren en klinische uitkomsten na revisieoperaties. Inten-
sieve en langdurige follow-up wereldwijd van patiënten met een MoM-implantaat zal helpen 
deze kwesties te verhelderen en zal in het huidige debat over de zorgen rondom de MoM- 
articulatie verder gebruik wel of niet rechtvaardigen.
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Promoveren is hard werken en dat doe je niet alleen. Veel mensen hebben op hun eigen 
manier een bijdrage aan dit proefschrift geleverd, en daar heb ik dankbaar gebruik van 
gemaakt. Op deze plek wil ik jullie hiervoor hartelijk danken. Allereerst de patiënten voor 
hun medewerking aan en het vertrouwen in dit onderzoek. Ook ben ik de sponsoren van 
dit proefschrift zeer erkentelijk voor hun financiële bijdrage. Een aantal mensen wil ik in het 
bijzonder bedanken.
Dr J.L.C. (Job) van Susante, beste Job, vanaf het moment dat ik als jonge co-assistent bij jou 
kwam praten over mijn aanstaand senior co-schap waarbij ik ‘ook wel wat onderzoek wilde 
doen’ heb je mij gecoacht in het onderzoek, het schrijven en het publiceren van artikelen. Zie 
hier het resultaat! Bijzonder snelle reacties met roodgestreepte manuscripten, honderden 
mails (sommigen bijna telepathisch tegelijk), motiverende telefoongesprekken en je bereid-
heid om mij bij verschillende gelegenheden naar voren te schuiven hebben mij enorm geïn-
spireerd en gemotiveerd om dit onderzoek te doen en dit proefschrift te schrijven. Ik had me 
geen betere supervisor, inspirator en co-promotor kunnen wensen! 
Prof. dr. ir. N.J.J. (Nico) Verdonschot, beste Nico, ik zette mijn eerste voorzichtige stappen 
op het wetenschappelijke pad bij jou in het Orthopaedic Research Lab met het schrijven 
van een artikel over kraakbeentransplantaties. En alsof het zo heeft moeten zijn speel je, als 
promotor, weer een cruciale rol bij deze volgende wetenschappelijke stap. Bedankt voor je 
biomechanische en kritische blik bij het afronden van dit proefschrift en je enthousiaste aan-
moedigingen om mijn promotie vooral goed te vieren. Dat gaan we doen!
Geachte prof. dr. W. van den Berg, dr. E. Adang en prof. dr. S.K. Bulstra, hartelijk dank voor 
jullie beoordeling van mijn manuscript en het gegeven vertrouwen.
Paranimfen Anneke van der Woude-Bech en Suzanne Witjes, bedankt dat jullie vandaag 
naast mij staan.
Anneke, je bent mijn oudste studievriendin. Vanaf dag één bij Geneeskunde hebben we 
elkaar gevonden en ook nog meerdere mooie avonturen meegemaakt in Afrika. We hebben 
ons daar ook door het SPSS-handboek geworsteld en ontdekt dat we beiden een onder-
zoekshart blijken te hebben. Bedankt voor de bijzondere vriendschap!
Suzanne, wat mag de orthopaedie blij zijn met zo’n enthousiaste, betrokken en uitgesproken 
orthopeed i.o. in haar gelederen. Als eerste auteur van het eerste hoofdstuk ben jij letterlijk 
en figuurlijk de kickstarter van dit proefschrift en daarvoor ben ik je erg dankbaar.
Annemiek Hol, als onderzoekscoördinator en mede-auteur zorgde jij dat patiënten op de 
juiste momenten op controle kwamen en alle data zeer punctueel in de database werden 
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ingevoerd. Dit heeft mij bergen werk en zeeën van tijd bespaard, zonder jou had dit proef-
schrift hier nu nog niet gelegen.
Lian Roovers, je was altijd bereid mijn statistische vragen uit te zoeken. Bedankt.
Pepijn Bisseling, je hebt mij ontzettend veel werk uit handen genomen bij twee artikelen, 
bedankt hiervoor. Ik ben benieuwd naar jouw boekje en jij vergeet van je leven de Bland-
Altman-plot niet meer.
Paul E. Beaulé, thank you for your co-authorship and your willingness to cross the Atlantic to 
attend my PhD defence. 
Koen Brakel, Baudewijn Hendrickx, Henk Hoekstra, Dean Pakvis, Pieternel Pasker, Willard 
Rijnberg, Ton Rijnders, Wim Schreurs, Thea Sijbesma, Catherine van der Straeten en  Walter 
van der Weegen, ook jullie wil ik hartelijk bedanken voor alle inspanningen die jullie als 
 mede-auteurs hebben verricht. 
Hartelijk dank aan alle AIOS Orthopaedie in de Sint Maartenskliniek, UMC St Radboud en 
Rijnstate. De goede sfeer en grote mate van collegialiteit zorgen ervoor dat ik er trots op ben 
met jullie in deze regio mijn opleiding te kunnen doen. 
Stafleden van de ROGOO, bedankt dat jullie mij voor de opleiding hebben aangenomen en 
voor jullie begrip dat onderzoek doen tijd kost. 
Ate Wymenga, bedankt voor de mogelijkheden die je me hebt gegeven om naast mijn op-
leiding dit onderzoek te kunnen doen. Ik ben benieuwd of het aan jou als opleider ligt dat ik 
tijdens mijn opleiding, ondanks mijn promotie in de heupprothesiologie, toch drie keer meer 
knieprothesen dan heupprothesen heb geplaatst.
Er zijn een aantal mensen die niet direct een bijdrage aan dit proefschrift hebben geleverd, 
maar wel meer dan waardevol waren om te blijven beseffen dat er ook nog een leven is naast 
de opleiding orthopaedie en het promotie-onderzoek. Roger, Lotte, Mirrin, Nadine, Xenia, 
Judith, onze favoriete buren, het strijkkwartet en tot slot de Twittervrienden die, altijd op 
het juiste moment en vaak bij nacht en ontij, voor mentale ondersteuning, tips en zelfs een 
stelling zorgden.
Sanneke en Rinke, wat ben ik gelukkig met zulke creatieve vrienden! Jullie wisten met de 
illustraties precies de persoonlijke noot te geven aan mijn proefschrift die ik voor ogen had.
Jan en José, Brechje, Ralf, Gitta, Vincent en Lieke, bedankt voor jullie interesse in mijn ogen-
schijnlijk eindeloos durende opleiding en onderzoek. 
Pap, bedankt voor het geven van een fantastische opvoeding waarbij je mij vol zelfvertrou-
wen de wereld in hebt laten stappen en mij hebt gesteund in elke keuze die ik maakte. Ik 
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heb je liefde voor Acces en queries niet geërfd, maar wel je onderzoeksgenen en je allergie 
voor Excel. 
Mama, ondanks dat je er niet meer bent, ben je er voor mij toch altijd bij. Jij hebt mij gemaakt 
tot wie ik ben en ik weet dat je niet anders dan trots zou zijn.
Kaere Mette, thank you for being there for Gidi and being so much more, you took my worries 
away. Mange tak!
Kris en Vincent, Petra en Robbert, bedankt voor de mooie jeugd waarbij wij als drie zussen 
het samen allemaal wel regelden. Ik ben blij dat we nog steeds altijd bij elkaar terecht kun-
nen. 
Lieve Tijmen, ‘achter elke succesvolle vrouw staat een huisman’ is jouw gezegde over onze 
omgekeerde rolverdeling — waar menig collega jaloers op is. Ik ben je ontzettend dankbaar 
dat jij, als thuiswerkende (en niet als huis-) man zorgt voor een stabiel thuisfront. Je veert 
mee wanneer het kan en stapt op de rem als het moet (‘En nu gaan we fietsen’). Door het 
onderzoek als mijn hobby te zien kon jij, als fanatieke wielrenner, begrijpen welke tijdsinves-
tering ik ervoor over had. Lieverd, ik hou van je en ben benieuwd welke nieuwe hobby de 
toekomst voor ons in petto heeft!
Koosje Jans, ons lieve, vrolijke meisje dat dagelijks duidelijk maakt dat niets meer relativeert 
dan een kind. Het is geen enkele opgave om naast AIOS en promovenda ook jouw moeder 
te zijn, integendeel! En bedankt dat je van (uit-)slapen houdt.
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José Smolders wordt op 27 juli 1982 in Lelystad geboren. Nadat het VWO-diploma op ISG 
Arcus is behaald gaat zij naar Nijmegen om Geneeskunde te studeren. Tijdens een weten-
schappelijke stage in The Gambia bij de Medical Reseach Council gaat het onderzoekshart 
van José ondanks statusonderzoek met onleesbare handschriften harder kloppen en kan er 
met een portie levenservaring èn SPSS-kennis aan haar co-schappen worden begonnen. 
Tijdens het co-schap Orthopaedie bij prof. dr. R.P.H. Veth in het UMC St Radboud wordt 
direct duidelijk dat bij dit specialisme haar toekomst ligt en dit wordt bevestigd in een senior 
co-schap in het Rijnstate. Hier zorgt een onderzoek naar de inschatting van patiënten over 
het honorarium van de orthopaedisch chirurg voor onrust bij de onderzoekgroep en het 
 ziekenhuis, maar ook voor de eerste publicatie. 
Na het arts-examen wordt er eerst drie maanden onderzoek gedaan in het Orthopaedic 
Research Lab te Nijmegen en daarna is het tijd om als AGNIO Orthopaedie in Ziekenhuis 
Elkerliek te Helmond ‘dokter te worden’. Na een succesvolle sollicitatie in regio Oost start in 
2008 de vooropleiding algemene chirurgie in het Rijnstate (opleider dr. M.M.P.J. Reijnen) en 
wordt er gestart met eerste aanzet voor dit proefschrift bij de afdeling Orthopaedie onder 
 supervisie van dr. J.L.C. van Susante. José begint in 2010 met de opleiding Orthopaedie in 
de Sint Maartenskliniek (opleider dr. A.B. Wymenga), UMC St Radboud (opleider dr. M.C. 
de Waal­Malefijt) en Rijnstate (opleider dr. W.J. Rijnberg), die zij eind 2014 zal afronden. 
José is getrouwd met Tijmen Moltmaker en samen hebben zij in 2011 dochter Koosje Jans 
gekregen.
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